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CHAPTER I 
 
INTRODUCTION 
 
 
“All thruth passes through three stages. First, it is ridiculed. Second, it is violently opposed. 
Third, it is accepted as being self-evident.”  
 
 
 Arthur Schopenhauer  
(°1788 - †1860; German philosopher) 
 
 
 
 
 
 
Parts of this chapter were published: 
 
Wynendaele E, Pauwels E, Van De Wiele C, Burvenich C, De Spiegeleer B. The potential role of 
quorum-sensing peptides in oncology. Medical Hypotheses 2012; 78(6): 814-817. 
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CHAPTER I 
INTRODUCTION 
1. THE HUMAN MICROBIOME 
The human microbiome, the collection of trillions of microbes in and on the human body, has 
recently attracted renewed attention through the Human Microbiome Project and the 
Metagenomics of the Human Intestinal Tract. A full characterisation of the microbial communities 
found at different human body sites was aimed, next to the exploration of possible correlations 
between the microbiome composition and health [1]. Studies of the human microbiome revealed 
that the composition of the microbiome primarily depends on the anatomical location (Figure 1) [2]. 
Secondly, the microbes occupying different habitats of the human body can differ remarkably 
between healthy individuals: diet, environmental conditions, host genetics and early microbial 
exposure were found to play a key role in these personal differences, with other factors still to be 
evaluated [3]. 
 
 
Figure 1. Microbiome composition at different anatomical locations.  
The figure indicates percentages of sequences at the taxonomic phylum level, 
which are temporarily stable in individuals, at specific body sites [3]. 
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A person’s microbiome is believed to originate since birth (vaginal delivery), with the microbial 
population closely resembling that of the mother’s vagina [4]. The initial gastrointestinal microbiome 
is then enriched by the consumption of mother’s milk, which mainly contains Lactococcus, 
Staphylococcus, Streptococcus and Weisella bacterial species [5]. The adult intestinal microbiome is 
stable over time in healthy persons, but changes with aging (> 65 years). Moreover, inter-individual 
differences are highly observed within this older population [6]. 
 
The microbiome has been indicated to be beneficial for health. Commensal gut bacteria for example 
supply nutrients, help metabolizing indigestible compounds and defend against colonization by 
opportunistic pathogens or damage by dietary toxins and carcinogens [7]. These beneficial effects of 
the gastrointestinal microbiota are elaborated using probiotics, i.e. live microorganisms which confer 
a health benefit on the host when administered in adequate amounts. Clinical evidence indicates 
their efficacy in the treatment or prevention of i.a. acute viral gastroenteritis, post-antibiotic-
associated diarrhea and inflammatory bowel disease (IBD) [8].  
Besides, the alteration of the human microbiome composition can be associated with different 
diseases as well, e.g. psoriasis [9], gastric adenocarcinoma [10], colorectal cancer [11], inflammatory 
bowel disease [12,13] and obesity [14]. These malignancies can be initiated by i.a. the bacterial-
dependent production of genotoxic agents (e.g. reactive oxygen species) and toxins (e.g. CagA), the 
increased metabolisation of compounds (e.g. oestrogen) or the activation of the adaptive immune 
response against specific pathogens [11, 15]. 
 
 
2. QUORUM SENSING 
Many (commensal and pathogenic) bacteria produce a variety of signal molecules which facilitate 
them to sense their environment and interact socially, thereby coordinating activities to function as a 
multicellular unit. This process, called ‘quorum sensing’, enables bacterial cells to establish cell-cell 
communication and to regulate the expression of specific genes in response to local changes in cell 
density [16,17]. Quorum sensing chemicals up till now identified as key components in bacterial cell-
cell communication can broadly be divided in three main groups [18]: N-acyl homoserine lactone 
derivatives (AHLs, auto-inducer-1), larger quorum sensing oligopeptides and boron-furanone 
derivatives (auto-inducer-2). The larger quorum sensing oligopeptides are recently recognized as 
important bacterial pheromones, especially in Gram-positive organisms [19-22].  
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In order to be referred to as quorum sensing signals, it is generally accepted that a few criteria should 
apply. First, its production occurs during specific stages of growth, in response to environmental 
changes or under certain physiological conditions. Second, an extracellular accumulation of the 
quorum sensing signal is recognized by a specific receptor. Third, at a critical threshold concentration 
of this quorum sensing signal, a concerted response is triggered. An important fourth criterion 
outlines that this response should entail more than just the metabolisation and detoxification of the 
quorum sensing signal. It enables the population of cells to prepare for problems connected to a high 
cell density or to take advantage of the opportunities that arise from it [23]. The quorum sensing 
signals thus serve as a type of ‘compartment sensing’, informing through diffusion about spatial 
separation of subpopulations, the number of cells, their physiological state and the environmental 
conditions they abide in [24]. 
In this dissertation, the emphasis is only on one group of quorum sensing signal molecules, namely 
the quorum sensing oligopeptides. A detailed description of the other groups of quorum sensing 
molecules is already extensively described in several recent review papers [25,26]. 
 
The quorum sensing oligopeptide space shows a distinct diversity in structure (Figure 1): cyclic 
peptides containing a (thio)lacton linkage (e.g. AIP-1 in Staphylococcus aureus), as well as short linear 
peptide fragments (e.g. PhrC in Bacillus subtilis and Bacillus mojavensis) are found [21,27]. Moreover, 
also a posttranslational isoprenylation can occur: for example, the signalling molecule for genetic 
competence in Bacillus subtilis, ComX, is a six amino acid peptide whose tryptophan residue has been 
modified and a geranyl group attached [28].  
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Figure 1. Quorum sensing peptides with diverse structures: AIP-1 from Staphylococcus aureus (left) and PhrC 
from Bacillus subtilis (right). 
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The quorum sensing peptides bind to (1) cell-surface-bound signalling proteins, or (2) cytoplasmic 
receptors, after which the transcription of one or more target genes is activated (Figure 2). The 
quorum sensing ligands interact with quorum sensing receptors in a concentration-dependent 
manner, consistent with traditional concepts of receptor binding [27]. Also consistent with the 
concepts of receptor binding is the observation that autoinducer ligands acting at the same quorum 
sensing receptor compete with each other. For example, a series of structural analogs of N-3-oxo-
dodecanoyl homoserine lactone compete with autoinducer binding to LasR and have varying degrees 
of agonist activity. Experimental evidence has also shown that cells respond to extremely low 
concentrations of the quorum sensing signal molecules: only one or two molecules per cell are 
sufficient, so that low nM concentrations are expected to be active [29]. 
 
Figure 2. A model for oligopeptide-mediated quorum sensing in Gram-positive bacteria. Oligopeptide signals 
are synthesized as precursor peptides that are processed, modified and exported using ABC export systems. For 
some oligopeptides (oligopeptide 1), a cellular two-component signal-transduction system detects the 
oligopeptide signal and transmits it into the cytosol through phosphorylation-mediated signal transduction 
from the two-component sensor kinase to the two-component response regulator. The phosphorylated 
response-regulator protein is thereby activated and regulates the transcription of target genes. For other 
oligopeptides (oligopeptide 2), the peptides are actively transported into the bacterial cell by a specific 
oligopeptide permease. The peptide then binds to a cognate regulatory protein, which in turn regulates the 
transcription of its target genes [30]. 
 
 
The best-studied quorum sensing pathway in Gram-positive bacteria is the system used by 
Staphylococcus aureus. The regulation of its virulence phenotype is mediated by an RNA molecule 
(RNAIII), whose expression level is controlled by the accessory gene regulator (agr) locus. This gene 
cluster also contains the operon that encodes the genes for the production and detection of the 
peptide signal AgrD (autoinducing peptide, AIP). Once a threshold concentration of AgrD is reached, 
the autoinducing peptide binds to a cognate receptor protein, AgrC, located on the cell exterior, 
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resulting in the activation of a two-component intracellular signalling system: a histidine kinase 
phosphorylates the intracellular response regulator AgrA, which leads to the regulated gene 
expression of AgrBDCA and RNAIII [31,32]. In Staphylococcus aureus, strains can be divided into four 
agr specific groups, resulting in four markedly different AgrC molecules (AgrC1-4) [33,34]. The 
integral membrane protein AgrB is involved in the processing and secretion of the autoinducing 
peptide as a thiolactone-modified cyclic oligopeptide [31,32].  
A second quorum sensing system in i.a. Staphylococcus aureus has been described as well, 
modulating the activity of agr and consequently, its virulence. This system is proposed to operate 
upstream of agr, controlling the activity of RNAIII via its own autoregulatory mechanism. Once the 
extracellular concentration of RAP (RNAIII-activating protein) has achieved a sufficient density, it 
activates its target protein, TRAP, and induces the phosphorylation of three conserved histidine 
residues. From here, TRAP interacts with the agr system [35,36]. 
 
Like for S. aureus, the ComX-derived peptide pheromones in e.g. Bacillus subtilis are mediated by a 
sensor histidine kinase (ComP) and a response regulator (ComA) protein as well. After binding of the 
peptide pheromone to ComP, ComA is activated via signal transduction, which ultimately results in 
the development of genetic competence and the transcription of quorum sensing controlled genes. 
The synthesized ComX peptide is then cleaved and modified by ComQ before export to the 
extracellular environment occurs [37,38]. 
The second type of peptide signalling pathway in i.a. Bacillus subtilis involves the cell-penetration of 
CSF (Competence and Sporulation Factor) peptides through an oligopeptide permease (Opp) and the 
subsequent interaction with the cytoplasmic receptor Rap (receptor aspartyl phosphatase). The 
Bacillus subtilis family of Rap phosphatases comprises 11 members, of which RapA, RapC, RapE and 
RapF are most frequently observed [39]. Intracellularly, the phosphatase regulator (Phr)-derived 
peptide inhibits the phosphatase activity of the Rap receptor, resulting in a phosphorylated ComA 
protein and sporulation induction [38,40]. 
 
The quorum sensing signal molecules were originally found as intra-species communication tools in 
bacteria, but recent evidence indicates interspecies and host signalling as well [41,42]: AHLs have 
been found to be directly recognised by eukaryotic cells and even to influence the behaviour of 
eukaryotic organisms. For example, 3-oxo-dodecanoyl homoserine lactone exhibits potent immune 
modulatory activities by suppressing the interleukin- (IL-) 12 and tumour necrosis factor alpha 
(TNF-α) secretion *43]. Another example indicates that some AHLs can have cardiovascular effects by 
inducing relaxation of blood vessels, next to the induction of apoptosis in several breast cancer cell 
lines by 3-oxo-dodecanoyl homoserine lactone, the quorum sensing molecule secreted by 
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Pseudomonas aeruginosa [17, 44]. A third example concerns the quorum sensing peptide antagonist, 
siamycin, which seems to qualify as an HIV-cell fusion inhibitor. This molecule exerts a strong 
inhibitory effect on syncytium formation, targeting the HIV envelope glycoprotein gp41 [45,46]. In 
addition, the Bacillus subtilis quorum sensing peptide CSF (Competence and Sporulation Factor) 
activates p38 mitogen-activated protein kinase and protein kinase B in host intestinal epithelial cells 
and induces cytoprotective heat shock protein synthesis [47]. Despite these interesting ‘crosstalk’ 
observations between bacteria and eukaryotes, research mainly focuses on the bacterial intra- and 
interspecies signalling cascades as a tool to develop new antibiotic therapeutics. Quorum sensing 
inhibition, the mechanisms developed to interfere with the bacterial cell-to-cell communication 
pathways, has used quorum sensing antagonists to inhibit (virulence) gene expression or enzymes 
that interact with quorum sensing molecules (‘quorum quenching’), leading to deactivation of the 
quorum sensing process [48]. 
 
 
3. PEPTIDES 
Therapeutic peptides have taken a long time to come of age, with the first chemical synthesis of a 
therapeutic peptide, i.e. oxytocin, in 1953. All-in-all, in 2012, about 65 peptide-based drug products 
have reached approval, with over 75% of these coming in the last three decades; 100-200 peptides 
are currently in clinical trials and 400-600 in pre-clinical studies (Figure 3). The number of new 
peptide-based drug products achieving approval, together with the widening range of medical 
indications, thus underlines the increasing maturity of peptides as a class of pharmaceutical actives. 
Therapeutic peptides contribute significantly to the treatment of diabetes, osteoporosis, oncologic 
malignancies, gastroenterologic diseases, cardiovascular disorders, immune suppression, 
acromegaly, enuresis, obesity, or have antiviral, antibacterial or antifungal indications [49-51].  
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Figure 3. Overview of disease classes in which peptides are currently investigated for their 
therapeutic potential (clinical studies, situation in 2013) [52].  
 
 
Peptide-based research, diagnostic and therapeutic compounds have attracted great attention owing 
to their high affinity, strong selectivity for their targets and low toxicity. In contrast to proteins and 
antibodies, they have a good penetration of tissues because of their small size, are less 
immunogenic, show more specific tissue binding and are chemically more under consistent control, 
thus leading to more functional quality [53,54]. The advantages over small molecules include the 
higher selectivity for their targets, the greater efficacy, the lower toxicity of their degradation 
products and the limited tissue-accumulation. Despite these attractive features, peptides have an 
increased proteolytic instability compared to small molecules and monoclonal antibody therapeutics. 
To meet this main drawback, peptides can be cyclised or chemically modified at both the amide 
bonds and side-chains, rendering peptidomimetics that are resistant to this enzymatic degradation. 
Moreover, peptides show a poor ability to cross physiological barriers, including the intestinal 
mucosa, because of their general hydrophilicity. Bioavailability is therefore optimised using novel 
peptide delivery technologies for different routes of administration, e.g. dermal patches, nasal spray 
or protease inhibitors for oral delivery [55,56]. 
 
 
4. ONCOLOGY 
Cancer is one of the leading causes of death worldwide and accounts for approximately 8 million 
deaths per year. This disease can affect everyone and represents a tremendous burden on patients, 
families and society [57,58]. Lung (1.59 million), liver (745 000), stomach (723 000), colon (694 000) 
CHAPTER I – INTRODUCTION 
  
 
24 
and breast (521 000) cancer cause the most cancer deaths each year. The changes in cell properties 
are mostly the result of the interaction between a person’s genetic factors and several categories of 
external agents, including physical (e.g. radiation), chemical (e.g. tobacco smoke) and biological (e.g. 
infections) carcinogens [57]. 
 
Conventional cancer therapies, such as surgery or radiation to achieve local control and 
chemotherapy to exert systemic effects, are currently the methods of choice for cancer management 
[59,60]. However, there is still a clear need for the development of innovative preventive, diagnostic 
and therapeutic strategies, maximizing cure rates with minimal toxicity that exploit the emerging 
insights in tumour biology and the increased pharmaceutical developmental capabilities [61,62]. 
During the last decades, different peptides were investigated for their antitumour characteristics in 
order to fill this therapeutic and diagnostic gap.  
The underlying action mechanisms of antitumour peptides are diverse, with multiple actions for 
some peptides demonstrated, offering the advantage of combination therapy in a single compound 
[53]. For example, some of the necrosis-inducing peptides and apoptosis-inducing peptides have also 
additional anti-angiogenic properties, e.g. the lactoferricin-derived peptides [63-65].  
Necrosis-inducing peptides are a group of cell membrane lytic peptides. The outer membranes of 
cancer cells over-express negatively charged phosphatidylserine and O-glycosylated mucins in 
comparison with normal cells, favouring their selective attack by necrosis-inducing peptides, which 
are mainly short, positively charged amphipathic structures. Upon binding of the necrosis-inducing 
peptides to cell-membranes, these are disrupted via micellization or through pore formation, leading 
to the necrotic death of cancer cells. Necrosis-inducing peptides have a higher degree of selectivity 
for cancer cells than traditional chemotherapeutic drugs. Moreover, these peptides kill 
chemoresistant cancer cells by membrane lysis, bypassing the cellular mechanisms responsible for 
multidrug resistance. Cecropins, melittins and defensins are examples of currently known necrosis-
inducing peptides [53,63].  
Another action mechanism is based on the knowledge that cancer cells have an elevated apoptotic 
threshold: several peptides such as magainin-2, bovine lactoferricin and cathelicidin derived peptides 
(e.g. BMAP-28, hCAP109-135), as well as several plant-derived peptides have been shown to induce 
mitochondria-dependent intrinsic apoptosis [61]. Other apoptotic pathways, such as the p53-
controlled apoptosis regulation or through extrinsic death receptors like Tumour necrosis factor 
receptor (TNFR), are targeted by peptides as well, e.g. Ala-Val-Pro-Ile tetrapeptide [66].  
As tumours express increased proteolytic enzymes facilitating invasion and metastasis, e.g. 
cathepsins, urokinase-type plasminogen activator (uPA) and matrix metalloproteinases (MMPs), 
selective protease inhibitor peptides have been shown to suppress migration and inhibition, e.g. His-
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Trp-Gly-Phe tetrapeptide [67]. Other peptides have anti-angiogenic properties, e.g. CVX15, due to 
their interaction with cancer cell-surface selective receptors [68]. Some peptides have been shown to 
bind to cell-adhesion proteins as well, e.g. the Arg-Gly-Asp tripeptide derivatives like cilengitide are 
able to inhibit αvβ3 integrin-mediated cell adhesion to extracellular matrix proteins, thereby blocking 
tumour invasion and angiogenesis [69,70]. Interactions with laminin receptors or neural-cadherin 
glycoproteins are other cell-adhesion targets for peptide drugs, e.g. Tyr-Ile-Gly-Ser-Arg pentapeptide 
[71]. Protein kinases are commonly activated in cancer cells, and have hence become an attractive 
target for anticancer therapy as well, whereby small peptides have been developed to inhibit the 
interaction of kinases with their substrates [53]. Last, peptides with immunostimulatory activity have 
been identified [72,73], activating the innate and acquired immune system, e.g. muramyl dipeptide, 
and its analogues like romurtide, or bestatin which has in addition shown also protease inhibitor and 
anti-angiogenic activity. These peptides stimulate macrophages, natural killer cells and T-
lymphocytes to release proinflammatory molecules like IFN-γ *74,75]. 
Recently, attempts have been started to integrate the different peptide functionalities: antimicrobial 
peptides, which have been found in bacteria, fungi, plants and animals, are investigated [76] and 
indeed emerging as anticancer peptides as well, belonging to the apoptosis-inducing, necrosis-
inducing, anti-angiogenic or immune-stimulating peptides [61,77-80]. In conclusion, while the exact 
inhibitory mechanisms of the different antitumour peptides are far from being elucidated, current 
data at least show great potential and different possibilities, depending upon the peptide structure 
and the heterogeneous tumour biology. 
Already now, many peptides are used in the treatment and diagnosis of various cancers, while the 
development of nutraceuticals containing cancer-preventive peptides is a very promising area as well 
[81]. Chronic administration of Luteinizing Hormone-Releasing Hormone agonists (e.g. Decapeptyl, 
Leuprolide, Buserelin and Goserelin) is being utilized to induce the regression of prostate and breast 
cancer [62]. Somatostatin analogues (Octreotide, Lanreotide) are used for the treatment of 
neuroendocrine tumours of the gastroenteropancreatic system [62,82]. The molecular basis for this 
clinical application is the presence of a high density of somatostatin receptors, whereby the subtypes 
(sst1, sst2, sst3, sst4 and sst5) are differently expressed in the various types of cancer [83]. Moreover, 
the radiolabelled peptidic compound 111In-DTPA-[D-Phe1]octreotide has become the most widely 
used tracer for somatostatin receptor scintigraphy, while 90Y-DOTA-Tyr3-octreotide is the most 
frequently used analogue for radiotherapy [84]. Currently, 21 peptide drugs are marketed for cancer 
therapy, and the total peptide drug pipeline (in oncology) contains 232 peptide drugs in various 
stages of clinical development, applied in 587 developmental cancer projects [85]. 
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5. STUDY OBJECTIVES 
Despite the increasing evidence of the human microbiome influencing health, up till now, no 
research has been performed describing the role of quorum sensing peptides on tumour progression. 
However, important parallels are seen between the bacterial quorum sensing mechanisms and the 
biochemical and biological mechanisms metastatic cancer cells use to function as a society of 
malignant cancer cells. The process of biofilm formation has many of the characteristics of metastatic 
colonization, including motility of cells towards appropriate surfaces, attachment and interaction of 
cells with each other, surface adhesion and colonization, formation of a complex, heterogeneity,... 
[86].  
We surely believe this information can be of high importance, not only from a fundamental point of 
view (i.e. “Do quorum sensing molecules interact with cancer cells and how is this interaction 
achieved?”), but also for health in general (i.e. “Does this interaction affect cancer fate, either 
positively or negatively?”). Therefore, the goal of this thesis is to explore the effect of quorum 
sensing peptides on tumour cell behaviour. Obviously, it is impossible to obtain a complete and full 
explanation of this crosstalk phenomenon within the given time and resource boundaries. However, 
the goal is to have some foundations laid down for the first time where upon future research (e.g. in-
depth fundamental and biomedical investigations) can be built. 
 
In order to explore this interaction, different questions are put forward as objectives: 
(1) Which quorum sensing peptides are produced by which bacteria and what is their current 
bacterial functionality? 
A comprehensive quorum sensing peptide database will be developed to obtain a structured 
overview of these peptides and their synthetic peptide analogues. Their species origin, as 
well as the functional information currently available, will also be included. 
(2) How is the chemical space of these quorum sensing peptides organized? 
Structural information of the quorum sensing peptides will be used to cluster these peptides 
and to select model compounds. 
(3) Can a possible effect on tumour cells be caused by peptide impurities originating from 
peptide synthesis? 
In order to correctly assign functional properties to the quorum sensing peptides, the purity 
of chemically synthesized quorum sensing peptides will be investigated using 
chromatographic techniques. As some peptide impurities can be biomedically active or even 
alter the main peptide’s activity, it is important to explore this (often neglected) quality 
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parameter, already in this very early, exploratory basic biomedical research. The investigation 
towards the functional quality of (peptide) pharmaceuticals is the main research topic of 
DruQuaR, so this third objective fits perfectly the strategic ambition of our laboratory.  
(4) Do quorum sensing peptides interact with colorectal cancer cells and can they influence the 
metastatic processes involved in tumorigenesis? 
 Seen the increasing evidence of microbiome-related development of colorectal cancer, 
selected quorum sensing peptides will be investigated for their crosstalk behaviour with 
human colorectal adenocarcinoma cells, i.e. HCT-8/E11. Both tumour invasive and pro-
angiogenic properties will be studied to explore the metastatic potential of these molecules. 
(5) Can the observed crosstalk between quorum sensing peptides and tumour cells be 
elaborated to breast cancer? 
 The very recent identification of different Gram-positive bacteria in the breast tissue excited 
the research in the microbiome’s influence on breast cancer cells. To this end, we will 
investigate the effect of quorum sensing peptides, synthesized by these bacteria, on breast 
adenocarcinoma cells (i.e. MCF-7/AZ). 
(6) Do quorum sensing peptides, when present in the blood circulation, penetrate the blood-
brain barrier and what is their tissue distribution? 
 One of the narrowest barriers in the human body is the blood-brain barrier (BBB), protecting 
the central nervous system from potentially harmful chemicals while regulating transport of 
essential molecules and maintaining a stable environment. Moreover, there is increasing 
evidence that different central nervous system disorders are microbiome-related. Up till now 
however, no data are available concerning the blood-brain barrier permeability 
characteristics of quorum sensing peptides which may be present in the blood. 
(7) Can quorum sensing peptides, when present in the intestines, reach the blood circulation 
and what is their possible toxicity on different cell types? 
 The human gut consists of trillions of microorganisms, with some of these bacterial species 
capable of producing quorum sensing peptides. Therefore, in this thesis, the permeability of 
some quorum sensing peptides through the intestinal barrier will be investigated in order to 
evaluate the possible tumour-influencing effects elsewhere in the human body. When 
quorum sensing peptides reach the blood circulation, it is important to explore their toxicity 
as well. Hence, the effect on red blood cell haemolysis will be investigated, next to their 
direct toxicity on both healthy and cancerous cells. Moreover, the stability of the quorum 
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sensing peptides will be investigated in cell medium as well as in human plasma, in order to 
support the in vitro and in vivo significance of the biological functionality results. 
(8) How can radiolabelled peptides be developed for use in biomedical research, as diagnostics 
or therapeutics? 
In the last chapter, consistent with the DruQuaR tradition, a more general regulatory-quality 
oriented overview is presented. We reviewed the quality aspects of radiolabelled peptides as 
used not only in the biomedical research but also as diagnostics or therapeutics in the 
current shift towards personalized medicine.  
 
 
6. THESIS OUTLINE 
As this exploratory research covered different aspects in parallel, the chapters of this thesis are not 
chronologically ordered, but rather go from in silico over quality control to cell functionality, 
pharmacokinetics and toxicity, ending with a more formal regulatory overview in line with DruQuaR 
tradition. Therefore, each chapter is written and presented so that it can be read as a “stand-alone” 
text, with the introduction giving the specific context of the chapter.  
 
In Chapter II, the Quorumpeps® database is presented, which gives a structured, literature-based 
overview of the currently known quorum sensing peptides. In this database, information concerning 
their chemical characteristics, their microbial origin (species) and their bacterial functionality 
(receptor and activity) is summarized, thereby serving as a central information point about quorum 
sensing peptides. Moreover, this database serves as a useful tool to rationalize peptide choices for 
evaluating different responses or to study quantitative structure-property relationships (QSPR) of 
these quorum sensing molecules. 
In Chapter III, the chemical information, obtained from the Quorumpeps® database, is used to 
explore the chemical space of quorum sensing peptides. Using multivariate techniques, a number of 
chemically distinct peptide groups can be distinguished, which serves as a basic tool for ‘model 
peptide’ selection. Besides, the species distribution is investigated as well, demonstrating the 
diversity of synthesized peptide structures by specific bacterial species.  
In Chapter IV, the purity of a set of chemically synthesized quorum sensing peptides is screened 
using U/HPLC-UV and the identity of main peak and related impurities examined using U/HPLC-
ESI/MS. This study intends to demonstrate the importance of a thorough characterization of peptides 
when used during functional assays, even in basic biomedical research settings. 
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The main research question “Do quorum sensing peptides influence tumour cell behaviour?” is partly 
answered in Chapter V. In this chapter, the metastatic potential of selected quorum sensing peptides 
on colorectal cancer cells is investigated both in vitro and in vivo by collagen type I invasion and Chick 
Chorioallantoic Membrane (CAM) assays, respectively. Moreover, an initial pathway-map is 
developed to elucidate the effects of quorum sensing peptides on these cancer cells. The same 
approach is used for breast cancer cells, with the results of this study described in Chapter VI. Seen 
the recent findings of a possible breast (cancer) tissue microbiome, the effects of the quorum sensing 
peptides on breast cancer progression can confirm the microbiome-tumour crosstalk observations. 
By using the word ‘crosstalk’, emphasis is placed on bacterial to mammalian communication. Both 
studies (Chapter V and VI) intend to indicate, as an initial proof-of-principle, that the human 
microbiome, through their quorum sensing peptides, is one of the factors influencing cancer 
metastasis. 
In Chapter VII, the permeability of chemically diverse quorum sensing peptides through the blood-
brain barrier (BBB) is investigated. Although no effect of the quorum sensing peptides on brain 
(cancer) tissue is yet described, the permeability kinetics of these peptides can guide future 
functionality assays: only quorum sensing peptides that cross this physiological barrier should be 
studied for their effect on the central nervous system and its disorders.  
In Chapter VIII, the in vitro stability of selected quorum sensing peptides is investigated in cell 
medium as well as in human plasma, in order to correctly interpret the in vitro and in vivo 
functionality results obtained in Chapter V, VI and VII. Moreover, the intestinal permeability of some 
quorum sensing peptides is studied as well, of which the results can indicate the possibility of 
crosstalk behaviour at distant sites of the human body. Finally, the toxicity of the quorum sensing 
peptides is initially explored. This study thus intends to correlate the obtained functionality results 
with initial peptide stability and toxicity information. 
Chapter IX gives an overview of the currently available techniques that are used in the development 
of radiolabelled peptides and proteins. Moreover, the importance of thorough quality control 
measurements after radiolabelling within a regulated context is emphasized. Based on our 
exploratory findings of quorum sensing peptide interaction with cancer cells, the information 
presented in this chapter can be applied to more efficiently develop radiolabelled analogues. 
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CHAPTER II 
 
QUORUMPEPS® 
DATABASE: CHEMICAL 
SPACE, MICROBIAL 
ORIGIN AND 
FUNCTIONALITY OF 
QUORUM SENSING 
PEPTIDES 
 
“Happiness and bacteria have one thing in common; they multiply by dividing!” 
 
Rutvik Oza  
(Indian film writer) 
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C, De Tré G, De Spiegeleer B. Quorumpeps database: chemical space, microbial origin and 
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ABSTRACT 
Quorum sensing peptides are biologically attractive molecules, with a wide diversity of structures and 
prone to modifications altering or presenting new functionalities. Therefore, the Quorumpeps 
database (http://quorumpeps.ugent.be) is developed to give a structured overview of the quorum 
sensing oligopeptides, describing their microbial origin (species), functionality (method, result, 
receptor), peptide links and chemical characteristics (3D-structure derived physicochemical 
properties). The chemical diversity observed within this group of quorum sensing signalling molecules 
can be used to develop new synthetic bio-active compounds. 
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CHAPTER II 
QUORUMPEPS DATABASE:  
CHEMICAL SPACE, MICROBIAL ORIGIN AND 
FUNCTIONALITY OF QUORUM SENSING 
PEPTIDES 
Main focus in this chapter: 
 To construct a database, containing chemical, species-origin and functional data of quorum 
sensing peptides. 
 To present an easy applicable tool to explore quorum sensing peptide-related information. 
 
1. INTRODUCTION 
Quorum sensing (QS) enables bacterial cells to establish cell-cell communication and to regulate the 
expression of specific genes in response to local changes in cell density [1,2]. The concept of 
intercellular communication within bacterial populations originates from two independent discoveries 
in the 1960s and 1970s. In 1965, Tomasz stated that a hormone-like extracellular peptide was 
important for genetic competence in Streptococcus pneumoniae [3]. In 1970, Hastings et al. reported 
that luminescence in the marine bacterium Vibrio fischeri was produced only at high cell density, but 
not in dilute suspensions. They called the responsible component ‘autoinducer’, which was later 
identified as N-(3-oxohexanoyl)-homoserine lactone [4,5].  
Several classes of microbially derived signalling molecules have now been identified. In general, Gram-
negative quorum sensing bacteria use acylated homoserine lactones (AHLs) as autoinducers, while 
Gram-positive bacteria predominantly communicate with each other using oligopeptides that often 
contain chemical modifications [6]. In addition, a third family of compounds termed as autoinducer-2, 
derived from the common precursor 4,5-dihydroxy-2,3-pentanedione, has been found to be 
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widespread in the bacterial world [7]. Using these quorum sensing signalling molecules, bacteria are 
able to regulate a diverse array of physiological activities in a cell-density-dependent manner. 
Processes controlled by quorum sensing are usually those that are unproductive when undertaken by 
an individual bacterium, but become effective when undertaken by a group. Thus, quorum sensing 
allows bacteria to behave like a multicellular organism. In addition to genetic competence, 
bioluminescence, conjugation and swarming motility, quorum sensing also controls virulence factor 
secretion, biofilm formation and sporulation [6,8,9,10]. 
In the past decade, a significant increase in interest in bacterial quorum sensing is noticed. The 
discovery of the quorum sensing mediated virulence factor expression in many clinically relevant 
pathogens, raised the idea of quorum sensing antagonist production. Blocking quorum sensing is now 
recognized as a viable approach for the development of novel antibiotics [11]. Moreover, the 
increased antimicrobial resistance, due i.a. to the formation of a biofilm in which the micro-organisms 
are protected against antimicrobial chemotherapy and the immune system of the host, has called the 
attention to the quorum sensing system [12]. Intriguingly, recent evidence indicates chemical 
communication not only between bacteria of different species but also between bacteria and host as 
well. For example, AHLs have been found to be directly recognised by eukaryotic cells and even to 
influence the behaviour of eukaryotic organisms (immune suppression, blood vessel relaxation) [2,13]. 
These quorum sensing signalling peptides may thus have diagnostic and therapeutic properties in 
oncology and other pathologies as well [14]. 
Peptides have recently attracted renewed attention for their use in research, disease prevention, 
diagnosis and/or therapy. These physiologically active molecules demonstrate high affinity, strong 
selectivity and low toxicity, and can be synthetically modified in order to optimize their affinity for a 
particular receptor and to display a more specific biodistribution pattern [15,16]. The main drawback 
of the use of peptide-based compounds is their low stability to peptidases and proteases found in 
most tissues [16]. However, metabolic stability can be increased by substitution of unnatural amino 
acids or D-isomers, amidation or acetylation of peptide termini, cyclisation..., hereby increasing the 
probability of obtaining useful drugs, structurally related to the parent lead-peptides [17,18]. Peptides 
can thus reverse the increased attrition rate observed with small-molecule drugs. 
Seen the increased interest in bacterial quorum sensing signalling molecules and the potential of 
peptides as new therapeutic or diagnostic drugs, we present here a database of (modified) quorum 
sensing peptides with the acronym ‘Quorumpeps’ (http://quorumpeps.ugent.be). This database 
encompasses the structures and microbial origin, as well as functionality responses of the quorum 
sensing derived signalling peptides, as described in the literature. 
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2. ORGANIZATION OF THE DATABASE 
Data model 
In order to list all relevant data about the quorum sensing signalling peptides, a relational database is 
constructed [19]. The usage of such a relational model facilitates the insertion of new and/or 
additional data. Moreover, it avoids the occurrence of duplicate data and data inconsistencies to the 
largest extent possible. The schematic database model is available through the Quorumpeps website 
(Figure 1). In this visual representation, each block describes the structure of a table, with the table 
name mentioned in the header of the block. In each block, the names of the columns are listed. The 
column names marked in bold font together determine the primary key of the table. This means that 
the combination of values for these columns is unique for each row in the table. For clarity, the 
primary key columns are separated from the other columns by means of a dotted line. Relationships 
between tables are symbolized by an arrow.  
The central table in the Quorumpeps database model is ‘Experiment’, representing the binding-
analysis of a peptide (identified by MoleculeID) with a specific receptor (identified by ReceptorName), 
using a given method (identified by MethodName). The resulting response (result type, measurement 
and unit) is also given in this table. The table ‘Molecule’ summarizes the chemical information about 
the peptides, including the peptide name, the peptide chemical sequence, the Simplified Molecular 
Input Line Entry Specification (SMILES)-string and some physicochemical properties. Moreover, also 
the optimized three-dimensional structure is given in the database in .HIN format, acquired using 
HyperChem 8.0 (Hypercube, Gainesville, FL, USA). The bacterium that produces the signalling 
molecule is given in the table ‘Origin’, while derived molecules are connected to the molecules from 
which they are derived through the table ‘Molecule_Modification’. The receptors are listed in the 
table ‘Receptor’. All methods used to analyse the functionality of the peptides and the references 
used are summarized in the tables ‘Method’ and ‘Publication’, respectively. The observed activity (e.g. 
agonist or antagonist) of a peptide, bound to a specific receptor, is stored in the additional table 
‘Binding’. 
The Quorumpeps database has been implemented on a MySQL backend and is publicly available 
through the website http://quorumpeps.ugent.be. The website is implemented by using the content 
management system Drupal and provides a simple, keyword-based search interface to access the data 
available. Several search options are presented: peptide information (including sequence, trivial 
name, SMILES or molecular formula), origin, functionality method, receptor and literature information 
(Figure 2). Each performed search results in an overview of peptides that match the query. From this 
overview page, detailed information about the selected peptides or related literature can be 
obtained. User-information can be found at the help page of the Quorumpeps website. 
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Figure 1. Scheme of Quorumpeps database design 
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Figure 2. Homepage of the Quorumpeps® database. 
 
Data collection 
For loading information in the database, literature data was gathered by using the search engines 
Web of Knowledge, PubMed and Google, covering the period 1955-2012. The terms ‘Quorum 
sensing’, ‘autoinducer’ and ‘pheromone’, each separately, as well as ‘peptide’, ‘agonist’ and 
‘antagonist’, using the Boolean operation ‘AND’, were used. The obtained literature was processed 
manually and all relevant information was stored in the database. The data were used as described 
by the authors to ensure the data are exactly the same as originally published (data integrity as part 
of data quality). In order to expand the data available in the database, a data submission page has 
been constructed on the website allowing researchers to inform us of new information. 
 
 
3.  QUORUMPEPS IN DETAIL 
Chemical information 
The chemical information about the quorum sensing peptides includes the IUPAC one-letter code 
amino acid sequence, with or without any (post-translational) modification, trivial name, SMILES, 
molecular formula and physicochemical properties (molecular weight, logP and isoelectric point (pI)). 
The trivial name comprises every name that is given to the specific peptide, thus allowing group 
names (e.g. Autoinducing peptide, AIP) as well as individual peptide names (e.g. PhrA).  
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Before calculating the different physicochemical properties, the geometrical structure of these 
quorum sensing peptides was optimized using HyperChem 8.0. The geometry optimization was 
obtained by the molecular mechanics force field method using the Polak–Ribière conjugate gradient 
algorithm with a root mean square gradient of 0.1 kcal/ (Å×mol) as stop criterion. Afterwards, these 
Cartesian coordinate matrices were used to calculate the different descriptors, using HyperChem 8.0 
and Marvin Beans 5.3.3 (Chemaxon, Budapest, Hungary) software programs. This optimized .HIN 
structure is available through the Quorumpeps website, together with the 2D-SMILES notation. 
These formats allow the user to perform any sort of analysis on their various chemical properties, 
e.g. QSAR or multivariate data analysis [20]. Diversity analysis using the diversity index (described by 
the Tanimoto coefficient) of the 231 quorum sensing peptides currently available in the Quorumpeps 
database, indicated that this dataset is extremely diverse (DI = 0.21) and thus suitable for QSAR or 
QSPR studies [21,22]. 
 
Species origin 
In general, quorum sensing peptides are synthesized by Gram-positive bacteria, e.g. Staphylococcus 
aureus and Bacillus subtilis. As numerous different species are reported in literature, an overview of 
all listed bacteria is available at the Quorumpeps homepage, by using the information-icon: using this 
scroll-list, rapid directed searches can be performed by the user of Quorumpeps. 
Chemical modifications (e.g. amino acid substitution) of an original quorum sensing peptide are 
visualized in the ‘Species origin’ section by referring to its original counterpart. 
 
Functionality 
The functional properties of the quorum sensing signalling peptides are described in the 
Quorumpeps database. Moreover, an overview of the receptors and methods can be found at the 
homepage of Quorumpeps, using the information-icon next to the appropriate characteristic.  
The functionality of the signalling peptides is characterized by the method used to study their 
quorum sensing activity. The methods are using either the isolated signalling peptides or the 
(genetically modified) bacteria to investigate a biological activity. The target genes or their products 
are then qualitatively or quantitatively measured using antibacterial assays [23,24], biosensors [25-
31], biofilm assays [32,33], analytical and immunoassays [34,35], DNA and RNA detection [36,37] or 
viability measurements [34,38-41]. Moreover, different quorum sensing pathways are reported, 
which can be divided into mainly cell membrane receptor mediated activation and, to a much lesser 
amount, cytoplasmic receptor activation after cell-penetration of the peptides. The vast majority of 
quorum sensing peptides initiate a signalling pathway by activating a membrane-integrated histidine 
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kinase, after which the cytoplasmic response regulator mediates the output response. This cascade 
of reactions is species specific, with homology seen between the different organisms. Different 
pathways can be distinguished, which are given in the Quorumpeps database: AgrC/AgrA and TRAP 
virulence system [42-47], ComD/ComE competence system [48], ComP/ComA and Rap competence 
or sporulation system [49-52], FsrC/FsrA virulence system [53] and NisK/NisR system or analogues 
[54,55]. Furthermore, also the quantitative binding results of the quorum sensing peptides with a 
specific receptor are given in the Quorumpeps database, in which agonistic or antagonistic properties 
can be distinguished. 
 
Links 
This ‘Links’ section allows the user of Quorumpeps to link the reported quorum sensing peptides 
through their binding properties (i.e. receptor) or microbial origin. Peptides that bind with the same 
receptor as the selected peptide are given in the appropriate table, differentiating them based on 
their agonist or antagonist activity. Moreover, peptides that are synthesized by the same species are 
again listed in this information section. 
 
Literature 
All information gathered to develop this Quorumpeps database is summarized in the ‘Literature’ 
section, described by a publication-ID; detailed information is obtained after ID-selection: journal 
name, title, year and author names in the same order as they appear on the publication. Moreover, 
the possibility to download this publication is also available, through their PubMed ID-number and 
related link. 
 
 
4.  CONCLUSIONS 
This database (http://quorumpeps.ugent.be) gives an overview of reported quorum sensing 
signalling peptides and their derivatives, summarizing their chemical and functional properties, 
together with species information. Therefore, this database can function as a useful tool to justify 
peptide choices for evaluating different responses or to study quantitative structure-property 
relationships (QSPR) of these quorum sensing molecules. Quorumpeps will quarterly be updated by 
the authors, ensuring up-to-date information of this interesting and expanding field for other 
researchers.  
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ABSTRACT 
Quorum sensing peptides, i.e. signalling molecules produced by mainly Gram-positive bacteria, can 
exert different effects, ranging from inter-species bacterial virulence to bacterial-host interactions. 
To better comprehend these functional differences, we explored their chemical space, bacterial 
species distribution and receptor-binding properties using multivariate data analyses, with 
information obtained from the Quorumpeps database. The quorum sensing peptides can be 
categorized into three main clusters, which, in turn, can be divided into several subclusters: the 
classification is based on characteristic chemical properties, including peptide size/compactness, 
hydrophilicity/lipophilicity, cyclisation, and the presence of (unnatural) S-containing and aromatic 
amino acids. Most of the bacterial species synthesize peptides located into one cluster. However, 
some Streptococcus, Stapylococcus, Clostridium, Bacillus and Lactobacillus species produce peptides 
that are distributed over more than one cluster, with the quorum sensing peptides of Bacillus subtilis 
even occupying the total peptide space. The AgrC, FsrC and LamC receptors are only activated by 
cyclic (thio)lacton or lactam quorum sensing peptides, while the lipophilic isoprenyl-modified 
peptides solely bind the ComP receptor in Bacillus species. 
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CHAPTER III 
EXPLORING THE CHEMICAL SPACE OF 
QUORUM SENSING PEPTIDES 
Main focus in this chapter: 
 To indicate chemical differences and similarities between quorum sensing peptides. 
 To link the chemical diversity of quorum sensing peptides with bacterial taxonomy and receptor 
interaction. 
 
1. INTRODUCTION 
‘Quorum sensing’ is the phenomenon of cell-to-cell communication between bacteria, leading to a 
regulated gene expression in response to fluctuations in cell density. Gram-positive bacteria thereby 
produce and release oligopeptide molecules as communication tools in order to control e.g. 
virulence, competence, sporulation or biofilm formation [1]. The quorum sensing peptides described 
in the literature is up-to-date stored in the Quorumpeps database (http://quorumpeps.ugent.be), 
giving both (physico)chemical information about the peptides and quorum sensing process-related 
details (e.g. receptor, activity, species) [2].  
Gram-positive bacteria are commensally present in and on the human body, thereby mainly 
occupying the gastrointestinal tract, vagina, skin, mouth and oropharynx of healthy individuals. The 
microbiome composition however differs remarkably between individuals, due to e.g. variations in 
diet, environment, host genetics or early microbial exposure [3]. Streptococcus species are highly 
present in the oral cavity, causing dental caries (predominantly by Streptococcus mutans) [4] or 
forming dental biofilms (Streptococcus mitis) after quorum sensing process activation [5]. 
Lactobacillus species (e.g. Lactobacillus sakei and Lactobacillus plantarum) are mainly found in 
human vaginal specimens, the oral cavity and the gastrointestinal tract [3,6,7]. Lactobacillus species 
in the oral cavity can be linked to dental plaque (biofilm) formation, next to hyposalivation and 
dental caries. Staphylococcus aureus is a natural inhabitant of the nose and skin, but can cause 
various infections in human beings as well, ranging from minor skin infections to severe pneumonia. 
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Many infections caused by S. aureus are not caused by free-living cells, but rather by biofilms, which 
may require quorum sensing mechanisms and the use of signaling peptides [8]. Other Gram-positive 
cocci can cause nosocomial infections (scleral buckles, contact lenses, vascular grafts, orthopedic 
devices, penile prostheses), involving biofilm formation, as well [9]. Escherichia coli, although its 
Gram-negative classification, also produces a signaling peptide (i.e. Extracellular Death Factor, EDF) 
to activate the quorum sensing cascade system [10]. This bacterium is commensally present in the 
human colon but can cause biofilm-involved biliary tract infection, bacterial prostatitis or urinary 
cystitis [9]. Although not yet demonstrated, the presence of quorum sensing peptides in the human 
body is very likely, seen the biological incidence of Gram-positive bacteria and the physiological 
detection of other quorum sensing signaling molecules [11]. 
The quorum sensing process thus can contribute to host virulence due to e.g. biofilm formation after 
intra-species bacterial communication. This communication phenomenon can be extended to 
different bacterial species as well (i.e. inter-species), thereby promoting bacterial virulence: e.g. the 
lantibiotics nisin and subtilin, produced by Lactococcus lactis and Bacillus subtilis respectively and 
originally investigated for their antimicrobial activities, were recently found to act as signaling 
molecules that regulate their own synthesis (i.e. quorum sensing peptides) [12]. The effects of the 
quorum sensing peptides are however not limited to the bacteria themselves (intra- and 
interspecies) [13]: recent investigations from our group have revealed a selective crosstalk 
phenomenon between these peptides (e.g. Phr0662, EDF and PhrG) and mammalian cancer cells, 
thereby influencing tumour cell invasion and angiogenesis [14,15]. Moreover, the Bacillus subtilis 
quorum sensing peptide CSF (Competence and Sporulation Factor) activates p38 mitogen-activated 
protein kinase and protein kinase B in host intestinal epithelial cells as well and induces 
cytoprotective heat shock protein synthesis [16]. 
To better comprehend the effects of the different quorum sensing peptides, as well as to structure 
this group of molecules, we investigated their chemical space using multivariate data analyses, with 
data available from the Quorumpeps database. 
 
 
2. MATERIALS AND METHODS 
Chemical descriptors 
Before calculating the different chemical properties of the Quorumpeps peptides (n = 231, 
September 2014), the geometrical structure of these peptides was optimized using HyperChem 8.0 
(Hypercube, Gainesville, FL, USA). The geometry optimization in vacuo was obtained by the 
molecular mechanics MM+ force field method using the Polak–Ribière conjugate gradient algorithm 
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with a root mean square of 0.1 kcal/(Å×mol) as stop criterion. Afterwards, these Cartesian coordinate 
matrices were used to calculate more than 3000 descriptors, using Dragon 5.5 (Talete, Milan, Italy), 
HyperChem 8.0 and Marvin Beans 5.3.3 (Chemaxon, Budapest, Hungary) software programs. After 
removing the non-discriminative descriptors which were constant for all peptides, the remaining 
descriptors were divided by the peptide’s molecular weight as some descriptors were highly 
correlated with this descriptor. A final 231 x 1468 data-matrix was then obtained. Next, the data 
were transformed by z-scaling to minimize the effects of differences in measurement units and 
variance and to render the data dimensionless [17]. 
 
Multivariate data-analyses 
Multivariate data-analyses were performed using Principal Component Analysis (PCA) and 
Hierarchical Cluster Analysis with SIMCA-P+ 12.0 (Umetrics AB, Umeå, Sweden) and SPSS 21.0 (IBM, 
Illinois, USA) software programs, respectively. To obtain a dendrogram of the chemical clustering, 
average-linkage clustering was performed using the Euclidean distance as the dissimilarity criterion. 
Peptide numbering used in the Quorumpeps database is retained in this study. 
 
 
3.  RESULTS AND DISCUSSION 
Chemical space 
The first two principal components (PCs) of the calculated PCA-model explain already more than 60% 
of the total variability (Table 1). Based on the dendrogram of the Hierarchical Cluster Analysis and the 
score plot of the PCA, the 231 quorum sensing peptides could be categorized into three main 
clusters, which again could be subdivided into several other subclusters (Figure 1). 
 
Table 1. PCA summary describing the eigenvalues of the covariance matrix, the total variance explained (R
2
, 
cumulative) and the predictive ability (Q
2
, cumulative). 
Principal Component Eigenvalue Cumulative R
2
 Cumulative Q
2
 
1 127 0.548 0.542 
2 20.4 0.636 0.626 
3 13.1 0.693 0.678 
4 11.9 0.745 0.728 
5 6.07 0.771 0.744 
6 5.25 0.794 0.763 
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Figure 1. Score plot of the first en second (A) and first and third (B) principal component (PC) from PCA of the 
quorum sensing signalling peptides (1468 descriptors). Three main clusters can be distinguished (blue, green, 
red), each subdivided into smaller groups. 
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The chemical space of the quorum sensing peptides, divided into three main clusters (Figure 1), is 
mainly described by the peptide size and its compactness (1st principal component), given by the 
Radial Distribution Function (RDF) descriptors, Burden eigenvalues (BEH, BEL), Randic shape indices, 
autocorrelation descriptors (ATS, GATS), Weighted Holistic Invariant Molecular (WHIM) descriptors, 
Balaban indices and the lopping centric index. Second, lipophilicity/hydrophilicity determines the 
chemical space as well through the logP values, topological polar surface area (TPSA) descriptors and 
number of H-bond donor (nHDon) and acceptor (nHAcc) atoms, together with connectivity indices 
describing peptide cyclisation and HOMA, AROM and ARR aromaticity descriptors (2nd principal 
component). The 3rd principal component is mainly defined by the S-evaluating descriptors, 
describing e.g. thiol groups, thiolactons or disulfides (Figure 2). 
 
The first cluster (Figure 1, blue) predominantly contains 4 different subclusters, i.e. the lantibiotics, 
the larger linear quorum sensing peptides, the bacteriocin-related peptides and the very large 
peptide Carnobacteriocin B2. The lantibiotics nisin A (ID70), subtilin (ID78), pep5 (ID207) and 
mersacidin (ID24) are classified in one group, together with the anti-HIV peptide Siamycin I (ID74). 
The lantibiotics are heat-stable, post-translationally modified antimicrobial peptides containing 
dehydrated amino acids (dehydroalanine and dehydrobutyrine). This peptide group is also 
characterized by specific polycyclic thioether amino acids (lanthionine and β-methyllanthionine) [18] 
or disulfide bridges, which are responsible for the separate clustering as observed in the loading plots 
by the S-evaluating descriptors (Figure 2). Due to the high difference in peptide size/compactness 
(principal component 1) and lipophilicity (principal component 2), mersacidin and Siamycin I are 
however separated from the other lantibiotics, forming a different subcluster. The linear bacteriocin-
related peptides (IDs 49, 101, 112, 125, 183) form a separate subcluster, despite the identical size as 
the lantibiotics: these peptides are classified separately due to the absence of the characteristic 
lanthionine and β-methyllanthionine amino acids. These bacteriocin-related peptides are in turn 
separated from the medium-sized quorum sensing peptides of the second cluster, again based on 
peptide size and shape. The fourth subcluster contains the very large bacteriocin Carnobacteriocin B2 
(ID56), a representative of the cationic and heat-stable antimicrobial peptides with quorum sensing 
activity, with a molecular weight of more than 4000 Dalton [19,20]. 
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S-evaluating descriptors
 
Figure 2. Loading plots of the first, second and third principal components, with visualisation of the most 
important descriptor groups. (A) PC1 describes the peptide size and compactness (blue), (B) PC2 its 
hydrophilicity/lipophilicity, cyclisation and aromaticity (green), and (C) PC3 the presence of sulphur atoms or 
sulphur-containing groups (red). 
 
The second cluster (Figure 1, green) contains different subclusters as well: the medium-sized cyclised 
signalling peptides, including Gelatinase Biosynthesis-Activating Pheromone (GBAP, ID97) and its 
derivatives, the isoprenyl-modified peptides and the medium-sized linear peptides. The peptides can 
A 
B 
C 
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be cyclised between the carboxyl end or COOH-side chain (D and E amino acids) of the peptide and 
the side chain of cysteine or serine, or its amino terminus, resulting in a thiolacton, a lacton or a 
lactam moiety; the ring is typically composed of 5-9 amino acids. The post-translationally modified 
quorum sensing peptides, containing a geranyl or farnesyl molecule on a tryptophan amino acid, 
form a tricyclic structure as well by this modification (i.e. a newly formed five-membered ring, next to 
the two tryptophan rings). Both groups of cyclic peptides are chemically separated from each other 
based on the difference in lipophilicity (logP values) and (valence and solvation) connectivity indices. 
RNAIII-inhibiting peptide and its medium-sized derivatives belong to the linear peptides of this 
cluster. However, not all of the RNAIII-inhibiting peptide-derivatives are grouped into the same 
(second) cluster: 2 smaller derived peptides with RNAIII-inhibiting biological properties, i.e. IDs 156 
and 157, are grouped in the third cluster of compact quorum sensing peptides.  
This third cluster (Figure 1, red) contains the smaller, compact peptides, again subdivided into the 
small thiolacton or lactam cyclised quorum sensing peptides and the linear peptides, including the 
Extracellular Death Factor (EDF, ID19) and its derivatives. The cyclised peptides thus clearly occupy a 
distinct portion of the quorum sensing peptide space as they are spread over both the second and 
third cluster, according to their size distribution. 
Representative quorum sensing peptides from each subcluster are listed in Figure 3, together with 
some representative key descriptor values. 
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Peptide sequence
VNYGNGVSCSKTKCSVNWGQAFQERYTAGINSFVSGVASGAGSIGRRP
I(Dhb)AI(Dha)LA(Abu)PGAK(Abu)GALMGANMK(Abu)A(Abu)AHASIHV(Dha)K
A(Abu)F(Abu)LPGGGGVA(Abu)L(Abu)(Dha)EAI
GWWEELLHETILSKFKITKALELPIQL
DLRNIFLKIKFKKK
FW(Geranyl)E
DSACVFGA (thiolacton bridge)
ALILTLVS
NNWNN
CVGIW (thiolacton bridge)
ID
56
70
24
112
31
87
36
17
19
22
Typical descriptor values (z-score)
cLogP = -32.59 (-1.13)
RDF095m = 515.51 (1.65)
T(O..S) = 5975 (6.62)
X5 = 44.17 (-0.21)
T(O..S) = 1111 (1.89)     X5 = 25.51 (0.35)
cLogP = -8.44 (-0.53)
T(0..S) = 0 (-0.56)
RDF095m = 353.76 (1.85) 
T(O..S) = 0 (-0.56) cLogP = -2.91 (0.41)
X5 = 22.75 (-0.53)
T(O..S) = 0 (-0.56)         cLogP = 4.36 (3.13)
X5 = 10.84 (2.88)
T(O..S) =  86 (-0.10)       cLogP = -3.84 (-0.68)
X5 = 9.20 (-0.85)
T(O..S) =  0 (-0.56)         cLogP = 0.26 (1.02)
X5 = 9.51 (-1.39) RDF095m = 33.86 (-0.58)
T(O..S) =  0 (-0.56) RDF095m = 33.45 (-0.24)
X5 = 9.11 (0.22)
T(O..S) =  24 (-0.39)       RDF095m = 13.30 (-1.19)
X5 = 8.10 (0.73)
Cluster Principal Component
S S S
S
S
S S S
S
 
Figure 3. Overview of representative quorum sensing peptides from different (sub)clusters. The values of some 
representative key descriptors responsible for the clustering are given on the right. Coloring is used as 
indicated in Figure 1 (cluster) and Figure 2 (principal component). 
 
 
Species distribution 
Bacillus species, i.e. B. anthracis, B. cereus, B. halodurans, B. mojavensis, B. pumilus, B. 
stearothermophilus, B. subtilis and B. thuringiensis, synthesize a diverse collection of peptides, 
ranging from small and medium-sized linear peptides, over isoprenyl-modified structures, to large 
complex lantibiotic molecules (Figure 4). The Bacillus species are solely responsible for the 
production of the geranyl- or farnesyl-containing peptides. Next to these lipophilic compounds, 
(small) hydrophilic peptides can be synthesized as well, as observed in the score plot by the 2nd 
principal component: both directions of the axis are ‘filled’ with quorum sensing peptides. The 
(thio)lacton or lactam cyclised peptides are synthesized by either Lactobacillus plantarum, 
Staphylococci, Clostridium species or Enterococcus faecalis, of which the latter is the only one 
responsible for the production of a 9-membered cyclic structure (i.e. GBAP). Next to these (small or 
medium-sized) cyclised structures, Enterococcus faecalis and Clostridium acetobutylicum synthesize 
medium-sized linear peptides as well, while this is not observed for C. sporogenes or C. botulinum. 
The same is true for Lactobacillus plantarum: both cyclised and linear peptides are produced by the 
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bacteria, with the linear bacteriocin-related peptides (IDs 49 and 125, first cluster) being larger 
compared to the cyclised peptide (ID22, third cluster). The other Lactobacillus species, i.e. 
Lactobacillus sakei, only synthesizes these large linear peptides. Next to the medium-sized cyclised 
peptides of the second cluster, Staphyloccus areus and Staphylococcus epidermidis are the only 
Staphylococcus species that make a medium-sized linear peptide for activation of the quorum 
sensing pathway, namely RNAIII-inhibiting peptide. Moreover, S. epidermidis produces a (large) 
lantibiotic peptide as well (first cluster). The Carnobacterium species that are included in the 
Quorumpeps database only produce large linear peptides, including the largest peptide of the 
database, Carnobacteriocin B2. The larger linear quorum sensing peptides are mainly synthesized by 
Streptococcus species, with a few medium-sized linear peptides produced by S. mutans and S. 
thermophilus. 
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Figure 4. Distribution of quorum sensing peptides, according to the species origin.  
The score plot of the Bacillus peptides indicates a wide spread of the peptides over the three clusters 
(Derived: chemically modified quorum sensing peptides). 
 
 
The phylogenetic tree of Firmicutes [21,22], i.e. the most abundant phylum in the Quorumpeps 
database, distinguishes 4 main groups: (1) Thermoanaerobacterium and Clostridium species; (2) 
Phytoplasma, Mycoplasma and Ureaplasma species; (3) Lactobacillus, Enterococcus, Lactococcus, 
Carnobacterium and Streptococcus species; and (4) Staphylococcus, Listeria, and Bacillus species. In 
contrast to group 1, 3 and 4, there are no reported Quorumpeps peptides produced by Phytoplasma, 
Mycoplasma or Ureaplasma species. The second and third chemical clusters of quorum sensing 
peptides contain peptides that are synthesized by all three Firmicutes groups. The first cluster 
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however does not contain peptides from Clostridium species and is therefore not completely covered 
by the Firmicutes species. 
Moreover, some bacterial (Firmicutes) species are not (yet) reported to synthesize quorum sensing 
peptides while others do so, despite the phylogenetic relationship between both species 
(www.patricbrc.org). For example, Lactobacillus reuteri, a commensal bacterium of the human gut 
[23], is closely related to Lactobacillus plantarum, which is already listed in the Quorumpeps 
database. However, no quorum sensing peptides have until now been reported for the former 
bacterial species. This is the case for C. sporogenes and C. botulinum as well: while only C. 
acetobutylicum was found to synthesize linear peptides, it is very likely that the other Clostridium 
species synthesize these peptides too, seen the strong phylogenetic relationship between these 
Clostridium species. We therefore believe research concerning the quorum sensing system is far from 
being completed, with several signaling peptides still to be elucidated which can then strengthen or 
complete the obtained clustering results. 
 
While the meaning of the term ‘Quorum sensing’ has evolved over time, with still several 
interpretations possible, there is consensus that the increased production of the quorum sensing 
signals by unicellular organisms should occur during specific stages in response to certain conditions. 
The extracellular accumulation of the quorum sensing signal is recognized by a specific receptor, 
leading to i.a. their own synthesis [12,24]. Although not (yet) considered sensu stricto to be quorum 
sensing peptides, some peptides originating from proteins (cryptic peptides) have similar structures 
as their quorum sensing counterparts. For example, BLAST [25] searches of ID76, an analogue of the 
quorum sensing peptide produced by Enterococcus faecium, revealed that part of the amino acid 
sequence is synthesized by i.a. Streptococcus agalactiae (located at position 269874 to 269918 of the 
complete genome). These protein-derived peptides thus can have quorum sensing-related effects 
and should therefore be further investigated. 
 
Microbial receptor-binding properties 
The AgrC receptors are only activated by the (thio)lacton or lactam cyclised peptides, containing 
maximum 6 amino acids in their ring structure. The size of the peptides is not crucial: both medium-
sized and small cyclic peptides are found to bind with these receptor subtypes; yet, no large cyclic 
peptides were investigated for their AgrC receptor-binding potential. The comparable FsrC receptor 
is activated by 9-membered (thio)lacton or lactam cyclic peptides, with again no linear binding 
peptides included in the Quorumpeps database. Here, medium-sized as well as large (ID74) quorum 
sensing peptides were found to bind the FsrC receptor. Only one cyclic peptide, i.e. LamD (ID22), 
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interacts with the LamC receptor of Lactobacillus plantarum. The lipophilic peptides, containing a 
geranyl or farnesyl moiety on a tryptophan amino acid, bind with the ComP receptor; the interaction 
with other peptides is apparently not yet reported in the literature. The Rap receptor is mainly 
activated by short linear peptides of Bacillus species, next to the medium-sized linear peptides of 
Clostridium acetobutylicum. 
 
 
4.  CONCLUSIONS 
The quorum sensing peptides (n = 231; Quorumpeps database) can chemically be divided into three 
main clusters, which again can be categorized into several subclusters. The clustering is caused by 
differences in peptide size and compactness, lipophilicity/hydrophilicity, cyclisation and the presence 
of sulphur atoms and aromatic amino acids. While most of the Gram-positive bacteria synthesize 
chemically similar peptides, i.e. peptides that are grouped into the same cluster, the quorum sensing 
peptides produced by Bacillus subtilis are chemically very diverse, occupying the total space of 
quorum sensing peptides. 
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ABSTRACT 
Peptides are becoming an important class of molecules in the pharmaceutical field. Closely related 
peptide-impurities in peptides are inherent to the synthesis approach and have demonstrated to 
potentially mask biomedical experimental results. Quorum sensing peptides are attracting high 
interest in R&D and therefore a representative set of quorum sensing peptides, with a requested 
purity of at least 95.0%, was evaluated for their purity and nature of related impurities. In-house 
quality control (QC) revealed a large discrepancy between the purity levels as stated on the supplier’s 
certificate of analysis and our QC results. By using our QC analysis flowchart, we demonstrated that 
only 44.0% of the peptides met the required purity. The main compound of one sample was even 
found to have a different structure compared to the desired peptide. We also showed that the 
majority of the related impurities were lacking amino acid(s) in the desired peptide sequence. Relying 
on the certificates of analysis as provided by the supplier might have serious consequences for 
peptide research and peptide-researchers should implement and maintain a thorough in-house QC. 
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CHAPTER IV 
QUALITY EVALUATION OF SYNTHETIC 
QUORUM SENSING PEPTIDES USED IN R&D 
Main focus in this chapter: 
 To demonstrate the need for a thorough quality control of synthetic peptides. 
 To give an overview of expected related impurities in peptides. 
 
1. INTRODUCTION 
Peptides are becoming an important class of molecules in the biomedical and pharmaceutical field 
owing to their high affinity, strong selectivity for their targets and low toxicity [1]. Despite potential 
limitations such as overall low oral bio-availability, low metabolic resistance, potential 
immunogenicity, poor membrane permeability and financial aspects, several peptide drugs have 
entered the market [2,3]. The promising future of peptide therapeutics is further highlighted by the 
number of peptides in clinical and preclinical phases [4]. In 2012, approximately 200 peptides 
entered the clinical phase, while another 400 were at advanced preclinical stages [4-6]. 
Quorum sensing peptides are a group of peptides currently attracting high interest. Quorum sensing, 
the process of cell-to-cell communication between bacteria, has been the subject of a great number 
of scientific research papers [7-9]. Three main groups of quorum sensing molecules can be 
distinguished: N-acylhomoserine lactone derivatives (AHL or auto-inducer-1), quorum sensing 
peptides and boron-furan derivatives (auto-inducer-2). The quorum sensing peptides, mainly found 
in Gram-positive bacteria, show a large structural diversity: short, linear fragments as well as cyclic 
(thiolacton) derivatives, with or without post-translational isoprenyl modifications, are observed [10]. 
These peptides bind to (i) bacterial membrane associated receptors, or (ii) cytoplasmatic receptors, 
after which the transcription of the target genes is activated. Interfering with this bacterial quorum 
sensing pathway might open interesting application perspectives. 
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Chemical peptide synthesis for medicinal purposes has become economically viable [11]. The 
possibility to produce small, medium (5 to 20 residues) to large (20 to 50 residues) peptides evolved 
dramatically, hereby frequently outperforming the biotechnological approaches as they are known to 
date [6]. In 1965, Merrifield cleared the way for Solid-Phase Peptide Synthesis (SPPS), thus 
introducing and facilitating a totally new concept in peptide synthesis [12]: a peptidic chain, fixed to a 
solid support, is created by the consecutive addition of the appropriate amino acids. The reaction can 
be automated and possible solubilization-issues are avoided due to the fixation of the peptide to the 
solid matrix [13]. During SPPS, different side-reactions can occur, resulting in several types of peptide 
impurities [14]: e.g. (i) diketopiperazine structures [15,16], (ii) aspartimide residues [17-19], (iii) 
cysteine racemization [16], (iv) diastereoisomeric products [20,21], (v) dimers [22], (vi) acid 
precursors and protected sequences [20], (vii) oxidation and reduction of amino acids [19,23], (viii) 
amino acid deletions [15,23-26], (ix) amino acid insertions [23,24], (x) products of side chain 
reactivity and (xi) amino acid modifications during cleavage [16,19,23,24,26-30]. Thus, the crude 
peptides obtained from SPPS mostly will contain many by-products. These impurities, if present even 
after purification, have to be quantified and characterized to meet pharmaceutical regulatory 
requirements, but they need to be under control as well during the unregulated biomedical research 
and discovery phases [31,32]. Due to budgetary constraints, peptides used in research are often 
purchased at undefined or low purity levels, e.g. 70.0% [31]. Generally, the peptide purity used for 
biomedical research and discovery purposes ranges from as low as 50.0% to more than 95.0% 
[22,26]. However, closely related impurities of the target peptide may possess stronger binding 
affinities compared to the native peptide [26], thus potentially causing erroneous conclusions. 
Investigations by de Beukelaar et al. indicated different immune responses of a protein-spanning 
peptide pool of 70.0% pure peptides due to the impurities [33]. False-positive results in a HIV-vaccine 
trial were also ascribed to impurities in the peptide-mixtures [34]. Zhang et al. were unable to 
reproduce their initial obestatin results in vitro, possibly due to impurities present in the initially 
examined peptide [35]. Additionally, Verbeken et al. observed different biofunctional responses in a 
set of tissue-organ bath experiments caused by impurities of the examined peptides [31]. Impurities 
are thus able to potentially mask biomedical experimental outcomes and may cause false negative or 
positive results.  
 
Quorum sensing peptides are currently being actively investigated, i.a. for their possible role in the 
crosstalk between the microbiome and its host [36,37]. Therefore, a thorough in-house QC analysis 
of a selected set of quorum sensing peptides will be conducted, followed by identification of the 
observed impurities. These data not only demonstrate the need for routine QC in peptide research, 
but also can help in building a global overview of expected related impurities in peptides. 
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2. MATERIALS AND METHODS 
Chemicals and reagents 
A set of 98 representative peptides was selected from the Quorumpeps database [38]. Linear peptide 
synthesis was conducted by an international supplier, while another supplier synthesized the cyclic 
peptides, both by means of Fmoc-SPPS. A minimal purity of 95.0% was requested at order. The 
sequences of the 98 peptides are provided in Table 1. Acetonitrile HPLC-MS and UPLC-MS grade were 
purchased from Fisher Scientific (Aalst, Belgium). Formic acid (LC-MS grade) and DMSO (p.a. ≥ 99.9%) 
were obtained from Sigma-Aldrich (Diegem, Belgium). Trifluoroacetic acid (TFA), NaH2PO4· H20 and 
Na2HPO4 were purchased from Merck (Overijse, Belgium). Water was purified using an Arium 611 
purification system (Sartorius, Gottingen, Germany) yielding ≥ 18.2 MΩ.cm quality water. Eppendorf 
Protein LoBind 2.0 and 1.5 mL tubes were purchased from Eppendorf (Nijmegen, the Netherlands). 
UPLC/HPLC vials and inserts were purchased from Waters (Milford, MA, USA). The Vydac Everest C18 
(250 mm × 4.6 mm, 5 µm) column and Alltech Prevail Organic Acid column (250 mm × 4.6 mm, 5 µm), 
both protected with guard columns, were obtained from Grace (Deerfield, IL, USA). The Acquity UPLC 
BEH 300 C18 column (100 mm × 2.1 mm, 1.7 µm) with guard column was purchased from Waters 
(Milford, MA, USA). 
 
Sample preparation 
0.5 – 1 mg of each lyophilized, linear peptide was dissolved in water or a mixture of water and 
DMSO, depending on the calculated logP values and the solubility in water, to obtain a concentration 
of approximately 1.0 mg/mL (Table 1). The quantity of DMSO used was determined experimentally, 
by adding DMSO stepwise to the peptide-water suspension until no more precipitate was observed. 
The dissolved peptides were stored at -35°C. The cyclic peptides (i.e. ID5, 22, 32, 40, 71, 97, 107, 148 
and 218) were dissolved in DMSO-water (50/50, V/V) to obtain a concentration of approximately 
0.5 mg/mL. 
 
HPLC and UPLC 
QC purity profiling 
Three LC systems were consecutively applied in the analysis. To avoid carry-over peaks, 50% 
acetonitrile in water was always used as needle wash.  
Each peptide was first analysed with the Acquity UPLC BEH300 C18 column. Sample compartment was 
kept at 5°C (± 2°C) and column maintained at 30°C (± 2°C). Injection volume was set at 2 µL for the 
linear and 5 µL for the cyclic peptides. Mobile phases consisted of 0.1% (m/V) formic acid in water (A) 
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and 0.1% (m/V) formic acid in acetonitrile (B). A general linear gradient was applied running from 
95% A to 20% A during 22 min followed by returning to initial condition and re-equilibration with a 
flow rate set at 0.5 mL/min. Analysis was conducted using a Waters Acquity UPLC Class 
BioQuaternary Solvent Manager, a Waters Acquity Bio-sample Manager, combined with a Flow 
Through Needle and a Waters Acquity UPLC PDA (500 nL – 10 mm path length analytical flow cell) 
detector (Waters, Milford, MA, USA). Empower 2 software was employed for data acquisition and 
analysis. Peptides and related impurities were quantified by area-normalization at 210 nm, using a 
sampling rate of 20 points/s and a detector time constant of 0.1 s. A reporting threshold (i.e. 0.1% of 
main peak area under the curve in the UV chromatogram) and identification threshold (i.e. 0.5% of 
main peak area under the curve in the UV chromatogram) as stated in the European Pharmacopoeia 
were applied [39]. Solvent and system peaks, observed in the blank (i.e. the solvent used to dissolve 
a certain peptide, Table 1), were excluded.  
If no retention of the peptides was observed using the Acquity UPLC BEH300 C18 column, peptides 
were analysed with the Vydac Everest C18 column on a Waters Alliance 2695 HPLC apparatus 
equipped with a Waters 2695 Separations Module, combined with a Flow Through Needle, and a 
Waters 2996 Photodiode Array Detector with Empower 2 software for data acquisition. Mobile 
phases consisted of 0.1% (m/V) TFA in water (A) and 0.1% (m/V) TFA in acetonitrile (B). A general 
linear gradient was applied running from 95% A to 20% A during 30 min followed by returning to 
initial condition and re-equilibration with a flow rate set at 1.0 mL/min. For peptide ID191, a slightly 
modified linear gradient was applied, i.e. running from 98% A to 80% A during 10 min followed by 
returning to initial conditions and re-equilibration with a flow rate set at 1.0 mL/min. Sample 
compartment was kept at 5°C (± 2°C) and column maintained at 30°C (± 2°C); 20 µL of the samples 
dissolved in suitable solvent composition were injected. UV detection was performed at 215 nm, 
using a sample rate of 1.0 point/s combined with a detector time constant of 0.2 s. The flow rate was 
set to 1.0 mL/min. The peptide purity was quantified through normalization, by calculating the area 
(UV) of the most abundant peak as a percentage of total peak areas. 
Finally, peptides ID18, 51, and 192 were analysed using a Grace Alltech Prevail Organic Acid column 
(250 mm × 4.6 mm, 5 µm), using the same Waters Alliance 2695 HPLC equipment as used with the 
Vydac column. Mobile phases consisted of 10 mM phosphate buffer (pH 7) (A) and acetonitrile (B). A 
general linear gradient was applied running from 95% A to 60% A during 20 min followed by 
returning to initial condition and re-equilibration with a flow rate set at 1.0 mL/min. Sample 
compartment was kept at 5°C (± 2°C) and column maintained at 30°C (± 2°C). 20 µL of the samples 
dissolved in suitable solvent composition were injected. UV detection was performed at 215 nm, 
using a sample rate of 1.0 point/s combined with a detector time constant of 0.2 s. The peptide 
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purity was quantified through normalization, by calculating the area (UV) of the most abundant peak 
as a percentage of total peak areas.  
 
Identification of main LC peak and related impurities 
Mass spectroscopic characterization was performed with a Thermo HPLC system consisting of a 
Waters 2487 dual λ absorbance UV/VIS-detector (UV at 215 nm), a Finnigan LCQ ion trap mass 
spectrometer with electrospray ionization (ESI) and Xcalibur software version 2.0 for data acquisition. 
The LC-MS equipment is yearly qualified using a tune solution and qualification solution according to 
the EDQM guideline [40]. The tune solution consists of 100 µL 1.0 mg/mL caffeine (Sigma-Aldrich, 
Diegem, Belgium) in methanol, 15 µL 5 nmol/µL MRFA (Met-Arg-Phe-Ala) (Research Plus inc., Atlantic 
City, NJ, USA) in 50/50 methanol/water (V/V), 2.5 mL 0.1% (V/V) Ultramark 1621 (Alfa Aesar, 
Karlsruhe, Germany) in acetonitrile, 50 µL glacial acetic acid (Riedel de Haen, Diegem, Belgium) and 
2.34 mL of 50/50 methanol/water (V/V). The EDQM qualification solution consists of a 10.0 µg/mL 
reserpine (Flandria, Ghent, Belgium) solution in acidified methanol (i.e. 1% acetic acid in methanol 
(V/V)). The reserpine solution is infused in the mass spectrometer with a flow rate of 3 µL/min with a 
collision energy of 35.00 eV. The m/z value of 609.4 is selected as parent ion and the m/z range for 
the daughter ions is set to m/z 165.0-800.0. The obtained m/z values are compared to the 
acceptance criteria as set by the EDQM.  
For the analysis of the quorum sensing peptides, column temperature was set at 30°C (± 2°C) and 
samples were kept at room temperature. 20 µL of aqueous peptide solution was injected into the 
HPLC system and a flow rate of 1.0 mL/min was applied. All 15 selected quorum sensing peptides 
were analysed using the Vydac Everest C18 column (250 mm × 4.6 mm, 5 µm). Mobile phases 
consisted of 0.1% (m/V) formic acid in water (A) and 0.1% (m/V) formic acid in acetonitrile (B) with a 
flow rate of 1.00 mL/min. An isocratic period consisting of 95% A during 5 min was maintained, 
followed by a linear gradient running from 95% A to 40% A in 60 min and returning to the initial 
conditions and re-equilibration afterwards. The ion transfer capillary was operated at 250°C, nitrogen 
was used as sheath gas (80 arbitrary units corresponding to 1.2 L/min) and helium as auxiliary gas (20 
arbitrary units corresponding to 0.2 L/min). The spray voltage was 4.50 kV and the capillary voltage 
was 46 V. MS1 (100 – 2000 m/z) and MS2 (data dependent, i.e. highest abundant MS1 m/z value for 
MS²) data were obtained. All m/z values possessing an abundance higher than 25% in the according 
MS1 spectrum were subject to identification via their respective MS² fragmentation pattern. 
Theoretical MS² fragmentation patterns of the peptides were calculated in silico with 
ProteinProspector [41] (University of California, San Francisco, CA, USA). The proposed sequences of 
the related impurities was confirmed using the by ProteinProspector generated MS2 spectra. The 
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nomenclature originally proposed by Roepstorff and Fohlman is used to annotate MS² fragments 
[42]. 
 
 
3.  RESULTS AND DISCUSSION 
Quorum sensing peptide analysis flow chart 
To determine the purity of the QS peptides, we developed a UPLC/HPLC-analysis flow chart 
(Figure 1). Each peptide was analysed first with the Acquity UPLC BEH300 C18 column, using the 
method described above. A C18 column with a 0.1% (m/V) formic acid in water/acetonitrile gradient is 
widely used for peptide analysis and was therefore selected as the initial method of analysis. If no 
retention of the peptides was observed, the peptides were analysed with the Vydac Everest C18 
column with TFA as ion-pairing reagent, which is known to have a narrowing effect on peak width 
and an increased retention. Finally, if no retention was observed with the aforementioned columns, 
the Prevail Organic Acid column (mobile phase of pH 7) with a 10 mM phosphate buffered 
water/acetonitrile gradient was used for peptide quality control. Previous experience indicated that 
peptides which had no retention using standard C18 peptide columns might have appropriate 
retention using a polar-embedded column for highly hydrophilic compounds, like the Prevail Organic 
Acid column. 
 
Acquity UPLC 
BEH300 C18
0.1% formic acid in 
water/acetonitrile
gradient
Grace Alltech Prevail 
Organic Acid column
10 mM phosphate 
buffer/acetonitrile 
gradient
Vydac Everest C18
column
0.1% trifluoroacetic
acid in 
water/acetonitrile
gradient
Quality control of 
peptide
Baseline separation with solvent peaks?
1.
2.
3.
 
Figure 1. (U)HPLC column flow chart for quorum sensing peptide analysis. 
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QC purity assay 
Despite a requested purity of at least 95.0%, only 43 out of 98 peptides met these purity 
specifications (Figure 2). However, all 98 peptides were accompanied by a certificate of analysis 
stating at least 95.0% purity. Our QC analysis upon arrival showed purity levels sometimes far below 
the demanded purity level (Table 1).  
 
 
 
Figure 2. Purity levels of quorum sensing peptides determined by in-house QC. 
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Table 1. Peptide information. 
Quorumpeps 
ID 
Sequence 
Molecular 
weight 
Solvent Column
1 
Purity
2
 (%) 
2 FNTIPSY 839.95 Water C18-FA 83.31 
5 Ac-CGSLF, thiolacton linkage between C1 and F5 549.72 Water + 50% DMSO C18-FA 88.30 
7 FNTWPSY 913.00 Water C18-FA 98.46 
10 ADLPFEF 837.93 Water C18-FA 99.20 
11 AGTKPQGKPASNLVECVFSLFKKCN 2667.14 Water C18-FA 72.93 
13 AIFILAS 733.91 Water + 58% DMSO C18-FA 97.82 
14 AITLIFI 790.01 Water + 60% DMSO C18-FA 72.48 
15 AKDEH 598.61 Water C18-TFA 69.26 
16 AKTVQ 545.64 Water C18-TFA 96.20 
17 ALILTLVS 829.05 Water + 60% DMSO C18-FA 94.43 
18 ARNQT 588.62 Water Organic Acid 92.33 
19 NNWNN 660.64 Water C18-TFA 92.66 
22 CVGIW, thiolacton linkage between C1 and W5 558.78 Water + 50% DMSO C18-FA 60.39 
24 CTFTLPGGGGVCTLTSECIC 1962.3 Water + 1% DMSO C18-FA 12.21 
25 CVFSLFKKCN 1188.47 Water C18-FA 47.92 
28 DIRHRINNSIWRDIFLKRK 2480.91 Water C18-FA 93.68 
30 DLRGVPNPWGWIFGR 1770.03 Water C18-FA 91.62 
31 DLRNIFLKIKFKKK 1791.26 Water C18-FA 76.74 
32 DMCNGYF, thiolacton linkage between C3 and F7 831.04 Water + 50% DMSO C18-FA 58.05 
34 DRVGA 516.55 Water C18-TFA 98.30 
40 DSVCASYF, thiolacton linkage between C4 and F8 873.06 Water + 50% DMSO C18-FA 31.61 
42 DWRFLNSIRDLIFPKRK 2204.61 Water C18-FA 97.86 
44 EKMIG 576.71 Water C18-FA 99.41 
45 EMRISRIILDFLFLRKK 2178.71 Water C18-FA 81.91 
46 EMRKSNNNFFHFLRRI 2109.44 Water C18-FA 96.43 
47 EMRLPKILRDFIFPRKK 2187.72 Water C18-FA 98.46 
49 EQLSFTSIGILQLLTIGTRSCWFFYCRY 3346.92 Water + 17% DMSO C18-FA 52.58 
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Table 1. Peptide information (continued). 
Quorumpeps 
ID 
Sequence 
Molecular 
weight 
Solvent Column
1 
Purity
2
 (%)
 
50 ERGMT 592.67 Water C18-TFA 98.76 
51 ERNNT 632.63 Water Organic Acid 98.24 
52 ERPVG 556.62 Water C18-TFA 99.75 
53 ESRLPKILLDFLFLRKK 2116.62 Water C18-FA 65.11 
54 ESRLPKIRFDFIFPRKK 2177.62 Water C18-FA 99.30 
55 ESRVSRIILDFLFQRKK 2135.54 Water C18-FA 96.90 
56 VNYGNGVSCSKTKCSVNWGQAFQERYTAGINSFVSGVASGAGSIGRRP 4969.46 Water C18-FA 33.57 
58 DSRIRMGFDFSKLFGK 1904.22 Water C18-FA 95.72 
62 ESRISDILLDFLFQRKK 2108.47 Water C18-FA 99.27 
71 QNCPNIFGQWM, lacton linkage between S3 and M11 1319.70 Water + 50% DMSO C18-FA 77.64 
75 SINSQIGKATSNLVECVFSLFKKCN 2731.2 Water C18-FA 30.03 
76 SNLVECVFSLFKKCN 1731.06 Water C18-FA 80.63 
81 FNTIPKY 881.04 Water C18-FA 99.29 
82 NTIPKY 733.87 Water C18-FA 69.22 
84 FFNTCPSY 978.09 Water C18-FA 96.54 
85 FNTCPSY 830.91 Water C18-FA 92.98 
92 FHWWQTSPAHFS 1530.66 Water C18-FA 99.54 
93 FLVMFLSG 913.14 Water + 33% DMSO C18-FA 91.31 
97 QNSPNIFGQWM, lacton linkage between S3 and M11 1303.63 Water + 50% DMSO C18-FA 43.95 
99 GKAEF 550.61 Water C18-FA 99.33 
100 GKATSSISKCVFSFFKKC 1968.36 Water + 33% DMSO C18-FA 28.65 
101 GLWEDILYSLNIIKHNNTKGLHHPIQL 3167.67 Water C18-FA 96.92 
102 GLWEDLLYNINRYAHYIT 2254.53 Water + 33% DMSO C18-FA 97.98 
103 GNWNN 603.59 Water C18-FA 97.70 
105 GSQKGVYASQRSFVPSWFRKIFRN 2846.25 Water C18-FA 99.31 
107 GVNACSSLF, thiolacton linkage between C5 and F9 879.13 Water + 50% DMSO C18-FA 39.15 
111 GWWEDFLYRFNIIEQKNTKGFYQPIQL 3434.91 Water + 50% DMSO C18-FA 89.72 
121 ILSGAPCIPW 1056.29 Water C18-FA 77.04 
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Table 1. Peptide information (continued). 
Quorumpeps 
ID 
Sequence 
Molecular 
weight 
Solvent Column
1 
Purity
2
 (%)
 
123 IRFVT 634.78 Water C18-FA 99.53 
125 KSSAYSLQMGATAIKQVKKLFKKWGW 2985.59 Water C18-FA 66.39 
132 LFSLVLAG 819.01 Water + 33% DMSO C18-FA 96.92 
133 LFVVTLVG 847.06 Water + 60% DMSO C18-FA 97.74 
134 LPFEF 651.76 Water + 50% DMSO C18-FA 17.17 
135 LPFEH 641.72 Water C18-FA 94.23 
137 LVTLVFV 790.01 Water + 50% DMSO C18-FA 84.02 
138 MAGNSSNFIHKIKQIFTHR 2229.59 Water + 17% DMSO C18-FA 81.90 
140 MKAEH 614.72 Water C18-FA 66.91 
143 MPFEF 669.79 Water C18-FA 86.24 
146 NEVPFEF 880.95 Water C18-FA 99.90 
147 NGWNN 603.59 Water C18-FA 94.53 
148 YSTCDFIM, thiolacton linkage between C4 and M8 961.25 Water + 50% DMSO C18-FA 44.40 
151 NNGNN 531.48 Water C18-TFA 96.79 
152 NNNWNNN 888.85 Water C18-FA 98.42 
153 NNWGN 603.59 Water C18-FA 99.10 
154 NNWNG 603.59 Water C18-FA 99.33 
155 NWN 432.44 Water C18-FA 98.40 
156 FNTIP 589.69 Water C18-FA 99.27 
157 FNTWP 662.75 Water C18-FA 99.23 
160 QKGMY 625.74 Water C18-FA 99.04 
162 QRGMI 603.74 Water C18-FA 94.36 
164 SDLPFEH 843.89 Water C18-FA 91.37 
165 SDMPFEF 871.96 Water C18-FA 99.44 
166 SGSLSTFFLLFNRSFTQALGK 2321.66 Water C18-FA 92.99 
174 SGSLSTFFRLFNRSFTQALG 2236.52 Water C18-FA 97.41 
176 SGSLSTFFRLFNRSFTQALGK 2364.69 Water C18-FA 98.96 
177 SGSLSTFFRLFNRSFTQALGKIR 2634.04 Water C18-FA 55.68 
180 SGSLSTFFRLFNRSQTQALGK 2345.65 Water C18-FA 99.06 
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Table 1. Peptide information (continued). 
Quorumpeps 
ID 
Sequence 
Molecular 
weight 
Solvent Column
1 
Purity
2
 (%)
 
184 SIFTLVA 749.90 Water + 33% DMSO C18-FA 93.17 
186 SKDYN 625.64 Water C18-TFA 92.88 
188 SLSTFFRLFNFSFTQALG 2083.37 Water + 33% DMSO C18-FA 85.61 
191 SRKAT 561.64 Water C18-TFA 78.31 
192 SRNAT 547.57 Water Organic Acid 81.74 
193 SRNVT 575.62 Water C18-TFA 81.49 
206 SYPGWSW 881.94 Water C18-FA 99.45 
207 TAGPAIRASVKQCQKTLKATRLFTVSCKGKNGCK 3595.31 Water C18-FA 32.42 
208 TNRNYGKPNKDIGTCIWSGFRHC 2668.01 Water C18-FA 89.19 
210 VAVLVLGA 740.94 Water + 33% DMSO C18-FA 92.98 
212 VPFEF 637.73 Water C18-FA 97.65 
214 WPFAHWPWQYPR 1670.89 Water C18-FA 58.94 
215 FNTWPKY 954.10 Water C18-FA 95.52 
218 YNPCSNYL, thiolacton linkage between C4 and L8 955.18 Water + 50% DMSO C18-FA 16.87 
1
: C18-FA: Acquity UPLC BEH 300 C18 column (100 mm × 2.1 mm, 1.7 µm). 
   C18-TFA: Vydac Everest C18 column (250 mm × 4.6 mm, 5 µm). 
   Organic Acid: Grace Alltech Prevail Organic Acid column (250 mm × 4.6 mm, 5 µm). 
2
: Purity assigned based on UV chromatogram with internal normalization to the most abundant peak. 
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In Figure 3, the chromatogram of ID76, as provided by the supplier on the certificate of analysis 
versus our QC analysis is given. The mobile phases of the supplier consisted of 0.1% (m/V) TFA in 
acetonitrile (A) and 0.1% (m/V) TFA in water (B). A general linear gradient was applied running from 
22% A to 47% A during 22 min with a Kromasil C18-5 (250 mm × 4.6 mm, 5 µm) column with 
quantification at 220 nm. The peptide was analysed in our laboratory with the Acquity UPLC BEH300 
C18 column, using the operational details as described above.   
 
 
Figure 3. The in-house QC control shows a distinct difference in peptide purity. (A) Chromatogram of supplier; 
Kromasil C18-5 (250 mm × 4.6 mm, 5 µm), quantification at 220 nm; (B) chromatogram of in-house QC; Vydac 
Everest C18 column (250 mm × 4.6 mm, 5 µm), quantification at 210 nm. 
 
The method applied by the supplier clearly lacked selectivity to determine the purity level of the 
peptide. We demonstrated the necessity of a reliable QC method, i.e. the need of a suitable 
chromatographic system to analyse peptide purity. The supplier claimed ≥ 95.0% purity using his 
system, where we determined a purity level of 80.6%. 
Especially the cyclic peptides (n = 9) are characterized by low purity levels: none of the peptides had 
a purity exceeding 90.0%. Of all cyclic peptides, 1 peptide had a purity between 80.0 and 90.0%, 
whereas 8 others had purity levels below 80.0%. Nevertheless, each of these peptides was 
accompanied by a certificate of analysis stating a purity of at least 95.0%. After communication with 
the supplier, they revealed that they were unable to produce these cyclic peptides at the requested 
purity level. 
 
A 
B 
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Identification of related impurities  
A set of 15 peptides with varying purities was selected to determine the identity of the impurities 
(Table 1, depicted in red). The main peak was characterized as the desired peptide for 14 out of 15 
peptides. The main peak from peptide ID25 was not the requested amino acid sequence. Instead of 
CVFSLFKKCN, a peptide with a mass difference of -2.1 Da compared to the requested peptide 
sequence was noted. Therefore, the formation of a disulfide bond (and thus cyclisation) between C1 
and C9 is suggested. Because sulfur-containing amino acids are prone to oxidation [43], a 
spontaneous cyclisation is suspected for this peptide (Figure 4). 
 
The MS1 spectrum of a related peptide impurity of peptide ID134 (retention time of 29.75 min) 
showed an impurity with a monoisotopic mass of 666.22 Da (Figure 5). The difference with the 
monoisotopic mass of the requested peptide sequence (LPFEF) amounts 14.04 Da, a mass difference 
that could be associated with the addition of a methyl group. The MS² fragmentation pattern of the 
related peptide impurity, found in Figure 5C, showed a difference of +14 Da with the requested 
peptide sequence fragmentation pattern at b4, y2-H2O, y4, MH-H2O, while the b3 fragment of 
requested peptide and related impurity are the same, suggesting thus the addition of a methyl group 
to Glu4. 
 
A related impurity of peptide ID82 (retention time 9.34 min) possessed a m/z value of 621.14 
(Figure 6). Compared to the desired peptide, i.e. NTIPKY, there was a mass difference of 114.02 Da, a 
mass difference which could be bridged by the deletion of Asn1. The suggested sequence TIPKY is 
confirmed by the MS2 spectrum in Figure 6C. On the other hand, we also demonstrated a related 
impurity characterized by the incorporation of an additional amino acid at the C-terminus of peptide 
ID121 (retention time 35.70 min) (Figure 7). The MS2 spectrum (Figure 7C) confirmed the addition of 
an extra Trp residue at the C-terminus of peptide ID121, thus resulting in the related impurity 
ILSGAPCIPWW. Another example of a related peptide impurity was the combination of both deleted 
and additionally inserted amino acids in the desired peptide sequence. In Figure 8, such an example 
is given: ILSGAPCIPPPP is a related impurity of peptide ID121 and lacks the C-terminal Trp residue, 
but is characterized by 3 additional Pro residues at the C-terminus. 
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Figure 4. TIC and UV chromatogram (A), MS
1
 (B) and MS² (C) spectra of the related impurity C1VFSLFKKC9N 
(disulfide bond between C1 and C9) of peptide ID25 at a retention time of 23.47 minutes with appointed 
isotopic mass patterns and b- and y-fragmentation. 
 
A B 
 
C 
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Figure 5. TIC and UV chromatogram (A), MS
1
 (B) and MS² (C) spectra of the related impurity LPFE(methyl)F of 
peptide ID134 at a retention time of 29.75 minutes with appointed isotopic mass patterns and b- and y-
fragment allocation. 
 
[M+H]
+ 
A B 
 
C 
 
CHAPTER IV – QUALITY EVALUATION OF SYNTHETIC QUORUM SENSING PEPTIDES 
  
 
80 
 
Figure 6. TIC and UV chromatogram (A), MS
1
 (B) and MS² (C) spectra of the related impurity TIPKY of peptide 
ID82 at a retention time of 9.59 minutes with appointed isotopic mass patterns and b- and y-fragment 
allocation. 
 
A B 
 
C 
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Figure 7. TIC and UV chromatogram (A), MS
1
 (B) and MS² (C) spectra of the related impurity ILSGAPCIPWW of 
peptide ID121 at a retention time of 35.70 minutes with appointed isotopic mass patterns and b- and y-
fragment allocation. 
 
A B 
 
C 
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Figure 8. TIC and UV chromatogram (A), MS
1
 (B) and MS² (C) spectra of the related impurity ILSGAPCIPPPP of 
peptide ID121 at a retention time of 33.55 minutes with appointed isotopic mass patterns and b- and y-
fragment allocation. 
 
 
A B 
 
C 
 
 CHAPTER IV – QUALITY EVALUATION OF SYNTHETIC QUORUM SENSING PEPTIDES 
 
  
 
83 
In total, 84 impurities (Table 2) were observed and 73% could be assigned a structure related to the 
requested peptide by means of MS². Analysis of these identified impurities revealed a high 
abundance of impurities with at least one deletion (i.e. in 74% of all identified impurities is involved) 
(Figure 9). Inappropriate deletion of blocking groups during synthesis results in such sequences, 
thereby lacking at least 1 amino acid [20,44]. A minority of the observed peptide impurities were 
characterized by the incorporation of additional amino acids. During synthesis, an excess of amino 
acid equivalents used to assure a maximum coupling efficiency might result in the incorporation of 
additional amino acids [20,45]. Impurities can also be a combination of alteration types, e.g one or 
more desired amino acid(s) might be missing at the N-terminus whilst at the C-terminus additional 
amino acid(s) are incorporated.  
 
 
Figure 9. Types of related peptide impurities found in the 61 experimentally determined sequences. 
 
 
4.  CONCLUSIONS 
In conclusion, “purified” synthetic peptides still contain a considerable amount and wide variety of 
related impurities, with peptides missing amino acid(s) being the most prominent. As a consequence, 
a thorough in-house quality characterization of peptides, already used in basic biomedical research, 
is mandatory. Remarkably, there is a large discrepancy between the certificates of analysis provided 
by the suppliers and the in-house quality control, which can at least partly be explained by the 
methods used. Finally, researchers should also be aware that the main peak observed in the 
chromatogram might be an impurity instead of the requested peptide; hence MS is requested in this 
QC. 
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Table 2. Overview of the observed peptides (blue) and impurities (purple). 
Peptide ID Purity (%)
1 Mr (exp.) 
(Da) 
Impurity sequence
3 Retention 
time (min)
 Alteration type 
19 
NNWNN 
92.66 
660.12 NNWNN 4.59 - 
661.10 Deamidated 5.73 Not yet identified 
44 
EKMIG 
99.41 576.19 EKMIG 3.83 - 
76 
SNLVECVFSLFKKCN 
80.63 
1778.20 XFSLFKKCN 35.18 Not yet identified 
1761.98 Not yet identified 38.31 Not yet identified 
1728.69 SNLVECVFSLFKKCN 40.59 - 
1641.10 
*NLVEC5VFSLFKKC13N,  
disulfide bond between C5 and C13 
45.59 Deletion + cyclisation 
134 
LPFEF 
17.17 
518.10 LPE(methyl)F 22.40 Deletion + functional group 
651.18 LPFEF 28.35 - 
665.22 LPFE(methyl)F 29.75 Functional group 
709.28 LPFEFX 31.49 Not yet identified 
679.21 Not yet identified 33.29 Not yet identified 
162 
QRGMI 
94.36 
- ND
4
 4.15 - 
546.07 QRMI 
4.94 
Deletion 
603.27 QRGMI - 
474.98 RGMI Deletion 
- ND
4 
5.80 - 
586.17 QR(ammonia-loss)GMI 14.82 Ammonia loss 
2143.56 QRGMRRXGMRGMRGMGMI 17.74 Not yet identified 
153 
NNWGN 
99.10 
546.05 NNWN 4.56 Deletion 
603.06 NNWGN 5.05 - 
604.05 NNWGGG 6.90 Deletion + insertion 
 
 
 
 CHAPTER IV – QUALITY EVALUATION OF SYNTHETIC QUORUM SENSING PEPTIDES 
 
  
 
85 
Table 2. Overview of the observed peptides (blue) and impurities (purple) (continued). 
Peptide ID Purity (%)
1
 
Mr (exp.) 
(Da) 
Impurity sequence
3 Retention 
time (min)
 Alteration type 
25 
CVFSLFKKCN 
47.92
2
 
985.42 FSLFKKCN 17.57 Deletion 
1084.45 VFSLFKKCN 19.53 Deletion 
1187.46 CVFSLFKKCN 
21.22 
- 
1086.42 C1FSLFKKC8N, disulfide bond between C1 and C8 Deletion + cyclisation 
1185.50 C1VFSLFKKC9N, disulfide bond between C1 and C9  23.47 Cyclisation 
1027.39 FKLFKKCN or acetyl-FSLFKKCN 25.26 
Deletion + insertion 
or deletion + acetylation 
1219.36 C1VFSFFKKC9N, disulfide bond between C1 and C9 25.74 Deletion + insertion + cyclisation 
1235.41 CFFSLFKKCN 
28.16 
Deletion + insertion 
1057.35 C1VFSLFC8N, disulfide bond between C1 and C8 Deletion + cyclisation 
1126.56 KVFLFKKCN 29.21 Deletion + insertion 
1213.38 KVFSLFKKCN 31.52 Deletion + insertion 
164 
SDLPFEH 
91.37 
696.16 SDLPEH 4.12 Deletion 
746.10 SDLFEH 14.72 Deletion 
570.06 acetyl-PFEH 
16.31 
Acid precursor + deletion 
714.27 SDLPFH Deletion 
728.95 SLPFEH Deletion 
785.22 SDXLPL 
16.87 
Not yet identified 
470.00 SDLH Deletions 
529.05 PFEH 
17.36 
Deletions 
843.24 SDLPFEH - 
641.17 LPFEH Deletions 
756.15 DLPFEH 18.33 Deletion 
939.30 SDLPPFEH or PSDLPFEH 26.76 Insertion 
1308.75 XLPFEH or LPFEHX 31.06 Not yet identified 
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Table 2. Overview of the observed peptides (blue) and impurities (purple) (continued). 
Peptide ID Purity (%)
1
 
Mr (exp.) 
(Da) 
Impurity sequence
3 Retention 
time (min)
 Alteration type 
53 
ESRLPKILLDFLFLRKK 
65.11 
2115.99 ESRLPKILLDFLFLRKK 29.87 - 
1620.81 SKILLDFLFLRKK 31.11 Deletion 
1959.46 ESRLPKILLDFLFLKK 35.89 Deletion 
1430.67 XDFLFLRKK 38.98 Not yet identified 
2131.14 Not yet identified 39.73 Not yet identified 
1627.78 XLDFLFLRKK 41.53 Not yet identified 
1740.71 XLLDFLFLRKK 43.52 Not yet identified 
138 
MAGNSSNFIHKIKQIFT
HR 
81.90 
- ND
4 
4.11 - 
2027.64 GNSSNFIHKIKQIFTHR 
21.09 
Deletion 
2229.01 MAGNSSNFIHKIKQIFTHR - 
- ND
4 
23.01 - 
2091.64 MAGNSSNFIHKIKQIFTR 
23.90 
Deletion 
1834.12 MAGNSSNFIHKIKQIF Deletion 
1307.38 HKIKQIFTHR Deletion 
2159.99 MAGNSXIHKIKQIFTHR 24.53 Not yet identified 
2123.85 RNSSNFIHKIKQIFTHR 
25.34 
Deletion + insertion 
1995.71 MANNFIHKIKQIFTHR Deletion 
121 
ILSGAPCIPW 
77.04 
- Not yet identified 24.73 Not yet identified 
- Not yet identified 25.85 Not yet identified 
614.10 ISIPW or LSIPW or PCIPW 26.06 Deletion 
830.13 SGAPCIPW 
27.25 
Deletion 
- GAPCIPXPCIPW Not yet identified 
754.22 ILSGAPCI(dehydrated) 
27.59 
Deletion + loss of water 
1027.41 XPW Not yet identified 
942.27 ILSGAPCPW 
29.31 
Deletion 
952.41 ILSGAPIPW Deletion 
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Table 2. Overview of the observed peptides (blue) and impurities (purple) (continued). 
Peptide ID Purity (%)
1
 
Mr (exp.) 
(Da) 
Impurity sequence
3 Retention 
time (min)
 Alteration type 
121 
ILSGAPCIPW 
(continued) 
77.04 
969.88 ILSGAPCIPT 
30.64 
Insertion  
1041.37 Deamination product Not yet identified 
1055.46 ILSGAPCIPW - 
927.34 ILSPCIPW 
31.71 
Deletion 
998.40 ILSAPCIPW Deletion 
968.35 ILGAPCIPW 32.56 Deletion 
1161.48 ILSGAPCIPPPP 33.55 Deletion + insertion  
- Not yet identified 
35.70 
Not yet identified 
1241.42 ILSGAPCIPWW Insertion 
36.25 
125 
KSSAYSLQMGATAIKQV
KKLFKKWGW 
66.39 
2912.62 Not yet identified 29.63 Not yet identified 
2984.46 KSSAYSLQMGATAIKQVKKLFKKWGW 29.73 - 
3089.70 KSSAYYSLQMATAIKQVKKLFKKWGW 32.36 Deletion + insertion  
31 
DLRNIFLKIKFKKK 
76.74 
1675.62 LRNIFLKIKFKKK 19.42 Deletion 
1790.03 DLRNIFLKIKFKKK 20.19 - 
1633.78 DLNIFLKIKFKKK 21.96 Deletion 
82 
NTIPKY 
69.22 
644.18 XKY 4.12 Not yet identified 
620.22 TIPKY 9.59 Deletion 
406.07 PKY 
11.22 Deletion 
734.24 NTIPKY 
897.30 NTIPKYY 
15.78 
Insertion 
569.09 YPKY or PKYY Deletion + insertion 
605.87 NTIPY(hydroxylated)
 
16.14 Deletion + hydroxylation 
662.18 acetyl-TIPKY 18.12 Protection group + deletion 
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Table 2. Overview of the observed peptides (blue) and impurities (purple) (continued). 
Peptide ID Purity (%)
1
 
Mr (exp.) 
(Da) 
Impurity sequence
3 Retention 
time (min)
 Alteration type 
82 
NTIPKY 
(continued) 
69.22 
1275.50 NTIPKTTIPKY or TIPKYTIPKNT or TIPKTNTIPKY 18.52 Insertion 
517.05 K(ammonia-loss)PKY 24.73 Deletion + insertion + modification 
976.34 
NNK 
NKN     -TIPKY 
KNN 
 
Or 
 
NNQ 
NQN     -TIPKY 
QNN 
32.98 Insertion 
75 
SINSQIGKATSNLVECVF
SLFKKCN 
30.03 
2421.00 Not yet identified 28.40 Not yet identified 
2743.23 Not yet identified 33.63 Not yet identified 
2256.32 SINSQIGKATSNLVECVFSLF 35.20 Deletion 
2729.40 SINSQIGKATSNLVECVFSLFKKCN 40.99 - 
2786.42 SINSQIGGKATSNLVECVFSLFKKCN 46.27 Insertion 
1
: Purity assigned based on UV chromatogram with internal normalization to the most abundant peak.
 
2
: The peptide C1VFSLFKKC9N (disulfide bond between C1 and C9) was the most abundant peak and was not the desired sequence. 
3
: Structural deviations were defined as follows:  
- Chemical modifications of an amino acid are depicted in between brackets following the modified amino acid.  
- X signals a “semi-identified” impurity with already part of the peptide sequence allocated in the MS² fragmentation pattern. 
4
: Solely observed in UV spectrum, no signal in TIC. 
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 “Look deep into nature, and then you will understand everything better.”  
 
Albert Einstein 
 
 
 
 
 
 
 
Parts of this chapter were published: 
 
Wynendaele E, Verbeke F, D’Hondt M, Hendrix A, Van De Wiele C, Burvenich C, Peremans K, De 
Wever O, Bracke M, De Spiegeleer B. Crosstalk between the microbiome and cancer cells by quorum 
sensing peptides. Submitted for publication. 
CHAPTER V – CROSSTALK BETWEEN THE MICROBIOME AND COLON CANCER CELLS 
  
 
94 
ABSTRACT 
To date, the precise role of the human microbiome in health and disease states remains largely 
undefined. Complex and selective crosstalk systems between the microbiome and mammalian cells 
are also not yet reported. Research up till now mainly focused on bacterial synthesis of virulence 
factors, reactive oxygen/nitrogen species (ROS/RNS) and hydrogen sulphide, as well as on the 
activation of exogenous mutagen precursors by intestinal bacteria. We discovered that quorum 
sensing peptides, produced by bacteria, interact with mammalian cells, in casu cancer cells: Phr0662 
(Bacillus sp.), EntF-metabolite (Enterococcus faecium) and EDF-derived (Escherichia coli) peptides 
initiate colon cancer cell invasion as well as promote angiogenesis. Our findings thus indicate that the 
human microbiome, through their quorum sensing peptides, is one of the factors responsible for 
cancer metastasis. 
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CHAPTER V 
CROSSTALK BETWEEN THE MICROBIOME 
AND COLON CANCER CELLS  
BY QUORUM SENSING PEPTIDES 
Main focus in this chapter: 
 To explore the biological role of quorum sensing peptides on colon cancer cells, as part of the 
microbiome-host interaction. 
 To initially identify the target of quorum sensing peptides involved in tumour progression. 
 
1. INTRODUCTION 
Studies of the human microbiome revealed an individual and age-related diversity of microbes, 
occupying different habitats like skin, mouth, mammary gland, vagina and gut [1-5]. The beneficial 
effects of the gastrointestinal microbiota are elaborated using probiotics. These products, most often 
positioned as functional foods, claim to restore the gut microbiota composition, possibly preventing 
gut inflammation or other intestinal or systemic disease phenotypes [6]. The most commonly studied 
organisms for probiotic therapies in the treatment of gastrointestinal diseases include organisms of 
the genera Bacillus, Enterococcus, Escherichia, Faecalibacterium and Propionibacterium. 
Enterococcus faecium, together with Bacillus subtilis and Lactobacillus spp., were investigated as 
probiotics for acute gastroenteritis, while Streptococcus spp., B. subtilis and E. coli were explored for 
their use as probiotics in irritable bowel syndrome; a reduced duration or decreased abdominal pain 
of both gastrointestinal diseases was established. Manipulation of the microbiota with rationally 
selected pre- or probiotics can inhibit pathogens, strengthen epithelial barrier functions and supply 
the host with key nutrients (e.g. vitamins) [7]. It has to be noted that certain safety aspects should be 
taken into account when using probiotics: taxonomic identification of the probiotic strain is 
necessary to avoid pathogenicity, as well as inhibiting the risk of infection and antimicrobial 
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resistance [8]. The use of probiotics was already associated with diverse side effects, e.g. bacteremia, 
fungemia and gastrointestinal ischemia; critically ill patients and immune-compromised individuals 
are the most-at-risk populations [9]. 
The interactions of the bacteria with the host can affect metabolic, neurological, inflammatory and 
immunological functions as well, and also the development of cancer can directly or indirectly be 
promoted [10]. For example, the progress of colorectal cancer can directly be initiated by DNA-
damaging superoxide radicals or genotoxins, both produced by gut (mucosa-associated) bacteria. 
Indirectly, bacteria can induce cell proliferation or pro-carcinogenic pathways by T-helper cells or 
Toll-like receptors, respectively [11]. Human microbiome studies have revealed significant 
differences between cancer patients and healthy controls regarding the relative abundance of 
certain microbes. In colon cancer patients, an increased population of e.g. Escherichia coli was 
observed in feces, inducing colitis and colibactin synthesis and thereby promoting inflammation and 
cancer [12]. 
Although the quorum sensing process within Gram-positive bacterial colonies is already extensively 
described in literature, the direct link between quorum sensing peptides and tumour development 
remains unexplored. Recent investigations revealed that the quorum sensing process is activated in 
the human gut: a set of acylhomoserine lactone (AHL) molecules, i.e. signaling molecules produced 
by Gram-negative bacteria, were identified in human feces of gastrointestinal disease patients as 
well as healthy subjects [13]. Moreover, bacterial quorum sensing molecules are likely to play a role 
in bacterial colonization of mucosa, thus requiring quorum sensing-mediated biofilm formation [14]. 
Finally, Casula and Cutting showed the germination of Bacillus subtilis spores in the murine 
gastrointestinal tract, thereby probably requiring signaling peptides for quorum sensing pathway 
activation [15]. Although thus not yet investigated, it is very likely that also quorum sensing peptides 
are found in the human intestinal tract.  
In this study, we utilize a collagen invasion assay, transcriptome assay, Chick Chorioallantoic 
Membrane (CAM) assay, cytokine profiling and phospho-receptor tyrosine kinase array to investigate 
the influence of quorum sensing peptides on mammalian cancer cells. Our preliminary observations 
unexpectedly reveal that quorum sensing peptides stimulate metastasis behavior of human colon 
cancer cells, thereby opening new perspectives on the role and applications of the microbiome on 
the guest’s health, with the possibility of translating these findings into other biological and applied 
medical fields as well. 
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2. MATERIALS AND METHODS 
Cell culture 
An epithelial subclone from human ileocecal colorectal adenocarcinoma cells (ATCC® CCL-224), i.e. 
HCT-8/E11, was grown in high-glucose Dulbecco’s Modified Eagle’s Medium, supplemented with 10% 
(V/V) fetal bovine serum (FBS), 1% (w/V) L-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin (all from Invitrogen/GIBCO, Gent, Belgium) in a humidified atmosphere of 5% CO2.  
 
Collagen type I invasion assay 
Morphology changes of HCT-8/E11 cells were investigated using previously described methods [16]. 
In brief, 10 000 cells were seeded per well in a 48-well plate, containing 150 µl of collagen type I gel 
per well, thereby investigating cell morphology 24 hours post-treatment (Leica DMI3000B phase 
contrast microscope). Peptide solutions (> 80% purity; all from GL Biochem, Shanghai, China) were 
prepared using ultrapure water, obtaining final peptide concentrations of 1 µM, 100 nM and 10 nM 
after 1:10 dilution using growth medium; the placebo sample solely contained ultrapure water. Two 
independent morphology ‘scorings’ were obtained for each of the 3 replicates; peptides were found 
positive if collagen-invasion or cell-stretching at minimum 2 consecutive concentrations was 
established. To quantify these visual results, the number of cells containing invasive extensions were 
counted and compared to the total number of cells in the field. 
 
Human Transcriptome Array  
Peptide treated cells were analysed in duplicate (independent treatment and analysis) for whole 
transcriptome expression using Affymetrix GeneChip Human Transcriptome Array 2.0. by AROS 
Applied Biotechnology A/S (Aarhus, Denmark); RNA expression was compared with placebo 
(ultrapure water) treated samples. Data analysis was performed using Transcriptome Analysis 
Console (Affymetrix) and MetaCore (Thompson Reuters) software programs. 
 
Chick Chorioallantoic Membrane (CAM) assay 
The Chick Chorioallantoic Membrane (CAM) assay was performed as described by Sys et al.: 6 days 
after (pre-treated, 100 nM) tumour cell transfer to the fertilized eggs, CAM was microscopically 
scored and histologically examined after H&E staining [17,18]. For quantification of microscopically 
observed neovascularisation, an average CAM score was calculated: the number of blood vessels in 
CHAPTER V – CROSSTALK BETWEEN THE MICROBIOME AND COLON CANCER CELLS 
  
 
98 
the 1 mm diameter ring around the 2 mm radius tumour centre was determined. Significant 
differences were evaluated using the Mann–Whitney U test. 
 
Cytokine profiling 
Cytokine expression was investigated using the Human XL Cytokine Array kit (R&D Systems, 
Abingdon, United Kingdom), following the instructions of the supplier. In brief, cell supernatant was 
obtained after 24 hours of incubation with Phr0662 (100 nM) and 102 different cytokines analysed in 
duplo using spotted capture antibodies, followed by incubation with detection antibodies and 
chemiluminescent visualization. Membranes are finally exposed to X-ray films for 1-10 minutes. The 
mean (blank corrected, n = 2) pixel density is calculated using ImageJ software and compared with 
placebo treatment. Significant differences were evaluated using the independent samples t-test. 
 
Phospho-receptor tyrosine-kinase array 
A human phospho-receptor tyrosine kinase (RTK) array kit (R&D Systems, Abingdon, United Kingdom) 
was used to detect phosphorylation levels of 49 different RTK after Phr0662 (100 nM) treatment of 
HCT-8/E11 cells, following the manufacturer’s instructions. Cell lysates were prepared after 
5 minutes of peptide incubation and incubated with capture antibodies (in duplo), followed by 
incubation with detection antibodies and Horseradish Peroxidase for chemiluminsescent 
visualization. X-ray films were again analysed for mean (blank corrected, n = 2) pixel density and 
compared with placebo results using the ImageJ software program. Significant differences were 
evaluated using the independent samples t-test. 
 
 
3.  RESULTS 
Epithelial to mesenchymal (EMT)-like transition and related cell migration 
activities 
To investigate the potential role of chemically diverse quorum sensing peptides in oncology [19], we 
explored their morphologic effect on a human epithelial colon cancer cell line, i.e. HCT-8/E11. Three 
quorum sensing peptides, or metabolites thereof, were found to significantly induce tumour cell 
invasion through a collagen type I extracellular matrix: Phr0662 (ERNNT), an EntF-metabolite 
(SNLVECVFSLFKKCN) and an EDF-analogue (NWN) (Figure 1), while others, e.g. cAM373 (AIFILAS) and 
iAD1 (LFVVTLVG), both originating from Enterococcus faecalis, do not induce invasive characteristics. 
This epithelial to mesenchymal (EMT)-like process (i.e. observation of invasive cellular extensions) is 
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one of the main mechanisms involved in colorectal cancer metastasis, establishing metastatic 
disseminations with potential life-threatening consequences [20].  
Peptide Phr0662 is synthesized by Bacillus species [21]. The quorum sensing peptide designated 
Extracellular Death Factor (EDF), originally described by Kolodkin-Gal et al., is responsible for the 
mazEF and chpBIK-mediated cell death in Escherichia coli. This intestinal commensal bacterium 
synthesizes this EDF peptide during logarithmic growth stages when stress-situations are induced 
[22,23]. Our study now enlarges the role of EDF to mammalian cells. EntF is synthesized by 
Enterococcus faecium, a commensal bacterium in healthy humans and animals, which is responsible 
for a number of nosocomial infections [24]. Enterococcus faecium, together with Enterococcus 
faecalis, is the primary source of reactive oxygen species (ROS), causing genomic alterations which 
are correlated to colorectal cancer [25]. However, based on the results of this study, its quorum 
sensing peptide (or its metabolite) can contribute to metastatic tumour behavior as well. 
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Figure 1. Collagen invasion of 3 quorum sensing peptides at 10 nM. (A) Morphologic changes of HCT-8/E11 
cells, observed 24 hours post-treatment with Phr0662 (ERNNT), EntF-metabolite (SNLVECVFSLFKKCN) and EDF-
analogue (NWN). Placebo sample serves as negative control and TGF-a (0.1 µg/ml) as the very strong positive 
control. (B) Mean (n = 3) percentage of cancer cells with induced morphology changes: a significant difference 
is observed between the peptide and placebo treatments (* p < 0.05 (Mann-Whitney U test)).  
Error bars represent SEM values. 
 
 
The microscopically observed invasive characteristics were further corroborated by whole 
transcriptome analyses on both placebo and peptide-treated tumour cells (Table 1). RNA extraction 
was performed on a heterogenous mixture (i.e. cells with and without induced invasive cellular 
extensions) instead of on isolated HCT-8/E11 cells, and only two duplicates were performed in this 
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exploratory study, so the standard (parametric) ANOVA p-values are only given for the sake of 
completeness but are not meant to conclude any statistical significance (requiring more data and 
non-parametric evaluation). This exploratory study was meant to observe trends based on the mean 
fold-change. The up- or downregulation of certain genes indeed supported the phenotypic 
observations of cellular invasiveness: e.g. the upregulation of histone cluster 1 H4 (HIST1H4A-F/H-L) 
and CXorf61 (Cancer/Testis Antigen 83 (CT83) or Kita-Kyushu Lung Cancer Antigen (KKLC1)) is 
associated with cell cytoskeleton remodelling. Histone H4 is involved in different biological pathways 
through its link with β-arrestin 1, activin A and Notch1. Via β-arrestin 1, Histone H4 is linked to cell 
migration and metastasis in colon cancer in vivo [26]. The Histone H4-activin A link is again associated 
with cell migration and cytoskeleton remodeling (via Smad3) and cell proliferation (via Smad4) in 
colon cancer [27,28]; in normal human epithelial cells, activin A can induce EMT as well. Finally, via 
the link with Notch1, in colon cancer, it causes metastasis and cell invasion; a deregulation of the 
Notch signaling pathway thus affects EMT and tumour aggressiveness [29,30]. Through its link with 
micro-RNA 520h (miR-520h), CXorf61 upregulation is associated with increased tumour cell mobility 
and enhanced in vitro cell invasion activity [31]. Moreover, downregulation of micro-RNA 558 (miR-
558) is associated with a bad prognosis of colon cancer outcome, indicating tumour metastases and 
thus EMT-like behaviour [32]. Micro-RNA 644a (miR-644a) functions by directly binding to its target 
site in the 3’ untranslated region of glyceraldehyde-3-phosphate dehydrogenase and -actin, thereby 
significantly repressing their expression [33]. Downregulation of miR-664a thus upregulates -actin 
levels, leading to increased cell motility and cell migration [30].   
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Table 1. Transcriptome alterations after quorum sensing peptide addition to HCT-8/E11 cells. Gene expression 
24 hours post-treatment, compared to placebo samples. Mean fold change is calculated from duplicate 
samples (cut off: > 1.5 or < -1.5). 
Phr0662 
Gene symbol Fold change  ANOVA p-value Description 
UP- 
REGULATED 
SCARNA10 1.99 0.024 Small Cajal body-specific RNA 10  
RN5S348 1.69 0.272 RNA, 5S ribosomal 348  
MIR4521 1.60 0.335 MicroRNA 4521  
HIST1H4A-F/H-L 2.02 0.647 Histone cluster 1, H4d,…  
CXorf61 1.54 0.054 Chromosome X open reading frame 61  
SNORA26 1.63 0.095 Small nucleolar RNA, H/ACA box 26  
DOWN- 
REGULATED 
RPL36AP33 -1.75 0.576 Ribosomal protein L36a pseudogene 33  
RNU6-51 -1.99 0.565 RNA, U6 small nuclear 51  
MIR222 -1.60 0.593 MicroRNA 222  
SNORD121B -1.88 0.242 Small nucleolar RNA, C/D box 121B  
SNORD85 -1.84 0.323 Small nucleolar RNA, C/D box 85  
ARL17A -1.74 0.543 ADP-ribosylation factor-like 17A  
RNU7-47P -1.72 0.463 RNA, U7 small nuclear 47 pseudogene  
EntF-metabolite 
Gene symbol Fold change ANOVA p-value Description 
UP- 
REGULATED 
RN5S62 1.79 0.534 RNA, 5S ribosomal 62  
OR52E6 1.58 0.479 
Olfactory receptor, family 52, subfamily 
E, member 6  
DOWN-
REGULATED 
RNU7-47P -1.83 0.340 RNA, U7 small nuclear 47 pseudogene  
MIR597 -1.65 0.599 MicroRNA 597  
MIR548T -1.58 0.597 MicroRNA 548t  
RNY4 -1.56 0.007 RNA, Ro-associated Y4  
MIR558 -1.68 0.090 MicroRNA 558  
LOC286437 -1.64 0.390 Uncharacterized LOC286437  
RNY4P2 -1.61 0.231 RNA, Ro-associated Y4 pseudogene 2  
MIR644A -1.98 0.443 MicroRNA 644a  
MIR3975 -1.63 0.088 MicroRNA 3975  
MIR553 -1.95 0.328 MicroRNA 553 
EDF-analogue 
Gene symbol Fold change ANOVA p-value Description 
UP-REGULATED OR52E6 1.70 0.384 
Olfactory receptor, family 52, subfamily 
E, member 6  
DOWN-
REGULATED 
MIR222 -1.51 0.641 MicroRNA 222  
RNU7-19P -1.68 0.008 RNA, U7 small nuclear 19 pseudogene  
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Angiogenesis confirms metastatic potential of quorum sensing peptides 
Downregulation of microRNA 222 (miR-222), as observed 24 hours after Phr0662 and EDF-analogue 
peptide addition, is associated with tumour growth reduction (through PUMA) and apoptosis 
induction [34], next to a bad cancer prognosis [32]. MicroRNA 222 is also highly expressed in 
endothelial cells, possessing anti-angiogenic properties through its targets c-kit (mast/stem cell 
growth factor receptor kit, CD117), p27Kip1, p57Kip2 (cyclin-dependent kinase inhibitor 1C) and 
cyclin G1 [35]. The downregulation after quorum sensing peptide addition thus initiates 
angiogenesis. This angiogenic effect was analysed for Phr0662, seen the highly changed 
transcriptomic profile of the cancer cells after 24 hours of treatment. Our Chick Chorioallantoic 
Membrane (CAM) assay results confirmed these pro-angiogenic properties (Figures 2a and 2b): its 
addition clearly promoted neovascularisation, thereby facilitating metastasis of the tumour. Without 
tumour cells, the addition of the peptide alone did not promote neovascularisation, confirming the 
crosstalk between the peptide and the cancer cells (i.e. indirect angiogenic effect) (Figure 2c). 
Histological evaluation of the membrane confirmed the invasive tumour cell properties through the 
chorion into the mesoderm, induced by the quorum sensing peptide (Figure 2d).  
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Figure 2. Neovascularisation and cell invasion after Phr0662 (100 nM) addition to HCT-8/E11 cells on CAM. 
Placebo sample serves as negative control and TGF-α (0.1 µg/ml) as positive control. (A) Macroscopic images, 
observed 6 days after (pre-treated) tumour cell transfer to the eggs. (B) Average CAM Score (i.e. number of 
blood vessels in the 1 mm diameter ring around the 2 mm radius centre) in the presence of tumour cells (mean 
± SEM, n = 5 (Phr0662), n = 7 (TGF-α) or n = 3 (placebo)). (C) Average CAM Score when no tumour cells are 
present (mean ± SEM, n = 8 (Phr0662 and placebo) or n = 6 (TGF-α)). (D) Histological H&E evaluation of the 
CAM, with orange arrowheads indicating invasion of the tumour cells into the mesoderm. * p < 0.05 (Mann-
Whitney U test) 
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Cytokine screening after Phr0662 treatment of the cancer cells revealed pro-angiogenic effects as 
well (Figure 3): the quantitative increase of the vascular endothelial growth factor (VEGF), 
hepatocyte growth factor (HGF), interleukin 6 (IL-6) and stromal cell-derived factor 1 (SDF-1α) all 
indicated an induction of angiogenesis by the investigated peptide [36]. IL-6 was also found to drive 
tumour initiation and subsequent growth and metastasis, with a poor clinical outcome observed in 
colorectal cancer patients. Through its link with STAT3, it promotes the expression of VEGF and 
Fibroblast Growth Factor (FGF), supporting the rapid vascularization required for tumour growth and 
metastasis [37,38].  
A
B
-20
0
20
40
60
80
100
120
VEGF IL-6 HGF SDF-1α
M
e
a
n
 p
ix
e
l 
d
e
n
s
it
y
 (
x
 1
0
0
0
)
Placebo
Phr0662
TGF-α
Placebo Phr0662
VEGF
HGF
IL-6
SDF-1α
*
*
 
Figure 3. Effect of quorum sensing peptide Phr0662 (100 nM) on cytokine expression in HCT-8/E11 colon 
cancer cells. Placebo sample serves as the negative control and TGF-α (0.1 µg/ml) as the positive control.  
(A) Mean (n = 2, ± SEM) pixel density of some pro-angiogenic cytokines, demonstrating increasing cytokine 
concentrations after Phr0662 addition (24 hours of peptide incubation); * p < 0.05 (independent samples t-
test). (B) Human XL Cytokine Array visually demonstrating increased cytokine levels after peptide treatment of 
HCT-8/E11 cells, compared to placebo samples. The selected pro-angiogenic cytokines (in duplo) are indicated. 
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Phr0662 targets the epidermal growth factor receptors EGFR and ErbB2 
Receptor Tyrosine Kinase (RTK) screening of Phr0662-treated HCT-8/E11 cells revealed a 2 times 
higher ErbB2 (HER2/neu) and a significant increase in epidermal growth factor receptor (EGFR, HER1 
or ErbB1) phosphorylation compared to the placebo cell samples (Figure 4). A comparable activity is 
observed for the Phr0662 quorum sensing peptide and the autocrine ligand TGF-a, 5 minutes after 
HCT-8/E11 treatment.  
The EGFR is overexpressed in many types of cancers, especially colorectal cancer, and is significantly 
associated with tumour-node-metastasis and a more aggressive clinical tumour progression [39]. This 
regulation of cellular functions is achieved by activating different intracellular signaling cascades: 
phosphatidylinositol 3-kinase (PI3K/Akt), the ras/raf/MEK/mitogen-activated protein kinase (MAPK) 
and the signal transducer and activator of transcription (STAT) pathways. EGFR signaling regulates 
the synthesis and secretion of different angiogenic growth factors as well, including VEGF; 
overexpression of ErbB2 also leads to increased angiogenesis [40]. 
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Figure 4. Effect of quorum sensing peptide Phr0662 (100 nM) on receptor tyrosine kinase activation in colon 
cancer cells. Placebo sample serves as the negative control and TGF-α (0.1 µg/ml) as the positive control.  
(A) Receptor tyrosine kinase (RTK) array demonstrating the tyrosine phosphorylation level of 42 RTK after 
Phr0662 treatment of HCT-8/E11. Each RTK is spotted in duplicate and the phosphorylated EGFR and ErbB2 are 
indicated. (B) Mean (n = 2, ± SEM) pixel density of ErbB2 and EGFR spots after Phr0662 addition (5 minutes of 
peptide incubation); * p < 0.05 (independent samples t-test). TGF-a serves as the cognate ligand for EGFR, 
demonstrating thus EGFR binding properties for the quorum sensing peptide. 
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4.  DISCUSSION 
Our results suggest that quorum sensing peptides exert (part of) their effects through the epidermal 
growth factor receptor (EGFR), thereby activating the Ras/raf/MEK/MAPK, PI3K/Akt and STAT 
intracellular signaling cascades [40], leading to an altered gene transcription and finally tumour 
metastasis (Figure 5). -arrestin 1, which is linked to HIST1H4 and thus possibly upregulated after 
peptide treatment, can activate the EGFR pathway as well, thereby playing a pivotal role in colon 
cancer metastasis [26]. Next, Smad proteins (i.e. Smad 2, 3 and 4) can be stimulated through Activin 
A binding with its ActRII receptor, linking both cell cytoskeleton remodeling and cell migration to 
quorum sensing peptide presence [27,41]. The upregulation of HIST1H4 can be associated with 
increased Notch1 stimulation, again connected to cancer metastasis, together with angiogenesis and 
NF-B production [29,42]; NF-B in turn contributes to the progression of colorectal cancer by 
regulating cell proliferation, angiogenesis and tumour metastasis [43]. Micro-RNA’s block mRNA 
translation and thus impede the synthesis of specific proteins by recruiting the micro-RNA-induced 
silencing complex (miRISC) to target mRNAs [44]; downregulation of micro-RNA 222 and 644a thus 
increases KIT and -actin protein expression, respectively, thereby promoting endothelial cell 
proliferation and migration (angiogenesis) [35,45] and tumour cell invasiveness and motility [33]. -
actin can be upregulated through the IL-6 receptor pathway as well: the increased IL-6 expression 
after quorum sensing peptide treatment, as observed with our cytokine array, activates -actin 
phosphorylation, again promoting tumour cell migration [46]. Both the transcriptome outcomes and 
cytokine results thus correspond well and are visually confirmed by the collagen invasion and CAM 
assays. A good correlation is observed for VEGF as well: an increased IL-6 pathway activation leads to 
VEGF upregulation [47], which is again observed in our cytokine array; VEGF can then trigger the 
VEGF receptor (VEGFR) pathway in endothelial cells, leading to altered gene transcription and 
subsequently angiogenesis. The pro-angiogenic cytokines SDF-1a and HGF both activate the 
Ras/raf/MEK/MAPK, PI3K/Akt and STAT intracellular signaling cascades through CXCR4 and MET 
receptor binding, respectively. These cytokine-receptor axes are involved in tumour progression, 
angiogenesis and metastasis [48,49]. 
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Figure 5. Possible pathway-map for quorum sensing peptides in tumour progression. Quorum sensing peptides 
promote cancer metastasis and tumour progression by activating different receptor pathways. 
 
 
 
These exploratory results thus indicate metastasis-promoting characteristics for some quorum 
sensing peptides. Assuming the in vivo presence of these molecules influenced by the individual 
microbiota composition, our findings may potentially have a great impact on the patient’s health, 
with effects on cancer metastasis. Exploiting our findings, it would be interesting to consider how we 
can prevent these pro-metastatic effects? First, it may be important to adjust the patient’s life style, 
including diet and hygiene measures. The influence of food patterns cannot be neglected, e.g. 
switching from a low-fat, plant (non- or limited digestible) polysaccharide-rich diet to a high-fat, high-
sugar diet can shift the structure of the gut microbiota within a single day [50,51]. Appropriate 
hygiene measures will diminish the risk of unwanted infections and thus an alteration in the 
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microbiota and quorum sensing peptide composition. Second, blocking the tumour receptor targets 
with designed peptide antagonist, directly or through probiotics, can help in the prevention of cancer 
metastasis as well. 
 
 
5.  CONCLUSIONS 
Our results clearly indicate a new way of crosstalk between the microbiome and mammalian cancer 
cells, i.e. through certain quorum sensing peptides excreted by mainly Gram-positive bacteria. By 
activating one of the suggested pathways, the quorum sensing peptides can promote cancer 
metastasis and thus possibly alter cancer outcome. These in vitro findings are not only important 
from a fundamental biological and evolutionary point of view, but may also have health 
consequences, clearly awaiting further in vivo studies.  
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“Two roads diverged in a wood and I, I took the one less travelled by,  
and that has made all the difference.”  
 
Robert Frost 
(°1874 - †1963, American poet) 
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O, Bracke M, Wynendaele E. Quorum sensing peptides promote angiogenesis and invasion of breast 
cancer cells. Submitted for publication. 
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ABSTRACT 
The role of the human microbiome on cancer progression remains unclear. Therefore, in this study, we 
investigated the influence of some quorum sensing peptides, produced by the guest’s microbiome, on 
breast cancer cell invasion and thus cancer outcome. Based on microscopy, transcriptome and Chick 
Chorioallantoic Membrane (CAM) analyses, four peptides (i.e. PhrG from B. subtilis, CSP from S. mitis and 
EDF from E. coli, together with its tripeptide analogue) were found to promote tumour cell invasion and 
angiogenesis, thereby potentially influencing tumour metastasis. Our results offer not only new insights 
on the possible role of the microbiome, but also further opportunities in cancer prevention and therapy 
by competing with these endogenous molecules and/or by modifying people’s life style. 
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CHAPTER VI 
QUORUM SENSING PEPTIDES PROMOTE 
ANGIOGENESIS AND INVASION  
OF BREAST CANCER CELLS 
Main focus in this chapter: 
 To investigate the possible interactions between quorum sensing peptides and breast cancer 
cells. 
 To study the pro-angiogenic and invasion effects of selected quorum sensing peptides. 
 
1. INTRODUCTION 
To date, cancer figures among the leading causes of death in human societies worldwide. Next to a 
person’s genetic factors and carcinogens exposure, the human microbiome recently gathered great 
attention in tumour development as well [1]. Helicobacter pylori, a commensal of the human 
stomach in almost half of the world’s population, was found to cause gastric adenocarcinoma 
through the CagA and VacA toxins [2]. Colon cancer on the other hand can be influenced by several 
gut bacteria, producing reactive oxygen/nitrogen species or bacterial toxins (e.g. Colibactin from 
Escherichia coli) [3, 4]. 
The vast majority of bacteria inhabit the human intestine, with as many as 1012 cells per gram of the 
average human faeces. Besides, other habitats like skin, mouth, vagina and mammary gland are 
occupied as well, next to the occasional presence in the blood (bacteremia or septicemia). The breast 
milk in the mammary gland is a continuous source of commensal, mutualistic and potentially 
probiotic bacteria to the infant gut, containing i.a. lactic acid bacteria, Staphylococcus and 
Streptococcus species [5]. In contrast to the breast milk, the human breast tissue was originally 
thought to be sterile. However, given the nutrient rich fatty composition of the female breast, 
together with the blood and lymphatic vasculature, and the diffuse location of the lobules and ducts, 
bacteria can spread within the mammary glands, resulting in a breast tissue microbiome. Urbaniak et 
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al. indeed found a higher abundance of Proteobacteria, Firmicutes (specifically the class Bacilli) and 
Actinobacteria in the breast tissue, while no signs or symptoms of infection were assigned [6]. These 
results, serving as a first indication, are eagerly waiting to be confirmed and further investigated 
towards its pathophysiological role. 
Bacteria communicate with each other by the use of signalling molecules in a cell-density dependent 
manner, a process called ‘quorum sensing’. The signalling molecules differ between the groups of 
bacteria: while Gram-negative bacteria predominantly use N-acyl homoserine lacton (AHL) 
molecules, the Gram-positive bacteria communicate by the use of oligopeptides; both Gram-positive 
and Gram-negative bacteria synthesize autoinducer-2 (AI-2) signalling molecules. The quorum 
sensing process was found to be activated in vivo as both the quorum sensing end products (e.g. 
biofilms or toxins) and signalling molecules were detected in different areas of the human body. 
Bacterial biofilms that can be produced after quorum sensing pathway activation can be detected at 
diverse physiological sites: e.g. dental plaques produced by Streptococcus mitis or Lactobacillus 
species, as well as nosocomial infections with vascular grafts or urinary catheters after biofilm 
formation by Staphylococci or Escherichia coli, were observed [7]. Moreover, N-acyl homoserine 
lacton signalling molecules were detected in human biological samples as well, including sputum, 
faeces and saliva [8,9]. Although thus not yet investigated, it is very likely that also quorum sensing 
peptides are found in the human body, at their site of origin or distributed throughout the human 
body via the blood circulation. 
The very recent identification of different Gram-positive bacteria in the breast tissue [6] together 
with the increasing incidence of breast cancer in women in both developed and developing countries 
*10+, excited the research in the microbiome’s influence on breast cancer cells. To this end, we 
investigated the effect of several quorum sensing peptides, synthesized by some commensal 
bacteria, on a human epithelial breast cancer cell line, i.e. MCF-7/AZ. 
 
 
2. MATERIALS AND METHODS 
Cell culture 
The epithelial breast adenocarcinoma cell line MCF-7/AZ (ATCC® CCL-224) was grown in high-glucose 
Dulbecco’s Modified Eagle’s Medium, supplemented with 10% (V/V) foetal bovine serum (FBS), 1% 
(w/V) L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (all from Invitrogen/GIBCO, Gent, 
Belgium) in a humidified atmosphere of 10% CO2 at 37°C.  
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Collagen type I invasion assay 
Morphology changes of MCF-7/AZ cells were investigated using previously described methods [11]. 
In brief, 10 000 cells were seeded per well in a 48-well plate, containing 150 µl of collagen type I gel 
per well, thereby investigating cell morphology 24 hours post-treatment (Leica DMI3000B phase 
contrast microscope). Peptide solutions (> 80% purity; all from GL Biochem, Shanghai, China) were 
prepared using ultrapure water, obtaining final peptide concentrations of 1 µM, 100 nM and 10 nM 
after 1:10 dilution using growth medium. The placebo sample solely contained ultrapure water. Two 
independent morphology ‘scorings’ were obtained for each of the 3 replicates; peptides were found 
positive if collagen-invasion or cell-stretching at minimum 2 consecutive concentrations was 
established. To quantify these visual results, the number of cells containing invasive extensions were 
counted and compared to the total number of cells in the field. 
 
Human Transcriptome Array  
Cells treated with either EDF, PhrG or CSP were analysed in duplicate (independent treatment and 
analysis) for whole transcriptome expression using Affymetrix GeneChip Human Transcriptome Array 
2.0. by AROS Applied Biotechnology A/S (Aarhus, Denmark); RNA expression was compared with 
placebo treated samples. Data analysis was performed using Transcriptome Analysis Console 
(Affymetrix) and MetaCore (Thompson Reuters) software programs. 
 
Chick Chorioallantoic Membrane (CAM) assay 
The Chick Chorioallantoic Membrane (CAM) assay was performed as described by Sys et al.: 6 days 
after (pre-treated, 100 nM) tumour cell transfer to the fertilized eggs, CAM was microscopically 
scored and histologically examined after H&E staining [12]. For quantification of microscopically 
observed neovascularisation, an average CAM score was calculated: the number of blood vessels in 
the 1 mm diameter ring around the 2 mm radius tumour centre was determined [13]. Significant 
differences were evaluated using the Mann–Whitney U test. 
 
Stability in cell medium and human plasma 
In vitro chemical and metabolic stability was determined in cell medium and human plasma, 
respectively, using previously described procedures [14]. In brief, 100 µg of peptide was incubated in 
Krebs-Henseleit buffer pH 7.4 with cell medium/plasma (500 µl) at 37°C while shaking. At 
predetermined time intervals (i.e. 0, 6 and 24 hours for cell medium; 0, 30 and 120 minutes for 
plasma), aliquots were immediately transferred into microtubes containing 1:1 volume of 1% (V/V) 
trifluoroacetic acid solution in water. The enzyme reaction was further stopped by heating the 
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solution at 95°C for 5 minutes. Next, the samples were centrifuged to precipitate the denatured 
proteins and the supernatant analysed using UPLC-PDA. Appropriate placebo solutions were similarly 
prepared. Assuming first-order kinetics, the rate constant k was obtained from ln(Pt/Pt0) = -kt, from 
which the half-life was determined as t1/2 = ln(2)/k. 
 
 
3.  RESULTS 
To investigate the crosstalk between the quorum sensing peptides produced by the host microbiome 
and human breast cancer cells, we selected different signalling peptides from the Quorumpeps® 
database [15]. Four quorum sensing peptides or analogues thereof were consistently (and 
concentration-dependently) found to induce tumour cell invasion through a type I collagen 
extracellular matrix: PhrG from Bacillus subtilis (EKMIG), a Competence Stimulating Peptide (CSP) 
from Streptococcus mitis (EMRKSNNNFFHFLRRI) and Extracellular Death Factor (EDF) from 
Escherichia coli (NNWNN), together with its analogue NWN (Figure 1). Other peptides (e.g. PhrA 
(ARNQT) from Bacillus subtilis or CSP (ESRLPKIRFDFIFPRKK) from Streptococcus mitis) did not induce 
invasive characteristics. These biologically active peptides were found to be sufficiently stable in cell 
medium (Table 1), meaning that the effects, observed after 24 hours of treatment, can be associated 
with the original peptide structures. These observations of invasive cellular extensions are linked to 
an induced epithelial to mesenchymal transition (EMT), an important process in breast cancer 
progression and metastasis and the primary cause of breast cancer-related deaths [16, 17].  
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Figure 1. Morphologic changes of non-invasive epithelial MCF-7/AZ cells, induced by quorum sensing peptides 
at 10 nM. (A) The invasive cellular extensions, observed 24 hours post-treatment with PhrG (EKMIG), CSP 
(EMRKSNNNFFHFLRRI), EDF (NNWNN) and the EDF-analogue (NWN), indicate tumour-promoting properties of 
these quorum sensing peptides. The placebo sample serves as the negative control and TGF-α (0.1 µg/ml) as 
the positive control. (B) Mean (n = 3) number of cancer cells with induced morphology changes: a significant 
difference is observed between the PhrG peptide or EDF-analogue and the placebo treatment (* p < 0.05, 
Mann-Whitney U test). Error bars represent SEM values. 
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Table 1. In vitro cell medium half-life values of quorum sensing peptides.  
Peptide Sequence Plasma half-life (hours) 
PhrG EKMIG 160
a
 
CSP EMRKSNNNFFHFLRRI 45.8 
EDF NNWNN 16.2 
EDF-analogue NWN 42.0 
aThe calculated half-life is 157.89 hours 
 
RNA extraction from the MCF-7/AZ cells was performed only in duplicate on a heterogenous mixture 
(i.e. cells with and without induced invasive cellular extensions) instead of on isolated cells, so 
statistically significant results (ANOVA p-values) are again not yet expected or looked for in this 
exploratory study; they are rather given for the sake of completeness (similar to the previous 
chapter). Trends were researched based on the mean fold change. The up-regulation of the Histone 
cluster 1 H4 gene (HIST1H4A-F/H-L) after EDF treatment, which was observed by our transcriptome 
expression results (Table 2), assigns tumour progressive characteristics to this quorum sensing 
peptide. Through its link with β-arrestin 1, EDF induces angiogenesis, thereby promoting the survival 
of breast cancer cells. Moreover, it promotes cytoskeleton reorganization of breast cancer cells as 
well through the cofilin pathway, which is crucial for tumour migration [18-20]; these morphologic 
alterations were already observed in our type I collagen invasion assay. With Notch1 over-
expression, a poor clinical outcome of breast cancer is correlated, again promoting angiogenesis and 
thus tumour progression [21]. Reproducible over-expression of the MTRNR2L2 and MTRNR2L6 
genes, leading to increased synthesis of the Humanin-like proteins 2 and 6 respectively, can be linked 
to an anti-apoptotic function of the EDF peptide [22]. Finally, up-regulation of EYA3-IT1 can be 
associated with increased tumour size and metastasis, due to the tyrosine phosphatase activity of 
the transcribed proteins, promoting the motility and invasiveness of cancer cells [23].  
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Table 2. Transcriptome alterations after EDF, PhrG or CSP quorum sensing peptide addition to MCF-7/AZ cells. 
Gene expression 24 hours post-treatment, compared to placebo samples.  
Mean fold change is calculated from duplicate samples (cut off: > 1.5 or < -1.5). 
Gene symbol Fold change  ANOVA p-value Description 
Upregulated 
MIR548W 1.92 0.566 MicroRNA 548w 
HIST1H4A-F/H-L 1.98 0.330 Histone cluster 1, H4(a-f/h-l) 
MTRNR2L2 1.69 0.010 MT-RNR2-like 2 
MTRNR2L6 1.58 0.243 MT-RNR2-like 6 
RNU2-4P 1.59 0.011 RNA, U2 small nuclear 4, pseudogene 
RNU4-4P 1.54 0.065 RNA, U4 small nuclear 4, pseudogene 
MIR320C2 1.67 0.076 MicroRNA 320c-2 
EYA3-IT1 1.75 0.087 EYA3 intronic transcript 1 
IGLJ4 1.58 0.011 Immunoglobulin Lambda Joining 4 
SNORD92 1.58 0.261 Small Nucleolar RNA, C/D Box 92 
FOXP1-IT1 1.63 0.390 FOXP1 Intronic Transcript 1 
MIR635 1.65 0.024 MicroRNA 635 
Downregulated 
RN5S217 -1.88 0.127 RNA, 5S ribosomal 217 
FOXQ1 -1.72 0.338 Forkhead Box Q1 
MAGEB5 -1.75 0.199 Melanoma Antigen Family B, 5 
MIR4718 -1.64 0.401 MicroRNA 4718 
LOC100128593 -1.56 0.084 Uncategorized LOC100128593 
 
 
The angiogenic properties of the quorum sensing peptides, as postulated by the transcriptome 
expression results, were confirmed using the Chick Chorioallantoic Membrane (CAM) assay. From 
Figure 2, it is clear that all investigated peptides significantly promoted neovascularisation after 
peptide treatment of the tumour cells, compared to the placebo sample. This recruitment of new 
blood vessels thereby contributes to the metastasis of tumour cells. Histological evaluation of the 
membrane confirmed the invasive tumour cell properties through the chorionic layer into the 
mesoderm, induced by the quorum sensing peptides (Figure 3). Groups of chorionic epithelial cells 
thereby indicated an aggressive invasion of MCF-7/AZ cells: the chorion is massively disrupted by the 
tumour cells, resulting in a collapse of the membrane (black arrowheads in Figure 3). 
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Figure 2. Neovascularisation after quorum sensing peptide treatment (100 nM) of MCF-7/AZ cells on CAM. 
Placebo sample serves as negative control. (A) Macroscopic images, observed 6 days after (pre-treated, 24 
hours) tumour cell transfer to the eggs. (B) Mean CAM score (i.e. number of blood vessels in the 1 mm 
diameter ring around the 2 mm radius centre) in the presence of tumour cells (mean ± SEM, n = 5 (PhrG and 
CSP), n = 3 (EDF) or n = 9 (placebo)). ** p < 0.05, * p < 0.1 (Mann-Whitney U test) 
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Figure 3. Histological H&E evaluation of the chorioallantoic membrane (CAM). Placebo sample serves as 
negative control. Tumour cells, when treated with the quorum sensing peptides, moved through the chorionic 
layer into the mesoderm (orange arrowheads). Clusters of chorionic epithelial cells are indicated by black 
arrowheads, indicating aggressive tumour cell invasion through the membrane. 
 
 
4.  DISCUSSION 
Our in vitro results thus clearly indicate that some quorum sensing peptides promote angiogenesis 
and induce invasion of human breast cancer cells. Based on these results, different questions related 
to their biological relevance now arise: (1) Do these quorum sensing peptides reach the breast cancer 
tissue, (2) Can we inhibit these negative microbiome-related effects, and (3) Does this have 
consequences for the patient’s life style? 
First, very recent investigations have shown that microbial DNA and viable bacterial cells are present 
in healthy and cancerous breast tissue, thereby indicating that bacteria or their components may 
influence the local microenvironment. The predominant bacteria found in breast tumours were 
Escherichia and Bacillus [24]. These findings elicit contradictions with previous insights, where it was 
assumed that the breast tissue was a sterile location, except for the nipple region; nipple duct 
contamination with skin flora is generally accepted and plays an important role in breast infection 
[25]. Clearly, future studies are needed to confirm the presence of a breast tissue microbiome under 
different personalised conditions and describe the different bacterial species that are present. Next, 
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a thorough exploration of the quorum sensing peptides in the breast tissue should be performed as 
well; if found, they can negatively influence the nearby breast cancer tissue. 
Quorum sensing peptides, produced by commensal or pathogenic bacteria at distant locations, can 
reach the breast tissue as well via the blood circulation. N-acylhomoserine lacton (AHL) molecules, 
another group of quorum sensing molecules, are already found in human sputum, faeces and saliva, 
whereby the last biological sample reflects the systemic AHL concentration [8, 26]. Besides, peptides 
that are synthesized in the gastrointestinal tract can pass the intestinal barrier as well and 
consequently reach the blood circulation [27]. The same is true for peptides that are synthesized by 
skin or mouth commensal bacteria: peptides can permeate the human skin or oral mucosa, thereby 
again reaching the circulation [28,29]. Occasionally, bacteria themselves can also be found in the 
blood circulation: Bacillus subtilis and Streptococcus mitis, commensals of the gastrointestinal tract 
or skin and oropharynx, respectively, were found to be present in the blood of cancer patients 
[6,30,31]. PhrG and CSP, when present in the blood circulation, thus can affect the clinical outcome 
of breast cancer, seen its pro-invasive characteristics on breast cancer cells and angiogenesis-
promoting properties. Although thus not yet confirmed, quorum sensing peptides might be available 
from the blood and influence breast cancer progression. One major limitation of this in vivo 
availability, is however the limited stability inherent to peptides, due to the presence of peptidases in 
the human plasma. As observed in Table 3, the investigated peptides are sufficiently stable in an in 
vitro plasma metabolization study, so this pharmacokinetic property will not be the critical 
parameter for the biological activity observed with these peptides. 
 
Table 3. In vitro plasma half-life values of quorum sensing peptides.  
Peptide Sequence Plasma half-life (hours) 
PhrG EKMIG >13
a
 
CSP EMRKSNNNFFHFLRRI 8.7 
EDF NNWNN >13
a
 
EDF-analogue NWN 4.5 
aThe calculated half-life is 13.16 hours 
 
To answer the second and third question, i.e. ‘Can we inhibit these microbiome-related effects and 
does this have consequences for the patient?’, the in vivo functionality of the quorum sensing 
peptides should be investigated to confirm our obtained in vitro results. If the quorum sensing 
peptides are found to be present in vivo, our preliminary in vitro findings of pro-metastatic effects of 
quorum sensing peptides can open up new perspectives. First, after identification of the tumour 
target, peptide antagonist can be developed to compete with these endogenous molecules for 
receptor binding. Second, a person’s life style may be adapted to possibly influence the observed 
CHAPTER VI – QUORUM SENSING PEPTIDES PROMOTE ANGIOGENESIS AND INVASION OF BREAST CANCER CELLS  
 
 
125 
bacteria-related effects. As a change in diet can drastically adapt the microbiota composition, and 
thus the quorum sensing peptide profile, this may possibly have consequences on cancer outcome 
[32]. Last, inadequate hygienic measures during e.g. surgery can induce breast infection as well. 
Moreover, during lactation, mastitis should be treated carefully to avoid unwanted bacterial 
infection of the breast tissue as well [33].  
 
 
5.  CONCLUSIONS 
The results of this in vitro study indicate that some quorum sensing peptides can stimulate breast 
cancer metastasis, which may possibly explain the existence of a crosstalk system between the 
human microbiome and breast cancer cells through quorum sensing peptides. More specifically, we 
showed that these quorum sensing peptides promote breast cancer cell invasion and angiogenesis. 
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“Biology gives you a brain. Life turns it into a mind.”  
 
 Jeffrey Eugenides 
(° 1960, American writer) 
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ABSTRACT 
Bacteria communicate with each other by the use of signaling molecules, a process called ‘quorum 
sensing’. One group of quorum sensing molecules includes the oligopeptides, which are mainly 
synthesized by Gram-positive bacteria. Recently, these quorum sensing peptides were found to 
biologically influence mammalian cells, promoting i.a. metastasis of cancer cells. In this study, three 
quorum sensing peptides were investigated for their brain influx and efflux properties in an in vivo 
mouse model: PhrCACET1 demonstrated a very high influx into the mouse brain (Kin = 
1.33 µl/(g×min)), while brain permeability of BIP-2 and PhrANTH2 was found to be low (Kin = 
0.35 µl/(g×min)) and very low (Kin = 0.18 µl/(g×min)), respectively. All three quorum sensing peptides 
were found to be metabolically stable in plasma during the experimental time frame. No significant 
efflux was observed for the three quorum sensing peptides. Initial tissue distribution data showed 
remarkably high liver accumulation of BIP-2.  
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CHAPTER VII 
QUORUM SENSING PEPTIDES SELECTIVELY 
PENETRATE THE BLOOD-BRAIN BARRIER 
Main focus in this chapter: 
 To indicate the permeability of quorum sensing peptides through the blood-brain barrier. 
 To excite the research on the microbiome’s influence on diverse central nervous system 
disorders. 
 
1. INTRODUCTION 
Bacteria communicate with each other by the use of chemicals (i.e. pheromones), produced and 
released by the bacteria and recognized by others. Once a threshold concentration of these 
molecules is reached, a coordinated change in bacterial behavior is initiated, e.g. biofilm formation, 
virulence factor production or competence induction. This process of cell-to-cell communication is 
called ‘quorum sensing’. Gram-negative and Gram-positive bacteria have different quorum sensing 
systems, each activated by specific quorum sensing molecules: N-acyl homoserine lactones (AHLs) 
trigger LuxI/LuxR circuits in Gram-negative bacteria, while Gram-positive bacteria mostly use 
peptides as signal molecules; both Gram-negative and Gram-positive bacteria produce autoinducer-2 
(AI-2) family molecules [1,2]. Although not yet investigated, the presence of quorum sensing 
peptides in the human body is very likely, seen the biological incidence of Gram-positive bacteria and 
the in vivo detection of biofilms and AHL molecules in human feces, sputum and saliva [3-5]. The 
quorum sensing signaling molecules were originally found as intra-species communication tools in 
bacteria, but recent evidence indicates interspecies and host signaling as well [6-8]. Some AHLs 
exhibit immunomodulating activities by influencing the Th1-Th2 balance in the infected host [9]. In 
addition, the Bacillus subtilis quorum sensing peptide CSF (Competence and Sporulation Factor) 
activates p38 mitogen-activated protein kinase and protein kinase B (Akt) in host intestinal epithelial 
cells and induces cytoprotective heat shock protein synthesis [10]. Moreover, investigations from our 
group have indicated a selective crosstalk phenomenon between these quorum sensing peptides and 
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mammalian cells: some quorum sensing peptides enhance breast or colon cancer cell invasion and 
promote angiogenesis, thereby potentially influencing cancer metastasis [11,12].  
The brain is protected by a physiological barrier between the bloodstream and the central nervous 
system, i.e. the blood-brain barrier (BBB). This barrier is formed by the endothelium lining the brain 
capillaries, possessing intercellular tight junctions, pericytes within the capillary basement membrane 
and astrocyte endfeet [13,14]. Research towards peptide-based therapeutics has been fuelled since 
the determination of the role of different neuropeptides in several neurological disorders. However, 
due to the presence of the BBB, inadequate delivery of these medicinally promising peptides to the 
brain is frequently observed. Currently, a number of peptides are used or investigated for their 
therapeutic purposes in e.g. epilepsy, depression, pain or brain cancer [15,16]. An increased success 
rate of peptide-based therapies is often observed due to a disruption of the BBB, which occurs in 
many neurological disorders, including brain cancer. However, in early stages of brain cancer, the 
BBB is generally intact, so early diagnosis and treatment are limited, though indispensable [17,18]. 
Some of the neurological diseases were associated with an altered microbiota composition as well. 
However, no clear explanation was given for these observations [19], with the role of the quorum 
sensing peptides not yet being investigated. Next to the peptides, a limited number of bacteria is 
capable of crossing the tight barrier between the bloodstream and the central nervous system as 
well, leading to bacterial meningitis. Here, the bacteria reach the blood circulation and then traverse 
the BBB, leading to inflammatory responses from the host and pathophysiological alterations (e.g. 
BBB disruption) [20].  
Based on our previous results of metastasis-promoting effects of quorum sensing peptides, together 
with the presence of an intact BBB in the early stages of brain cancer and the possible link with some 
other neurological disorders, we investigated the permeability of three chemically diverse quorum 
sensing peptides through the BBB: if BBB-transport is observed, this may have an impact on the 
development of several brain pathologies, including cancer. 
 
 
2. MATERIALS AND METHODS 
Reagents 
Calcium dichloride dihydrate, magnesium sulphate, potassium chloride, sodium chloride, sodium 
dihydrogen phosphate hydrate, sodium lactate and urethane were purchased from Sigma-Aldrich 
(Diegem, Belgium), while Bovine Serum Albumin (BSA), disodium hydrogen phosphate dihydrate, 
sodium iodide, sodium dihydrogen phosphate monohydrate, sodium metabisulphite and Chloramine-
T were obtained from Merck KGaA (Darmstadt, Germany). Calcium dichloride, D-glucose, formic acid 
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(FA) and HEPES were purchased from Fluka (Diegem, Belgium) and dextran from AppliChem GmbH 
(Darmstadt, Germany). For the mobile phases, acetonitrile was obtained from Fisher Scientific 
(Erembodegem, Belgium) and water was purified using an Arium 611 Pro VF purification system 
(Sartorius, Göttingen, Germany) to laboratory-graded water (18.2 MΩ × cm). For the radiolabeling of 
the peptides, Iodo-Gen® coated tubes were purchased from Thermo Scientific (Erembodegem, 
Belgium) and the radioactive sodium iodide solution (Na125I) from Perkin Elmer (Zaventem, Belgium).  
 
Animals  
Female, Institute for Cancer Research, Caesarean Derived-1 (ICR-CD-1) mice (Harlan Laboratories, 
Venray, The Netherlands) of age 7-10 weeks and weighing 25-34 g, were used during the BBB-
transport experiments. All animal experiments were performed in accordance with the Ethical 
Committee principles of laboratory animal welfare as approved by our institute (Ghent University, 
Faculty of Veterinary Medicine, number 2012-157). 
 
Peptide selection  
The currently known quorum sensing peptides are continuously collected into the Quorumpeps 
database (http://quorumpeps.ugent.be) [21]. To select chemically diverse quorum sensing peptides 
for BBB-permeability investigations, we optimized the three-dimensional structure of these 231 
peptides (status in August 2014) and calculated over 3000 descriptors for each peptide. After 
removal of the constant descriptors, and correction for molecular weight, a final dataset of 1468 
descriptors was retained. Multivariate data-analysis on this resulting 231x1468 data-matrix was 
performed using Principal Component Analysis (PCA) with SIMCA-P+ 12.0 (Umetrics, Sweden), and 
different clusters identified [22]. Finally, three chemically diverse quorum sensing peptides were 
selected to investigate their brain permeability characteristics. 
 
Peptide handling 
The quorum sensing peptides were purchased at GL Biochem (Shangai, China) and the positive 
control dermorphin at Bachem (Bubendorf, Switzerland). The peptide purity was determined to be 
 90%, based on UPLC-PDA analyses [23]. Prior to experimental use, the peptides were dissolved in 
phosphate buffer (25 mM) at a concentration of 1 µmol/ml. 
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Peptide 125I radiolabeling and purification 
Dermorphin and BIP-2 were labeled using the Iodogen method [24,25]. Briefly, 0.1 µmol of the 
lyophilized peptide was dissolved in 100 µl of phosphate buffer (pH 7.4, 25 mM). A Iodo-Gen® coated 
tube was previously rinsed with 1 ml of phosphate buffer. Subsequently, 50 µl of sodium iodide 
solution (1.1 µmol/ml) and 1 mCi of Na125I solution were transferred into this Iodo-Gen® coated tube. 
The oxidation reaction was allowed to proceed for six minutes at room temperature, after which the 
iodonium solution was transferred to 50 µl of peptide solution (1 µmol/ml). The iodination reaction 
of the peptide was allowed to proceed another six minutes at room temperature. Next, the reaction 
mixture was analysed by radio-HPLC and the eluting fractions determined for radioactive content (i.e. 
peptide concentration). The radio-HPLC apparatus consisted of a LaChrom Elite L-2130 pump with 
degasser (flow rate is 1 ml/min), a LaChrom Elite L-2300 column oven set at 30°C, a LaChrom Elite L-
2400 UV-detector set at 215 nm (all Hitachi, Tokyo, Japan), a Rheodyne 7725i manual injector with 
100 µl sample loop (Rheodyne, Rohnert Park, CA, USA), a Berthold LB500 HERM radioactivity 
detector (Berthold Technologies, Bad Wildbad, Germany) equipped with EZChrom Elite version 3.1.7 
software for data acquisition (Scientific Software, Pleasanton, CA, USA) and a fraction collector FC 
203 (Gilson International BV, Den Haag, The Netherlands). For separation, a Vydac Everest C18 (250 × 
4.6 mm, 5 µm particle size) column (Grace, Baltimore, MD, USA) was coupled to the HPLC system. 
Mixtures of water (0.1% FA m/V) and acetonitrile (0.1% FA m/V) were used to create appropriate 
gradients for separation of peptides and their iodinated forms. The mono- (and di-) iodinated peptide 
fractions were then concentrated (if necessary) by nitrogen drying and the appropriate peptide 
concentrations prepared using Lactated Ringer’s solution containing 1% of BSA. The negative control, 
i.e. BSA, was iodinated using the same procedure and the iodinated protein isolated from free iodine 
using an argent filter. 
Peptides phrANTH2 and phrCACET1 were iodinated using the Chloramine-T method [26]: 50 µl of 
peptide solution (1 µmol/ml) was subsequently mixed with 20 µl of 4.5 mg/ml NaI in 100 mM 
phosphate buffer (phrANTH2) or 0.1% m/V formic acid in water (phrCACET1), 1 mCi of Na125I solution 
and 30 µl of a 4 mg/ml Chloramine-T in phosphate buffer solution (100 mM). For phrCACET1, 40 µl of 
0.1% m/V formic acid in water was added before the Chloramine-T solution as well. The iodination 
reaction was continued for 120 (phrANTH2) or 40 (phrCACET1) seconds, after which 30 µl of sodium 
metabisulphite solution (8 mg/ml) was added to neutralize the oxidizing agent. Next, the reaction 
mixtures were analysed by radio-HPLC using the described procedures and the eluting fractions 
determined for radioactivity amount. Again, nitrogen drying was performed on the mono- (and di-) 
iodinated fractions and the solutions prepared using Lactated Ringer’s solution containing 1% of BSA. 
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Multiple time regression analysis 
In order to determine whether the peptides could enter the brain, in vivo multiple time regression 
analyses were performed. Therefore, ICR-CD-1 mice were anesthetized intraperitoneally using a 40% 
urethane solution (3 g/kg). Then, the jugular vein and carotid artery were isolated and 200 µl of the 
radiolabeled peptide solution, diluted to 30 000 cpm/µl using Lactated Ringer’s solution containing 
1% of BSA (LR/BSA), was injected into the jugular vein. At specified time points after injection (i.e. 1, 
3, 5, 10, 12.5 and 15 min, with start and end in duplicates), blood was obtained from the carotid 
artery followed by decapitation of the mouse. The isolated brain was weighed and radioactivity 
measured in a gamma counter (Wallac Wizard automatic gamma counter, Perkin Elmer, Shelton, CT, 
USA), as well as from 50 µl serum, which was obtained by centrifuging the collected blood at 
10 000 g for 15 min at 21°C. To evaluate the tissue distribution of the peptides during the BBB-
experiments, seven other tissues, i.e. spleen, kidneys, lungs, heart, duodenum, muscles and liver, 
were collected immediately after decapitation of the mice at the last time point of 15 min. After 
weighing the tissues, the radioactivity was measured in a gamma counter.  
The linear modeling of the multiple time regression analysis is based on the Gjedde-Patlak equation 
[27-29]:  
iin VK 
(t)C
(t)A
p
m
  where 


T
0
p
p
(t)C
dt(t)C
                 (1) 
and where Am(t) is the amount of radioactivity in the brain at time t, Cp(t) the amount of radioactivity 
in serum at time t, Kin the brain influx rate constant and Vi the initial brain distribution volume. 
During the multiple time regression experiments, peptides are intravenously injected, which causes 
clearance by the organs. Therefore, the exposure time is used during the modeling of the brain influx 
of the peptides to account for the decreasing concentrations. The exposure time ( ) represents the 
theoretical steady-state serum level of radiolabeled peptide at the serum concentration Cp(t) and is 
defined as the integral of the serum radioactivity over time divided by the radioactivity at time t. The 
integral of radioactivity over time is represented by the area under the curve [27,30,31].  
Finally, the brain/serum ratios (µl/g) were plotted versus the exposure time and the slope of this 
relationship measures the unidirectional influx rate (Kin) from blood to brain, whereas the intercept 
represents the initial brain volume of distribution (Vi). 
For the evaluation of the tissue distribution of the radiolabeled peptides 15 min after IV-injection, 
the percentage of the injected dose for each isolated tissue is calculated as follows: 
       (2) 
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where Atissue and Ainjected are the measured activity of the isolated tissue and the activity of 200 µl of 
Multiple Time Regression solution, respectively, while wtissue is the weight of the considered tissue 
and wanimal is the mass of the injected mouse. The results are the mean values of the duplicates. 
 
Capillary depletion 
This method was performed to determine whether the peptides, taken up by the brain, completely 
crossed the capillary wall instead of being trapped there. The method of Triguero et al., as modified 
by Gutierrez et al., was used [32,33]. Briefly, ICR-CD-1 mice were first anesthetized intraperitoneally 
using a 40% urethane solution (3 g/kg). After isolation of the jugular vein, 200 µl of the iodinated 
peptide solution, diluted to 10 000 cpm/µl using LR/BSA, was injected in the jugular vein. Ten 
minutes after injection, blood was collected from the abdominal aorta and the brain was perfused 
manually with 20 ml of Lactated Ringer’s buffer after clamping the aorta and severing the jugular 
veins. Subsequently, the brain was collected, weighed and the radioactivity measured in the gamma 
counter. Then, the brain was homogenized with 0.7 ml of ice-cold capillary buffer (10 mM HEPES, 
141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM MgSO4, 1 mM NaH2PO4 and 10 mM D-glucose adjusted 
to pH 7.4) in a pyrex glass tube and mixed with 1.7 ml of 26% ice-cold dextran solution in capillary 
buffer. The resulting solution was weighed and centrifuged in a swinging bucket rotor at 5400 g for 
30 min at 4°C, after measuring the radioactivity in the gamma counter. Pellet (capillaries) and 
supernatant (parenchyma and fat tissues) were collected, weighed and measured in a gamma 
counter. After centrifuging the obtained blood (10 000 g, 21°C, 15 min), the radioactivity of 50 µl 
serum was measured in a gamma counter as well.  
Compartmental distribution was calculated as follows: 
       (3) 
where CDtissue represents the ratio of the activity of the capillaries or parenchyma and the activity of 
serum for the fraction of radiolabeled peptide in the capillaries and parenchyma, respectively. 
 
Brain-to-blood transport  
This method was performed to quantify the amount of peptide pumped out of the brain by efflux 
transport as previously described [34]. ICR-CD-1 mice were anesthetized intraperitoneally using a 
40% urethane solution (3 g/kg). Then, the skin of the skull was removed and a hole was made into 
the lateral ventricle using a 22 G needle marked with tape at 2 mm at the following coordinates: 
1 mm lateral and 0.34 mm posterior to the bregma. The anesthetized mice received an 
intracerebroventricular injection of 1 µl of the diluted iodinated peptide solution using LR/BSA (25 
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000 cpm/µl) by pumping the peptide solution at a speed of 360 µl/h for 10 s using a syringe pump 
(KDS100, KR analytical, Cheshire, UK). At specified time points after intracerebroventricular injection 
(i.e. 1, 3, 5, 10, 12.5 and 15 min), blood was collected from the abdominal aorta and subsequently 
the mouse was decapitated. Then, the whole brain was collected, weighed and measured in a 
gamma counter, as well as from 50 µl of serum, which was obtained by centrifuging the collected 
blood at 10 000 g during 15 min at 21°C. The efflux half-life was calculated from the linear regression 
of the natural logarithm of the residual radioactivity in brain versus time as follows: 
           (4) 
where kout is defined as the efflux rate constant calculated as the negative value of the slope of the 
linear regression, applying first order kinetics. 
 
In vitro human plasma stability 
In vitro metabolic stability of the quorum sensing peptides was determined in human plasma using 
previously described procedures [35]. In brief, 100 µg of non-radiolabeled peptide was incubated in 
400 µl of Krebs-Henseleit buffer pH 7.4 and 500 µl of plasma at 37°C while shaking. At predetermined 
time intervals (i.e. 0, 30 and 120 minutes), aliquots were immediately transferred into microtubes 
containing 1:1 volume of 1% (V/V) trifluoroacetic acid solution in water. The enzyme reaction was 
further stopped by heating the solution at 95°C for 5 minutes. Next, the samples were centrifuged to 
precipitate the denatured proteins and the supernatant analysed using UPLC-PDA. The system 
consisted of a Waters Acquity H-Class Bio-samples Flow Through Needle (flow rate set at 0.5 ml/min), 
Waters Acquity H-Class BioQuaternary Solvent Manager, Waters Acquity H-Class column module (set 
at 30°C), Waters Acquity H-Class Photodiode Array Detector (PDA, quantification at 210 nm) or 
Waters Xevo TQ-S (Selected Ion Recording, SIR) and equipped with Waters Empower Pro software 
version 2 or MassLynx version 4.1 (Waters, Zellik, Belgium). Mixtures of water (0.1% FA m/V) and 
acetonitrile (0.1% FA m/V) were used to create appropriate gradients for separation of peptides and 
their metabolites. An appropriate placebo solution was similarly prepared. Assuming first-order 
kinetics, the rate constant k was obtained from 
           (5) 
from which the half-life was determined as 
           (6) 
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3.  RESULTS 
Peptide selection 
The clustering results of the quorum sensing peptides are given in Figure 1: three main, chemically 
diverse clusters can be distinguished [22]. From each cluster, we selected one peptide resulting in 
three chemically diverse molecules, i.e. BIP-2 (Quorumpeps ID102), PhrANTH2 (Quorumpeps ID186) 
and PhrCACET1 (Quorumpeps ID206). BIP-2, or bacteriocin-inducing peptide 2, is synthesized by 
Streptococcus pneumoniae, a commensal of the human nasopharynx [36,37]. PhrANTH2 is produced 
by Bacillus anthracis, while PhrCACET1 is formed by Clostridium acetobutylicum [38]. 
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Figure 1. Score plot of the PCA analysis, distinguishing 3 main clusters. The selected peptides are indicated by 
the purple rectangles, i.e. Quorumpeps
®
 ID102 (BIP-2), ID206 (PhrCACET1) and ID186 (PhrANTH2). 
 
Brain influx and tissue distribution 
Only 2 of the 3 investigated peptides showed a statistically significant influx into the mouse brain. In 
Figure 2, the ratio of the brain and serum radioactivity is plotted versus the exposure time; the 
quantitative influx parameters of the molecules are summarized in Table 1. The data were fitted 
using a simple linear regression model (equation 1). 
Dermorphin clearly showed an influx: the calculated influx rate constant is 0.26 µl/(g×min). In 
literature, it is well established that BSA shows a very small, almost negligible brain influx in the 
Multiple Time Regression technique [39]. Here, we confirmed this small influx into the brain for BSA: 
a Kin of 0.12 µl/(g×min) was calculated. Both controls thus indicated a good performance of the brain 
influx experiments and their obtained values can be used to benchmark the influx results of the 
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quorum sensing peptides. Peptide PhrANTH2 showed a very small influx into the brain, comparable 
to BSA: a Kin of 0.18 µl/(g×min) is measured and found not to be statistically significantly higher than 
the Kin of BSA. Peptide PhrCACET1 shows a very high influx into the brain as the Kin was determined 
to be 1.33 µl/(g×min); the high Vi value indicates a rapid influx as well. BIP-2 showed a small influx 
into the brain: a Kin of 0.35 µl/(g×min) was measured and found to be statistically significantly higher 
than the Kin of BSA,  comparable to dermorphin (not significantly different) but lower than the Kin of 
PhrCACET1.  
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Figure 2. Brain influx of the selected quorum sensing peptides, using the simple linear regression method.  
BSA and dermorphin were used as the negative and positive controls, respectively.  
PhrANTH2 shows no significant brain influx, while the results of PhrCACET1 and BIP-2 indicate BBB 
permeability, which is the highest for PhrCACET1. 
 
 
Table 1. Overview of the multiple time regression results using the linear regression model.  
Between brackets, the 65% confidence interval is mentioned (i.e. ± 1 SEM). 
Peptide Kin (µl/(g × min)) Vi (µl/g) 
BSA 
0.12 
[0.040, 0.20] 
14.59 
[13.36, 15.81] 
Dermorphin 
0.26 
[0.15, 0.36] 
22.83 
[21.25, 24.41] 
PhrANTH2 
0.18 
[0.15, 0.22] 
6.59 
[6.12, 7.06] 
PhrCACET1 
1.33 
[0.56, 2.11] 
35.53 
[25.41, 45.65] 
BIP-2 
0.35 
[0.24, 0.47] 
12.67 
[10.07, 15.28] 
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It is also clear that dermorphin, PhrCACET1 and BIP-2 showed a biphasic brain influx model [40], 
characterized by a rapid initial uptake followed by a plateauing equilibrium. This initial brain uptake 
kinetics of BIP-2 (from 1 to 3 minutes) was similar to dermorphin (3.0 and 3.4 µl/(g×min), 
respectively), while PhrCACET1 showed a much higher initial unidirectional blood clearance 
(11.3 µl/(g×min)). These initial brain influx results thus correspond well with the overall classification 
conclusions: PhrCACET1 showed the highest brain influx, followed by BIP-2 and dermorphin. 
The results of the capillary depletion study (Figure 3) at 10 min after injection validate the high brain 
influx of peptide PhrCACET1: the absolute amount of peptide in the brain (i.e. absolute y-axis values 
of Figure 3) is much higher for this peptide compared to the others. The relative amount of peptide 
that is effectively transferred into the brain showed a higher brain parenchyma (77% – 86%) versus a 
lower capillary retention (14% - 23%) for the three peptides. 
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Figure 3. Capillary depletion results of the quorum sensing peptides.  
The amount of peptide that is effectively transferred into the brain shows a higher brain parenchyma (green) 
versus a relatively low capillary (red) distribution for the three peptides. The capillary and parenchyma fraction 
(%) are indicated above the histogram. 
 
 
In Figure 4, the relative concentrations in the different tissues, obtained from Multiple Time 
Regression experiments at the last time points (i.e. at 15 minutes post-injection) are graphically 
presented. BSA showed a clear liver distribution, while dermorphin was mainly distributed in the 
duodenum, followed by the liver and serum, 15 min after i.v. injection. The high duodenum 
accumulation is explained by the presence of peripheral mu opioid receptors for which dermorphin 
shows high affinity [41]. PhrANTH2 showed a low tissue distribution, while PhrCACET1 shows a 
higher distribution in the kidneys and duodenum. BIP-2 showed a very high liver accumulation.  
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Figure 4. Tissue distribution of the quorum sensing peptides, 15 minutes after IV administration.  
BSA shows a higher spleen and liver distribution, while dermorphin is massively accumulated in the mice 
duodenum. PhrANTH2 shows no clear tissue distribution, while PhrCACET1 and BIP-2 are mainly distributed to 
the kidneys/duodenum and liver, respectively. 
 
 
Brain-to-blood transport  
The natural logarithm of the measured residual radioactivity in the brain was plotted versus the time, 
to calculate the efflux constant kout. No significant efflux was observed during the experimental time 
of 15 minutes for the three quorum sensing peptides (kout BIP-2 = -0.06 ± 0.02; 
kout PhrANTH2 = -0.05 ± 0.07; kout PhrCACET1 = -0.02 ± 0.03). 
 
In vitro human plasma stability 
In order to correctly interpret the BBB permeability results, we investigated the stability of these 
non-radiolabeled quorum sensing peptides in human plasma. All three peptides were found to be 
stable during the experimental set-up time (i.e. maximum 15 minutes) although quite different 
metabolization kinetics were observed: a half-life value of 56.4, 23.6 and 320.7 minutes was obtained 
for PhrANTH2, PhrCACET1 and BIP-2, respectively. 
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4.  DISCUSSION 
This study demonstrates that the quorum sensing peptide PhrCACET1 (SYPGWSW) efficiently crosses 
the BBB, with a measured brain influx that is higher than that of dermorphin (positive control), which 
generally shows a low but significant influx into the brain. The brain influx permeability of BIP-2 
(GLWEDLLYNINRYAHYIT) through the BBB is lower, i.e. higher than BSA but similar to the dermorphin 
brain influx values. In contrast, PhrANTH2 (SKDYN), shows no significant transport across the BBB in 
an in vivo mouse model. To evaluate these transport results, we compared them with the linear 
influx results of other investigated peptides, obtained using the same technique, for which the data 
are summarized in the Brainpeps® database [42]. The classification system of BBB influx data, using 
the BBBin response proposed by Stalmans et al. [43], indeed indicated a ‘very high influx’ (i.e. class 5, 
BBBin = 9) for the quorum sensing peptide PhrCACET1. A ‘low influx’ classification (i.e. class 2, 
BBBin = 2) is obtained for both BIP-2 and PhrANTH2: despite the clear difference in brain influx values 
between these two peptides, they are both organized in the same class. However, these two 
peptides have Kin values that lie on the edges of the interval ]1.80 × 10
-4; 3.68 × 10-4] ml/(g×min), with 
PhrANTH2 (1.83 × 10-4 ml/(g×min)) very close to ‘very low influx’ or class 1 and BIP-2 
(3.51 × 10-4 ml/(g×min)) very close to ‘median influx’ or class 3.  The brain influx values of dermorphin 
and BSA are correctly classified as ‘low’ and ‘very low’, respectively. 
The brain influx of PhrCACET1 and BIP-2 showed a biphasic behavior: after a steep increase in the 
ratio of the brain and serum activity, the curves reached a plateau phase. For PhrCACET1, this can be 
explained by the saturation of the BBB transport mechanisms and/or accumulation into the kidneys 
and duodenum. For BIP-2, the high liver accumulation will most likely influence the brain influx 
behavior, together with a saturation of transport mechanisms. Metabolization of the peptides is 
limited during the experimental time frame and thus no primary cause of steady-state appearance. 
BIP-2 is synthesized by the Gram-positive bacterium Streptococcus pneumoniae, a commensal of the 
nasopharynx in the majority of healthy children. Other commensal viridans streptococcal species, 
such as Streptococcus mitis, which are genetically highly related to Streptococcus pneumoniae, have 
commensal nasopharynx and oropharynx properties as well. Next to their commensal behavior, a 
variety of infectious complications can be assigned to these pathogens, including meningitis, 
endocarditis, bacteremia and septicemia [37,44]. Based on this bacterial presence, the quorum 
sensing peptides produced by these genetically related bacteria are expected to be available for 
transport to the brain, followed by BBB-penetration and subsequently biological activity. PhrCACET1 
is produced by Clostridium acetobutylicum, a non-pathogenic spore-forming soil bacterium which is 
also used in the production of acetone, butanol and ethanol by large-scale industrial fermentation 
[45]. However, due to the genetic homology of Clostridium acetobutylicum with other pathogenic 
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Clostridium species, i.e. Clostridium botulinum, Clostridium perfringens, Clostridium difficile and 
Clostridium tetani [46,47], comparable peptides can probably also be synthesized in the human body 
by these bacteria. These quorum sensing peptides, when present in the blood, thus can reach the 
brain tissue by penetrating the BBB barrier and exert there their effects.  
The three quorum sensing peptides mainly differ from each other in lipophilicity (principal 
component 2 in PCA plot) and size/compactness (principal component 1 in PCA plot): lipophilicity is 
determined by e.g. the clogP value, the number of hydrogen bonds (nHBonds) and the polarity of the 
molecule (TPSA), while size is evaluated by i.a. the WHIM size index and the Wiener W index. As BBB 
permeability generally increases with lipophilicity, i.e. PhrANTH2 < BIP-2 < PhrCACET1, this 
physicochemical descriptor can help in the prediction of BBB transport characteristics of quorum 
sensing peptides; these findings are thus in accordance with the current understandings in BBB-
permeability of peptides [48], although further research is required to deepen these initial ‘QSPR’ 
relationships. 
When we analyse the clustering results of all Quorumpeps peptides (n = 231, Figure 1) [21,22], and 
select the peptides with a comparable lipophilicity as PhrCACET1 (i.e. the peptide with the highest 
BBB permeability characteristics), we mainly find quorum sensing peptides that are synthesized by 
Bacillus subtilis, all of them containing an isoprenyl group on a tryptophan residue [49]. These 
peptides thus can, theoretically based on this in silico clustering, cross the blood-brain barrier and 
exert their biological effect in the brain. Bacillus subtilis, originally described as a soil organism, is also 
found in the human gut [50], so these PhrCACET1 lipophilicity-related quorum sensing peptides can 
be available for the brain once they have reached the blood circulation.  
 
As our results indicate that certain quorum sensing peptides can pass the blood-brain barrier, future 
research should explore their effect on the brain tissue. Different studies already reported a possible 
association between the microbiota composition and different neurological disorders, without any 
clear explanation for these observations; the study about the role of the quorum sensing peptides in 
these pathologies is thus interesting. Previously, it was suggested that the predominant presence of 
Clostridium spp. in the human gut could be associated with autism in children, due to toxin 
production of this overgrown population [51]. As the quorum sensing peptide PhrCACET1 largely 
crosses the BBB, the neurological effect of this peptide should be investigated as well, since our 
results could potentially explain the mechanisms by which commensal flora trigger autism. Because 
the link between autism and gut microbes is still a topic of debate [52], the study towards the effect 
of quorum sensing peptides on autism disorders is of high interest. Next to autism, recent studies 
have also indicated that microbiota have dramatic effects on other central nervous dysfunctions as 
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well. For example, a shift in the gut microbial composition was demonstrated in hepatic 
encephalopathic patients, indicating the possible involvement of the microbiota in the 
pathophysiology of this disease [53]. Moreover, the human microbiome also seems to play a role in 
depression, anxiety and stress. With depression, a decrease in mood disorders was observed with 
probiotics containing Lactobacilli and Bifidobacteria [19]. The same beneficial effect of these 
probiotics is observed on anxiety as well; in contrary, infection with Campylobacter jejuni elevated 
anxiety-like behavior [19,54]. An altered gut microbiota composition was also associated with stress: 
a decreased abundance of i.a. Bacteroides and an increased abundance of i.a. Clostridium was 
observed after stress exposure [55]. Immune-mediated neuro-psychiatric disorders may be 
influenced by the microbiota as well, including multiple sclerosis, neuromyelitis optica and Guillain-
Barré syndrome [19]. These recent findings, together with our results of BBB-penetration of quorum 
sensing peptides, thus excite the research on the influence of these signaling molecules on the 
development of central nervous system disorders. 
 
 
5. CONCLUSIONS 
We have demonstrated that some quorum sensing peptides (e.g. PhrCACET1 and BIP-2) can pass the 
blood-brain barrier when present in the blood circulation; BIP-2 demonstrated a high liver 
accumulation as well. Our results reported here, i.e. representing the first pharmacokinetic data of 
quorum sensing peptides, are awaiting for more information becoming available about the human 
microbiome (http://www.hmpdacc.org/) [56] as well as about the natural occurrence of quorum 
sensing peptides and their biological effects on mammalian cells, but already indicate a plausible, 
intriguing biological cross-talk mechanism. 
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“Live as if you were to die tomorrow. Learn as if you were to live forever.”  
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ABSTRACT 
Quorum sensing peptides, i.e. signalling molecules synthesized by mainly Gram-positive bacteria, 
have varying effects, going from intra- and interspecies signalling to host crosstalk properties. Their 
biological significance for mammals is only beginning to be explored. Therefore, in this study, we 
investigated their stability in cell medium and their metabolisation kinetics in human plasma, next to 
their in vitro toxicity (i.e. cell viability and haemolysis) on healthy cells as well as on tumour cells. 
Using a Caco-2 model, it was found that some quorum sensing peptides can enter the blood 
circulation via intestinal absorption. No haemolytic activity after a 1 hour incubation period was 
demonstrated and remarkably high plasma stability values were observed for some peptides as well. 
The quorum sensing peptides demonstrated no toxic effects on both healthy and tumour cells using 
MTT; no in silico (tissue and organ) toxicity could be predicted as well. However, tumour-promoting 
effects cannot be excluded for some of the quorum sensing peptides, adding to the growing body of 
data that suggest that quorum sensing peptides can influence cancer fate. 
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CHAPTER VIII 
IN VITRO CELL MEDIUM AND HUMAN 
PLASMA STABILITY, CACO-2 PERMEABILITY 
AND TOXICITY OF QUORUM SENSING 
PEPTIDES 
Main focus in this chapter: 
 To reflect the stability of quorum sensing peptides, in order to support the in vitro and in vivo 
significance of the obtained biological functionality results. 
 To investigate if quorum sensing peptides, when present in the human gastrointestinal tract, 
can reach the general circulation. 
 To denote the toxicity of quorum sensing peptides on eukaryotic cells. 
 
1. INTRODUCTION 
‘Quorum sensing’ is the process of cell-to-cell communication between bacteria by the use of 
signalling molecules regulating their gene expression. In contrast to Gram-negative bacteria, Gram-
positive bacteria mainly use oligopeptides to activate this quorum sensing process, leading to i.a. 
biofilm formation with Staphylococcus aureus, competence induction in Streptococcus species (e.g. 
Competence Stimulating Peptide, CSP) and sporulation in Bacillus subtilis (e.g. Competence and 
Sporulation Factor, CSF) [1-3]. These Gram-positive bacteria are found throughout the human body, 
mainly occupying the gastrointestinal tract, skin, mouth, vagina and mammary gland, next to the 
occasional presence in the blood (bacteremia or septicemia). Although not yet investigated, the 
presence of quorum sensing peptides in these different tissues is very likely, given the widespread 
commensal or pathogenic presence of these Gram-positive bacteria in different areas of the human 
body and the physiological detection of other signalling molecules (i.e. acylhomoserine lacton 
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molecules from Gram-negative bacteria) in sputum, faeces and saliva [4,5]. The effects of the 
quorum sensing peptides can be diverse, going from intra-species communication to inter-species 
antimicrobial activity. Moreover, recent investigations from our group have revealed a selective 
crosstalk phenomenon between these quorum sensing peptides and mammalian cells, more 
specifically with human colon and breast cancer cells: some of the quorum sensing peptides were 
found to promote tumour cell invasion and angiogenesis, thereby influencing tumour metastasis 
[6,7]. These findings open new perspectives for understanding the role of the microbiome on our 
health as well as for clinical diagnostic and therapeutic applications. 
In this study, we investigated the toxicity of the quorum sensing peptides on both healthy and 
cancerous cells, next to their effect on red blood cell haemolysis once they have reached the blood 
circulation (e.g. after intestinal absorption). Moreover, the stability of the peptides was investigated 
in cell medium as well as in human plasma, in order to support the in vitro and in vivo significance of 
the biological functionality results. 
 
 
2. MATERIALS AND METHODS 
Peptides 
Based on the clustering results of the first 231 quorum sensing peptides of the Quorumpeps® 
database (http://quorumpeps.ugent.be) [8,9], 98 of these peptides were selected and purchased 
from different suppliers. The peptide purity was determined using UPLC-PDA analyses [10]. An 
overview of these peptides is given in Table 1; the numbering used in the Quorumpeps database is 
retained in this table.  
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Table 1. Peptide information. 
Quorumpeps ID Sequence Solvent 
2 FNTIPSY Water 
5 Ac-CGSLF, thiolacton linkage between C1 and F5 Water + 50% DMSO 
7 FNTWPSY Water 
10 ADLPFEF Water 
11 AGTKPQGKPASNLVECVFSLFKKCN Water 
13 AIFILAS Water + 58% DMSO 
14 AITLIFI Water + 60% DMSO 
15 AKDEH Water 
16 AKTVQ Water 
17 ALILTLVS Water + 60% DMSO 
18 ARNQT Water 
19 NNWNN Water 
22 CVGIW, thiolacton linkage between C1 and W5 Water + 50% DMSO 
24 CTFTLPGGGGVCTLTSECIC Water + 1% DMSO 
25 CVFSLFKKCN Water 
28 DIRHRINNSIWRDIFLKRK Water 
30 DLRGVPNPWGWIFGR Water 
31 DLRNIFLKIKFKKK Water 
32 DMCNGYF, thiolacton linkage between C3 and F7 Water + 50% DMSO 
34 DRVGA Water 
40 DSVCASYF, thiolacton linkage between C4 and F8 Water + 50% DMSO 
42 DWRFLNSIRDLIFPKRK Water 
44 EKMIG Water 
45 EMRISRIILDFLFLRKK Water 
46 EMRKSNNNFFHFLRRI Water 
47 EMRLPKILRDFIFPRKK Water 
49 EQLSFTSIGILQLLTIGTRSCWFFYCRY Water + 17% DMSO 
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Table 1. Peptide information (continued). 
Quorumpeps ID Sequence Solvent 
50 ERGMT Water 
51 ERNNT Water 
52 ERPVG Water 
53 ESRLPKILLDFLFLRKK Water 
54 ESRLPKIRFDFIFPRKK Water 
55 ESRVSRIILDFLFQRKK Water 
56 VNYGNGVSCSKTKCSVNWGQAFQERYTAGINSFVSGVASGAGSIGRRP Water 
58 DSRIRMGFDFSKLFGK Water 
62 ESRISDILLDFLFQRKK Water 
71 QNCPNIFGQWM, lacton linkage between S3 and M11 Water + 50% DMSO 
75 SINSQIGKATSNLVECVFSLFKKCN Water 
76 SNLVECVFSLFKKCN Water 
81 FNTIPKY Water 
82 NTIPKY Water 
84 FFNTCPSY Water 
85 FNTCPSY Water 
92 FHWWQTSPAHFS Water 
93 FLVMFLSG Water + 33% DMSO 
97 QNSPNIFGQWM, lacton linkage between S3 and M11 Water + 50% DMSO 
99 GKAEF Water 
100 GKATSSISKCVFSFFKKC Water + 33% DMSO 
101 GLWEDILYSLNIIKHNNTKGLHHPIQL Water 
102 GLWEDLLYNINRYAHYIT Water + 33% DMSO 
103 GNWNN Water 
105 GSQKGVYASQRSFVPSWFRKIFRN Water 
107 GVNACSSLF, thiolacton linkage between C5 and F9 Water + 50% DMSO 
111 GWWEDFLYRFNIIEQKNTKGFYQPIQL Water + 50% DMSO 
121 ILSGAPCIPW Water 
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Table 1. Peptide information (continued). 
Quorumpeps ID Sequence Solvent 
123 IRFVT Water 
125 KSSAYSLQMGATAIKQVKKLFKKWGW Water 
132 LFSLVLAG Water + 33% DMSO 
133 LFVVTLVG Water + 60% DMSO 
134 LPFEF Water + 50% DMSO 
135 LPFEH Water 
137 LVTLVFV Water + 50% DMSO 
138 MAGNSSNFIHKIKQIFTHR Water + 17% DMSO 
140 MKAEH Water 
143 MPFEF Water 
146 NEVPFEF Water 
147 NGWNN Water 
148 YSTCDFIM, thiolacton linkage between C4 and M8 Water + 50% DMSO 
151 NNGNN Water 
152 NNNWNNN Water 
153 NNWGN Water 
154 NNWNG Water 
155 NWN Water 
156 FNTIP Water 
157 FNTWP Water 
160 QKGMY Water 
162 QRGMI Water 
164 SDLPFEH Water 
165 SDMPFEF Water 
166 SGSLSTFFLLFNRSFTQALGK Water 
174 SGSLSTFFRLFNRSFTQALG Water 
176 SGSLSTFFRLFNRSFTQALGK Water 
177 SGSLSTFFRLFNRSFTQALGKIR Water 
180 SGSLSTFFRLFNRSQTQALGK Water 
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Table 1. Peptide information (continued). 
Quorumpeps ID Sequence Solvent 
184 SIFTLVA Water + 33% DMSO 
186 SKDYN Water 
188 SLSTFFRLFNFSFTQALG Water + 33% DMSO 
191 SRKAT Water 
192 SRNAT Water 
193 SRNVT Water 
206 SYPGWSW Water 
207 TAGPAIRASVKQCQKTLKATRLFTVSCKGKNGCK Water 
208 TNRNYGKPNKDIGTCIWSGFRHC Water 
210 VAVLVLGA Water + 33% DMSO 
212 VPFEF Water 
214 WPFAHWPWQYPR Water 
215 FNTWPKY Water 
218 YNPCSNYL, thiolacton linkage between C4 and L8 Water + 50% DMSO 
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Cell culture 
MCF-7/AZ (human breast adenocarcinoma), HCT-8/E11 (human colorectal adenocarcinoma) and 
HEK-293 (human embryonic kidney) cells were grown in high-glucose Dulbecco’s Modified Eagle’s 
Medium, supplemented with 10% (V/V) foetal bovine serum (FBS), 1% (w/V) L-glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin (all from Invitrogen/GIBCO, Gent, Belgium) in a humidified 
atmosphere of 10% CO2 at 37°C. 
Caco-2 cells, originating from a human colorectal carcinoma, were cultured in high-glucose 
Dulbecco’s Modified Eagle’s Medium with L-glutamine, supplemented with 10% (V/V) foetal bovine 
serum (FBS), 1% of nonessential amino acids (100x), 100 U/ml penicillin and 100 µg/ml streptomycin 
(all from Invitrogen/GIBCO, Gent, Belgium) in a humidified atmosphere of 10% CO2 at 37°C. 
 
Caco-2 permeability assay 
For transport studies, Caco-2 cells were seeded at a density of 300 000 cells for each Transwell® 
(Corning Costar, New York, USA) membrane insert filter (0.4 µm pore size, 12 mm filter diameter). 
Cell culture medium was changed every second day until monolayers were formed (day 21-29); 
monolayer integrity was evaluated using resistance measurements. Transport experiments were 
performed in both the apical-to-basolateral and basolateral-to-apical direction in Hanks’ balanced 
salt solution (HBSS), according to Hubatsch et al. [11]. Peptide solutions (ID19, ID44 and ID155, each 
10 µM in HBSS) were added to the donor compartment and aliquots taken from the receiving 
solution after 30, 60, 90 and 120 minutes of incubation. Aliquots of the donor solutions after 
120 minutes were taken as well for calculation of the mass balance. Atenolol (50 µM) and 
propranolol (20 µM) were used as the low- and high-permeability control, respectively [12]. Peptide 
samples were analysed using UPLC-ESI/MS in selected ion monitoring (SIM, monoisotopic mass of 
the peptides) mode for the peptide analyte, with limits of detection of 0.56 – 0.58 pmol/ml. The 
system consisted of a Waters Acquity H-Class Bio-samples Flow Through Needle (flow rate set at 
0.5 ml/min), Waters Acquity H-Class BioQuaternary Solvent Manager, Waters Acquity H-Class column 
module (set at 30°C) and Waters Xevo TQ-S, equipped with Waters Empower Pro software version 2 
and MassLynx version 4.1 (Waters, Zellik, Belgium). Mixtures of water (0.1% formic acid m/V) and 
acetonitrile (0.1% formic acid m/V) were used to create appropriate gradients (95% to 80% of water 
in 3 minutes) and ACQUITY UPLC BEH300 C18 column (100 mm × 2.1 mm, 1.7 µm) for analysing the 
peptide solutions (5 µl injection volume). PepT1 transport (apical-to-basolateral direction) was 
investigated using the dipeptide LY (Leu-Tyr, 10 µM) substrate in combination with the quorum 
sensing peptide. 
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The apparent permeability coefficient (Papp in cm/s) was determined from the amount of compound 
transported per time and was calculated as follows (sink conditions): Papp = (dQ/dt) / (A×C0), where 
dQ/dt is the steady-state flux (pmol/s), A is the surface area of the filter (cm2) and C0 is the initial 
concentration of analyte in the donor chamber (pmol/ml).  
 
In vitro cell medium and human plasma stability 
In vitro chemical and metabolic stability of the quorum sensing peptides was determined in cell 
medium and human plasma, respectively, using previously described procedures [13]. In brief, 100 µl 
of peptide solution (Table 1, 1 µg/µl) was incubated in 400 µl of Krebs-Henseleit buffer pH 7.4 and 
500 µl of cell medium or plasma at 37°C while shaking. At predetermined time intervals (i.e. 0, 6 and 
24 hours for cell medium; 0, 30 and 120 minutes for plasma), aliquots were immediately transferred 
into microtubes containing 1:10 volume of 1% (V/V) trifluoroacetic acid solution in water. 
Metabolism was quenched by heating the solution at 95°C for 5 minutes. The samples were 
centrifuged to precipitate the denatured proteins and the supernatant was quantitatively analysed 
for the peptide assay using UPLC-PDA or UPLC-ESI/MS. The same system as described for Caco-2 
permeability measurements was used, adding the Waters Acquity H-Class Photodiode Array Detector 
(PDA, quantification at 210 nm) for these analyses as well. Mixtures of water (0.1% FA m/V) and 
acetonitrile (0.1% FA m/V) were used to create appropriate gradients for separation of peptides and 
their metabolites [10]. An appropriate placebo solution was similarly prepared. Assuming first-order 
kinetics, the rate constant k was obtained from ln(Pt/Pt0) = -kt, from which the half-life was 
determined as t1/2 = [ln(2)]/k. If a peptide was found to be stable at the end of the experiment, i.e. > 
90% relative to t0min at 24 hours for cell medium and 120 min for plasma, then the minimal half-life 
was calculated using the 90% value: t1/2 of minimum 157.9 hours for cell medium and minimum 
13.2 hours for plasma. 
 
Haemolysis assay 
A 10 µM stock solution is prepared for each quorum sensing peptide using water, with or without 
DMSO for solubility reasons, as described in Table 1. 40 µl of this stock solution is then diluted with 
280 µl of 100 mM sodium phosphate buffer, pH 7.4 to obtain the peptide sample. To prepare the red 
blood cell solution, freshly obtained human blood was centrifuged at 1500 rpm for 15 minutes and 
the precipitate washed three times using freshly prepared 150 mM NaCl solution. After the final 
centrifugation step, the precipitate was resuspended into 100 mM sodium phosphate buffer pH 7.4 
and mixed by inversion. The red blood cell solution was then diluted 1 to 10 with the same solvent to 
obtain the diluted red blood cell solution. To examine the haemolytic properties of the quorum 
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sensing peptides, 320 µl of the peptide sample was mixed with 80 µl of the diluted red blood cell 
solution to obtain a final volume of 400 µl and a final peptide concentration of 1 µM. Samples were 
incubated for 1 hour at 37°C while gently shaking. 100 mM sodium phosphate buffer pH 7.4 and 1% 
(V/V) Triton X-100 were chosen as the negative and positive control solutions, respectively. Blank 
solution was obtained by mixing 40 µl of water or aqueous DMSO (60%) with 280 µl of 100 mM 
sodium phosphate buffer pH 7.4 and 80 µl of diluted red blood cell solution. After 1 hour of 
incubation, all samples were centrifuged at 20 000 g for 5 minutes. The absorbance of the 
supernatant was measured at 405 nm and corrected for the blank absorbance. The percent 
haemolysis was then calculated using the following equation: [(Asample – Ablank) / (Apositive control – Ablank)] 
× 100 
 
In silico toxicity screening 
The geometrical structure of the quorum sensing peptides was drawn using HyperChem 8.0 
(Hypercube, Gainesville, FL, USA) as previously described [9]. Next, these peptide structures were 
loaded into the Derek Nexus 2.0 (Lhasa Limited, Leeds, United Kingdom) software program and the 
toxicity analysed using its toxicity knowledgebase. 
 
MTT cell viability assay 
HEK-293, HCT-8/E11 and MCF-7/AZ cells were suspended at 1 × 105 cells/ml, 2 × 104 cells/ml and 
1 × 104 cells/ml, respectively. 90 µl of this cell suspension was transferred to a well of a 96-well plate. 
After an overnight incubation at 37°C and 10% CO2, 10 µl of the selected peptide samples (10 µM, 
1 µM and 100 nM) was added to the wells. Blank wells only contained cell medium, while positive 
and negative controls contained 90 µl of cell suspension and 10 µl of DMSO or water, respectively. 
The cells were again incubated at 37°C and 10% CO2 for 24 hours. Next, 20 µl of a 12 mM MTT 
reagent solution was added to each well and the incubation continued for 2 to 4 hours. The cells 
were periodically viewed under the inverted microscope for presence of intracellular purple 
precipitates. When the purple precipitate was clearly visible, the cell medium was removed and 
100 µl of DMSO added to each well and swirled gently. The 96-well plate with cover was left in the 
dark for 10 minutes at 37°C. The absorbance of the solutions was measured at 570 nm in a microtiter 
plate reader. The number of viable cells was then calculated using the following equation: Viable 
cells (%) = [(Asample – Ablank)/(Anegative control - Ablank)] × 100. 
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3.  RESULTS 
Quorum sensing peptides may pass the intestinal barrier 
Extracellular Death Factor (EDF) ID19 (NNWNN), which is synthesized by the human gut commensal 
Escherichia coli, was found to be impermeable through the human epithelial enterocytes under our 
experimental Caco-2 conditions (i.e. Papp < 2.9 × 10
-9 cm/s as LoD = 0.58 nM). However, its tripeptide 
analogue ID155 (NWN) shows low intestinal permeability kinetics (Figure 1): a permeability 
coefficient (Papp,ab) of 1.41 × 10
-7 cm/s was calculated for the apical-to-basolateral transport. The 
efflux ratio (Papp,ba/Papp,ab) of 1.10 is doubled using a PepT1 substrate, i.e. dipeptide LY: the Papp,ab 
decreases to 6.94 × 10-8 cm/s, indicative for the active proton-dependent transport mechanism for 
ID155 peptide absorption. In vivo - in vitro correlation studies demonstrated that these in vitro Papp 
values correspond with the absorption of about 5-10% in humans (in vivo) [11,14]. 
Quorum sensing peptide ID44 (PhrG, EKMIG), produced by Bacillus subtilis, only shows very small 
blood efflux (basolateral-to-apical) transport properties after 120 minutes (1.37 × 10-8 cm/s), without 
significant Caco-2 influx kinetics (LoD = 0.56 nM, so Papp < 6.9 × 10
-9 cm/s).  
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Figure 1. Intestinal permeability of quorum sensing peptide ID155. 
(A) Mean (n = 5) apical-to-basolateral transport (i.e. intestinal absorption) of the EDF-analogue ID155 (NWN) 
through a Caco-2 monolayer; (B) mean (n = 6) basolateral-to-apical transport (i.e. blood efflux) of the ID155 
peptide. Error bars represent SEM values. 
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Remarkably high cell medium and plasma stability half-life values are 
observed for some quorum sensing peptides 
An overview of the estimated half-life values in cell medium and human plasma is given in Table 2. 
The half-life values of the quorum sensing peptides in cell medium range from relatively short (i.e. 
less than 36 minutes) to very high (i.e. more than 160 hours). The same is true for the human plasma 
stability with t1/2 values ranging from less than 3 minutes to over 13 hours.  
Almost 70% of the selected peptides have an in vitro plasma half-life value of 1 hour and more, with 
half of the peptides even having a half-life of more than 2.5 hours. More than 50% of the peptides 
have stability half-life values of over 24 hours in cell medium, which is the incubation period used 
during our cell viability assay. Most of the investigated quorum sensing peptides are thus relatively 
stable in cell medium and human plasma. 
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Table 2. Plasma and cell medium half-life values of the quorum sensing peptides. 
Quorumpeps ID Plasma half-life (h) Medium half-life (h) 
2 4.4 22.0 
7 2.2 5.6 
10 9.2 > 160
(2)
 
13 2.2 51.0 
16 0.8 22.5 
17 2.5
(1)
 29.8 
18 0.3
(1)
 10.3 
19 > 13
(1)(2)
 16.2
(1)
 
28 > 13
(1)(2)
 42.8 
30 -
(3)
 20.8 
34 > 13
(1)(2)
 > 160
(1)(2)
 
42 > 13
(1)(2)
 52.2 
44 > 13
(2)
 > 160
(1)(2)
 
45 -
(3)
 33.1 
46 8.7 45.8 
47 0.4 > 160
(1)(2)
 
50 > 13
(1)(2)
 > 160
(1)(2)
 
51 -
(3)
 18.3 
52 > 13
(1)(2)
 > 160
(1)(2)
 
54 8.8 > 160
(1)(2)
 
55 9.4 > 160
(1)(2)
 
58 1.3 10.9 
62 12.7 > 160
(1)(2)
 
76 -
(3)
 25.0
(1)
 
81 0.9 85.8
(1)
 
84 0.5 8.4
(1)
 
85 < 0.05
(1)(4)
 < 0.6
(1)(4)
 
92 0.4 10.4 
93 -
(3)
 45.3 
99 0.4 62.1 
101 -
(3)
 10.5 
102 -
(3)
 26.9
(1)
 
103 2.1 13.6 
105 9.3 > 160
(1)(2)
 
111 -
(3)
 51.1 
123 0.4 4.2 
132 9.3 13.5
(1)
 
133 9.0 12.7 
135 0.2
(1)
 17.3
(1)
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Table 2. Plasma and cell medium half-life values of the quorum sensing peptides (continued). 
Quorumpeps ID Plasma half-life (h) Medium half-life (h) 
137 8.0 24.6
(1)
 
138 1.5 36.0 
143 0.6 54.6 
146 > 13
(2)
 21.5
(1)
 
147 > 13
(1)(2)
 5.8 
151 -
(3)
 16.2 
152 > 13
(2)
 15.8 
153 > 13
(1)(2)
 5.8 
154 > 13
(2)
 8.6 
155 4.5 42.0 
156 0.9 11.2 
157 1.0 19.0 
160 0.3
(1)
 9.9 
162 1.5 2.7
(1)
 
164 > 13
(1)(2)
 75.6
(1)
 
165 1.8 129.9 
166 -
(3)
 34.0 
174 -
(3)
 > 160
(1)(2)
 
176 -
(3)
 > 160
(2)
 
180 12.4 > 160
(1)(2)
 
184 6.1 11.4
(1)
 
186 0.3
 (1)
 18.4
(1)
 
188 -
(3)
 31.0
(1)
 
192 1.2 51.1 
193 0.7 34.5 
206 0.4 6.9 
208 < 0.05
(1)(4)
 4.9
(1)
 
210 3.9 5.5
(1)
 
212 0.2
(1)
 26.0 
215 1.5 20.1 
(1)
 -: the half-life is calculated using 2 time points. 
(2) 
The calculated half-life is 13.2 hours and 157.9 hours for plasma and medium, respectively. 
(3) 
The half-life could not directly be calculated, due to co-elution of plasma or cell medium components in the 
applied LC-method. 
(4)
 At t = 6 h (cell medium) or t = 30 min (plasma), the peptide was no longer detectable. Under assumption that 
degradation follows first-order kinetics, at 10 times the t1/2 the peptide is considered to be completely degraded. 
Thus, t1/2 is considered to be < 0.6 h in cell medium and < 0.05 h in plasma.  
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The investigated quorum sensing peptides are not haemolytic 
All investigated quorum sensing peptides were found to be non-haemolytic, i.e. haemolysis values 
are below the permissible level of 0.8% according to the Council of Europe guidelines or 1% as per 
the US FDA guidelines for medical devices (Figure 2) [15]. No significant difference was observed 
between the water and DMSO blank solutions, indicating that aqueous DMSO, used for dissolution of 
the peptide, could not be responsible for eventually observed haemolysis of the red blood cells. The 
negative control solution gave a mean haemolysis value of 0.07%. Peptide ID99 showed the highest 
percentage of haemolysis, but it is still limited to 0.39% after a 1 hour incubation period. The 3-sigma 
upper control limit was 0.48%, which is still below the permissible level. The results of this in vitro 
toxicity test on red blood cells, used as a model system [16], thus indicate that the investigated 
quorum sensing peptides are not toxic against normal eukaryotic cells. 
 
 
Figure 2. Haemolysis values of the investigated quorum sensing peptides.  
All 99 quorum sensing peptides were found to be non-haemolytic at a peptide concentration of 1 µM.  
Upper Control Limit (UCL) = 0.48; average = 0.03; Lower Control Limit (LCL) = -0.43.  
Control limits: 0.003 probability limits (3-sigma). 
 
 
In silico tissue and organ toxicity of quorum sensing peptides 
The in silico toxicity evaluation of the quorum sensing peptides using Derek Nexus 2.0 is given in 
Table 3. There are no peptides found in the toxicity class ‘≥ probable’, so none of the selected 
quorum sensing peptides have a level of likelihood of ‘probable’ for at least one endpoint. The most 
frequent in silico toxicities observed are hepatotoxicity, chromosome damage in vitro and skin 
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sensitisation. Some peptides (36 out of 99) belong to the class ‘plausible’, having a level of likelihood 
of ‘plausible’ for at least one endpoint. This means that most of the selected quorum sensing 
peptides (63 out of 99) have a level of likelihood of equivocal or lower. The quorum sensing peptides 
show no in silico toxicity in bacterial species (class ‘impossible’). 
 
No direct cell-killing effect is observed with the quorum sensing peptides 
The selected quorum sensing peptides do not show a cell-killing effect on MCF-7/AZ and HCT-8/E11 
tumour cells, neither on healthy kidney cells (HEK-293) after 24 hours of treatment (Figure 3). 
Peptide ID76 (100 nM), in contrast to the other investigated quorum sensing peptides, induced an 
increased proliferation of HCT-8/E11 cells. The same is true for ID177 (1 µM), ID131 (100 nM), ID10 
(100 nM) and ID186 (10 nM) on the HEK-193 cells. These positive outliers indicate that some quorum 
sensing peptides could promote the proliferation of cells and therefore require further 
investigations. 
 
 
 
Figure 3. Boxplot of the mean cell viability results after quorum sensing peptide treatment during 24 hours.  
The investigated quorum sensing peptides do not directly kill the (A) MCF-7/AZ (n = 2), (B) HCT-8/E11 (n = 4) 
and (C) HEK-293 (n = 2) cells at the three investigated concentrations (i.e. 1 µM, 100 nM and 10 nM). DMSO 
(50% or 60% solution) is used as the positive control.
A B 
C 
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Table 3. In silico toxicity results of the quorum sensing peptides. 
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2                         
5                         
7                         
10                         
11                         
13                         
14                         
15                         
16                         
17                         
18                         
19                         
22                         
24                         
25                         
28                         
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31                         
32                         
34                         
40                         
42                         
44                         
45                         
46                         
47                         
49                         
50                         
51                         
52                         
53                         
54                         
55                         
56                         
58                         
62                         
69                         
75                         
76                         
81                         
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Table 3. In silico toxicity results of the quorum sensing peptides (continued). 
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82                         
84                         
85                         
92                         
93                         
97                         
99                         
100                         
101                         
102                         
103                         
105                         
107                         
111                         
121                         
123                         
125                         
131                         
132                         
133                         
134                         
135                         
137                         
138                         
140                         
143                         
146                         
147                         
148                         
151                         
152                         
153                         
154                         
155                         
156                         
157                         
160                         
162                         
164                         
165                         
166                         
174                         
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Table 3. In silico toxicity results of the quorum sensing peptides (continued). 
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176                         
177                         
180                         
184                         
186                         
188                         
191                         
192                         
193                         
206                         
207                         
208                         
210                         
212                         
214                         
215                         
218                         
The level of likelihood, a qualitative indication for the toxicity prediction of a chemical, is given as follows (in descending 
probability):  Plausible  ; Equivocal ; Doubted   ; Improbable   ; Impossible  .  
Empty cells in the matrix indicate that there is no evidence of toxicity, nor evidence of non-toxicity. 
M: mammal; B: bacterium 
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4.  DISCUSSION 
The vast majority of bacteria inhabit the human intestine, with as many as 1012 bacterial cells per 
gram of the average human faeces [17]. Quorum sensing peptides produced by these commensal or 
pathogenic bacteria thus can enter the blood circulation after passing the intestinal mucosa. As 
indicated by our Caco-2 permeability results, some of these peptides indeed cross the intestinal 
barrier: quorum sensing peptides originating from intestinal bacteria can thus be found in the blood, 
after which they can exert their effect at distant sites of the human body. Despite the presence of a 
PepT1 transporter protein at the apical membrane of enterocytes, responsible for the absorption of 
di- or tripeptides [18], intestinal permeability is not limited to these small peptide structures: 
previous studies have indicated that larger peptides and proteins can also cross the normal intestine 
in an intact form (e.g. insulin, β-casein) [19-21]. Moreover, the use of permeability enhancers (e.g. 
bile salts, fatty acids or glycerides) can increase the intestinal absorption of the quorum sensing 
peptides as well [22]. Quorum sensing peptides can also enter the circulation through the skin or oral 
mucosa, seen the highly present bacterial population at these sites of the human body [23] and the 
skin and mouth mucosa permeability-data already described for peptides [24,25]. In general, the oral 
mucosa is considered intermediately permeable, situated between the epidermis and the intestinal 
mucosa [26]. 
Once the quorum sensing peptides have reached the blood circulation, either after intestinal 
absorption or using alternative absorption routes (e.g. skin or mouth mucosa), the quorum sensing 
peptides are prone to metabolic degradation. A wide distribution of in vitro half-life values has been 
obtained for the quorum sensing peptides in human plasma, with a number of peptides even being 
stable for 13 hours and more. The stability in cell medium varies largely as well, with some peptides 
being stable for minimum 160 hours. However, very unstable peptides are also identified in both cell 
medium and human plasma. The effects observed during in vitro cell-based assays thus can be due to 
degradants arising during the experiment. For the vast majority of the quorum sensing peptides, the 
in vitro stability half-life values are smaller in human plasma than in cell medium, due to the 
presence of peptidases in the former solution. However, for some of the Extracellular Death Factor 
(EDF) peptide-analogues (ID147, ID153 and ID154), the opposite is observed: the stability of this 
defined peptide group is higher in human plasma (i.e. t1/2 > 13 hours) than in cell medium (i.e. t1/2 
values of around 7 hours). 
The quorum sensing peptides (1 µM) were found to be non-haemolytic after a 1 hour incubation 
period with human red blood cells. Haemolysis is one of the main drawbacks during the development 
of peptide-based therapeutics, with the antimicrobial, anticancer and cell-penetrating peptides 
belonging to the main peptide groups with haemolytic characteristics [16,27-30].  
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The toxicity of the quorum sensing peptides at different sites of the human body was investigated 
using in silico screening methods: none of the selected quorum sensing peptides showed toxicity 
(e.g. hepatotoxicity or chromosome damage) with high probability. These observations are in 
accordance with other recent predictions on peptide toxicity, where the high abundance of cysteine 
(C), asparagine (N) and proline (P) amino acids is associated with increased toxicity [31]; as the 
investigated quorum sensing peptides do not predominantly contain these types of residues (average 
19% of the peptide sequence), a low toxicity can thus be assumed. The ToxinPred (specific for 
peptides) toxicity predictions (http://crdd.osdd.net/raghava/toxinpred/index.html) of the peptides 
with the highest number of C, N or P amino acids, relative to the total amount of amino acids in the 
peptide sequence (e.g. ID152, ID22 and ID214) confirm the non-toxicity of the quorum sensing 
peptides [31].    
The investigated quorum sensing peptides, which represent a large part of the quorum sensing 
peptide space [9], do not directly kill healthy kidney cells, cancerous colon cells or breast cancer cells. 
In contrast to the cell-killing properties, the cell viability assay indicated cell proliferative effects for 
some quorum sensing peptides on HCT-8/E11 and HEK-293 cells. These initial findings add to our 
previous evidence implicating the selective role of quorum sensing peptides on tumour cells [6,7].  
 
 
5.  CONCLUSIONS 
In conclusion, some quorum sensing peptides, produced by different commensal or pathogenic 
bacteria, may pass the intestinal barrier, thereby reaching the blood circulation of the host and 
remain sufficiently stable. There, the peptides showed no haemolytic properties on red blood cells, 
so no primary toxicity on eukaryotic cells can be assigned to these molecules. Moreover, the peptides 
demonstrated no direct cell killing effect on other healthy cells or tumour cells as well, next to 
limited in silico probability of organ and tissue toxicity. 
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ABSTRACT 
Radiolabelled peptides and proteins have recently gained great interest as theranostics, due to their 
numerous and considerable advantages over small (organic) molecules. Developmental procedures of 
these radiolabelled biomolecules start with the radiolabelling process, greatly defined by the amino 
acid composition of the molecule and the radionuclide used. Depending on the radionuclide 
selection, radiolabelling starting materials are whether or not essential for efficient radiolabelling, 
resulting in direct or indirect radioiodination, radiometal-chelate coupling, indirect radiofluorination 
or 3H/14C-labelling. Before preclinical investigations are performed, quality control analyses of the 
synthesized radiopharmaceutical are recommended to eliminate false positive or negative 
functionality results, e.g. changed receptor binding properties due to (radiolabelled) impurities. 
Therefore, radionuclidic, radiochemical and chemical purity are investigated, next to the general 
peptide attributes as described in the European and the United States Pharmacopeia. Moreover, in 
vitro and in vivo stability characteristics of the peptides and proteins also need to be explored, seen 
their strong sensitivity to proteinases and peptidases, together with radiolysis and trans-chelation 
phenomena of the radiopharmaceuticals. In vitro biomedical characterization of the radiolabelled 
peptides and proteins is performed by saturation, kinetic and competition binding assays, analysing 
KD, Bmax, kon, koff and internalization properties, taking into account the chemical and metabolic 
stability and adsorption events inherent to peptides and proteins. In vivo biodistribution can be 
adapted by linker, chelate or radionuclide modifications, minimizing normal tissue (e.g. kidney and 
liver) radiation, and resulting in favorable dosimetry analyses. Finally, clinical trials are initiated, 
eventually leading to the marketing of radiolabelled peptides and proteins for PET/SPECT-imaging 
and therapy of different clinical diseases. 
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CHAPTER IX 
DEVELOPMENT OF PEPTIDE AND PROTEIN 
BASED RADIOPHARMACEUTICALS 
Main focus in this chapter: 
 To give an overview of the techniques used for the radiolabelling of peptides and proteins. 
 To summarize the different quality measures for peptide and protein radiopharmaceuticals and 
to indicate their importance to enhance the success rate of these theranostics. 
 To review the available in vitro biomedical and in vivo pharmacokinetic assays. 
 
1. INTRODUCTION 
In the past decades, the use of radiolabelled peptides in research, diagnosis and/or therapy has 
increased enormously. In contrast to most small-molecule drugs, peptides demonstrate high affinity, 
strong selectivity and low toxicity. They can be easily produced and synthetically modified in order to 
optimize their affinity for a particular receptor and to display a more specific biodistribution pattern. 
Moreover, due to their small size, peptides show rapid tissue penetration, together with favourable 
pharmacokinetic properties, i.e. fast clearance from the blood and non-target tissues [1-3]. The main 
drawback of the use of peptide-based compounds is their low stability to peptidases and proteases 
found in most tissues [3]. However, metabolic stability can be increased by substitution of unnatural 
amino acids or D-isomers, amidation or acetylation of peptide termini or cyclisation, hereby increasing 
the probability of obtaining useful drugs, structurally related to the parent peptides [4,5]. Since the 
Food and Drug Administration (FDA) approved the use of insulin as a drug in 1982, (radiolabelled) 
protein therapeutics have found their way in therapy and diagnostics [6]. The main advantage of the 
protein scaffold over small molecules is that the contact interface of protein-protein interactions is 
large (1500-3000 Å2), compared to the contact surface of protein-small molecule interactions (300-
1000 Å2). In addition, the contact surfaces of proteins that interact with other proteins are generally 
flat and often lack the grooves and pockets present at the surface that bind to small molecules [7]. 
Monoclonal antibodies for example show high affinity towards specific cell surface molecules, 
enabling high signal delivery to these targets. However, a major disadvantage of using intact 
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antibodies is that they generally have a long elimination half-life and usually circulate in the blood for 
several days, due to their large size. However, preliminary clinical studies with antibody fragments 
show promising pharmacokinetic results, encouraging the future use of radiolabelled antibody 
fragments [8]. Recent investigations of radiolabelled nanobodies, the smallest possible functional 
immunoglobulin-like antigen-binding fragments, have proven their potential use in e.g. mouse tumour 
models and for cardiovascular applications [9-12]. Pharmacokinetic and tumour targeting 
improvements are achieved through non-covalent interaction with albumin [13]. Recent studies 
indicate for example the potential use of 177Lu-labelled anti-HER2 nanobodies in HER2-overexpressing 
tumour cells, showing high specific tumour uptake combined with low background uptake [14]. 
Currently, different radiolabelled peptides are marketed or investigated in (pre-)clinical trials for their 
use in i.a. oncology (e.g. 111In-DTPA-Octreotide), inflammation and infection (e.g. 99mTc-RP128), 
thrombus imaging (e.g. 99mTc-Apcitide), atherosclerosis (e.g. 18F-Endothelin-1), diabetes mellitus (18F-
labelled C-peptide from insulin) and Parkinson’s (e.g. 18F-DOPA) and Alzheimer’s diseases (e.g. 125I-
amyloid β(1-40)). These peptides can be used as radiotherapeutic drugs or as diagnostics to evaluate 
the presence or progression of a disease. Currently, many tumour types show overexpression of all 
kinds of peptide-binding receptors, while some inflammatory diseases also demonstrate upregulation. 
Therefore, current research mainly focuses on the development of radiolabelled peptides and 
proteins in both these therapeutic areas [5,15-17]. 
To quantitatively detect the radiotracers, different molecular imaging modalities for preclinical 
research and clinical settings are available with different spatial resolutions and selectivity, of which 
positron emission tomography (PET) [18] and single photon emission computed tomography (SPECT) 
are commonly used. PET uses positron-emitting isotope (e.g. 18F, 64Cu, 68Ga) labelled molecules, which 
produce two gamma-rays (about 180° apart) that are crucial for the PET coincidence detection and 
reconstruction of the PET images. Gamma-emitting isotopes (e.g. 99mTc, 123I, 111In) are used for SPECT 
imaging; here, the gamma-cameras are rotating around the patient and collimation of the gamma-
rays is essential [19,20]. Dual-isotope imaging of different SPECT-radiotracers (e.g. 99mTc and 123I) can 
be performed as well, yielding improved performance and reduced acquisition time, hereby reducing 
the phenomenon of cross-talk between the emitted gamma-ray photons [21,22]. 
Finally, radiolabelled peptides and proteins have to undergo several steps to confirm their promising 
use as theranostics. Therefore, after efficient and stable radiolabelling of the peptide or protein, in 
vitro characterization is necessary, determining receptor binding affinity, internalization and cell 
dissociation properties. Next, the pre-clinical in vivo characteristics are defined, evaluating animal 
biodistribution and tissue (e.g. tumour) targeting qualities. Potential molecules are then further 
evaluated during clinical studies in humans, determining safety, efficacy, dose and pharmacokinetics 
[23-25]. 
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2. BASIC BUILDING BLOCKS 
Amino acids for peptides and proteins 
Twenty natural amino acids form the building blocks for peptides and proteins and their composition 
plays a key role in their radiolabelling opportunities and receptor binding characteristics. The diversity 
of the amino acids is distinguished by their different side chains R, dictating their unique physico-
chemical properties. Table 1 shows the different classes of amino acids as well as their chemical 
structure, grouped by their dominant chemical property. Although many strategies have been 
proposed to divide the amino acids into classes, none has been fully satisfactory. By placing a set of 
amino acids in a defined order, called the primary sequence, the blueprint for its three-dimensional 
structure and function is created (cfr. Ramachandran plot [26]). In general, the Ramachandran plot 
shows which conformations are sterically allowed for each residue and a single point defines a certain 
secondary structure (e.g. α helix or β sheet). However, the more bulky the side chains are, the smaller 
the allowed region is. For example, glycine with its -H side chain allows more conformations than 
arginine, which can extend more than about 7 Å from the Cα atom. All specific structural features of 
peptides and proteins (on secondary, tertiary and/or quaternary level) are the result of physical forces 
acting on a polypeptide chain of a defined sequence. Three products of these forces are: (1) 
Hydrophobic groups tend to cluster together and become excluded from water by burial in the 
protein interior (e.g. π-π interactions between aromatic residues); (2) Polar atoms which become 
buried nearly always form hydrogen bonds or salt bridges with other buried polar atoms (e.g. salt 
bridge between polar charged residues); (3) The backbone and side chain conformations that are 
adopted, tend to be those which are favourable for isolated residues.  
Some residues in peptides or proteins have essential structural or functional roles. When they are 
modified, the three-dimensional structure is changed or lost accompanied by a loss or gain of 
function, e.g. the peptide or protein is unable to bind to an interaction partner and perform its 
function. To demonstrate the importance of the amino acid composition and sequence in ligand-
receptor interactions, Liapakis et al. reported the critical role of phenylalanine at position 2 of 
somatostatin hexapeptides for binding to the mutant somatostatine receptor subtype 1 (SSTR1S305F) 
[27]. When this position was substituted by a tyrosine, binding to the SSTR1S305F receptor was 
hindered. The cannabinoid receptor on the other hand shows that an N-terminal extension of its 
peptide ligand changed the functionality from antagonist to agonist [28]. Also on protein level there 
have been different success stories reported based on these principles. Pegvisomant (Somavert) for 
example is a growth hormone receptor antagonist used in the treatment of acromegaly. By adding 
nine substitutions in the receptor binding site on human growth hormone, growth hormone receptor 
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dimerization was hindered and an antagonist was created [29]. In addition, these mutations had an 
additive effect on the binding affinity of this growth hormone analogue for site I on growth hormone 
receptor. However, not only substitutions can influence the structure and functionality of peptides 
and proteins, also residue modifications have been reported to (directly) interfere with the biological 
activity. For instance, 125I-labelling of the angiotensin-(1-7) peptide revealed that the monoiodinated 
form had a biological activity identical to the native compound, whereas this was lost in the di-
iodinated analogue [30]. Labelling of annexin V via amine-directed bifunctional agents, used for the 
detection of cell death, showed decreased biological activity [31]. Next, the reaction conditions used 
to introduce the label may promote some undesirable changes as well, such as oxidation, 
deamidation, side-chain isomerisation or aggregation [32]. 
Therefore, it is important to rationally choose a radiolabelling method for the subject peptide or 
protein (Table 1). Direct radio-iodination is possible through electrophilic aromatic substitution of an 
aromatic proton by radioiodine (I+-form) at tyrosine and histidine moieties [33,34] while direct 99mTc-
labelling is achieved by the reactive sulphide (thiol) groups of cysteine residues [5]. The amino groups 
of lysine and arginine are accessible for bifunctional chelating agent (BFCA) coupling and therefore 
also for radiolabelling. Fluorination of peptides is performed using 18F-labelled prosthetic groups 
through fluoroalkylation, fluoroacylation and fluoroamidation on amino, thiol, hydroxyl or carboxyl 
groups [33].  
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Table 1. Natural amino acids, symbols, structural formula and properties. 
Name, 
three-letter symbol 
and IUPAC one letter 
symbol 
Structural formula  
side chain 
pK1
(a) 
α-COOH 
pK2
(a) 
α-NH3
+ 
pKR
(a) 
side chain 
pI(b) 
Residue 
Mass (c) 
Labelling properties of side chain 
Amino acids with non-polar side chains 
Glycine 
Gly 
G 
 2.35 9.78 - 5.78 57.00 - 
Alanine 
Ala 
A 
 
2.35 9.87 - 5.98 71.1 - 
Valine 
Val 
V 
 
2.29 9.74 - 6.15 99.1 - 
Leucine 
Leu 
L 
 
2.33 9.74 - 6.14 113.2 - 
Isoleucine 
Ile 
I 
 
2.32 9.76 - 6.19 113.2 - 
Methionine 
Met 
M 
 
2.13 9.28 - 6.01 131.2 - 
Proline 
Pro 
P 
 
1.95 10.64 - 7.11 97.1 - 
Phenylalanine 
Phe 
F 
(Aromatic)  
2.20 9.31 - 5.96 147.2 - 
Tryptophan 
Trp 
W 
(Aromatic) 
 
2.46 9.41 - 597 186.2 - 
CHAPTER IX – DEVELOPMENT OF PEPTIDE AND PROTEIN BASED RADIOPHARMACEUTICALS 
 
 
180 
 
Table 1. Natural amino acids, symbols, structural formula and properties (continued). 
Name, 
three-letter symbol 
and IUPAC one letter 
symbol 
Structural formula 
pK1
(a) 
α-COOH 
pK2
(a) 
α-NH3
+ 
pKR
(a) 
side chain 
pI(b) 
Residue 
Mass (c) 
Labelling properties of side chain 
Amino acids with polar side chains (uncharged) 
Serine 
Ser 
S  
2.19 9.21 - 5.69 87.1 Fluorination using prosthetic group on hydroxyl group 
Threonine 
Thr 
T 
 
2.09 9.10 - 5.60 101.1 Fluorination using prosthetic group on hydroxyl group 
Asparagine 
Asn 
N 
 
2.14 8.72 - 5.21 114.1 - 
Glutamine 
Gln 
Q 
 
2.17 9.13 - 5.73 128.1 - 
Tyrosine 
Tyr 
Y 
(Aromatic)  
2.20 9.21 10.46 5.51 163.2 
Direct iodination at the ortho-position of the hydroxyl group; 
Fluorination using prosthetic group on hydroxyl group 
Cysteine 
Cys 
C  
1.92 10.70 8.37 5.67 103.1 
Direct 99mTc-labelling via thiol group; 
Radiolabelling using prosthetic group on thiol group 
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Table 1. Natural amino acids, symbols, structural formula and properties (continued). 
Name, 
three-letter symbol 
and IUPAC one letter 
symbol 
Structural formula 
pK1
(a) 
α-COOH 
pK2
(a) 
α-NH3
+ 
pKR
(a) 
side chain 
pI(b) 
Residue 
Mass (c) 
Labelling properties of side chain 
Amino acids with polar side chains (charged) 
Lysine 
Lys 
K 
 
2.16 9.06 10.54 9.82 128.2 
Radionuclide labelling via BFCA-coupling to amino group; 
Fluorination or iodination using prosthetic group on amino group 
Arginine 
Arg 
R 
 
1.82 8.99 12.48 10.77 156.2 
Radionuclide labelling via BFCA-coupling to amino group; 
Fluorination using prosthetic group on amino group 
Histidine 
His 
H 
 
1.80 9.33 6.04 7.69 137.1 Direct iodination at the positions 2 and 5 of the imidazole-ring 
Aspartic acid 
Asp 
D 
 
1.99 9.90 3.90 3.42 115.1 Fluorination using prosthetic group on carboxyl group 
Glutamic acid 
Glu 
E 
 
2.10 9.47 4.07 2.80 129.1 Fluorination using prosthetic group on carboxyl group 
(a) Data from Voet D, Voet JG, Pratt CW, Fundamentals of Biochemistry (2nd edition), pp76-93, John Wiley & sons, Inc. (2006) [35] 
(b) Determined using ChemSketch 11.02 Software (ADCLabs, Frankfurt, Germany) 
(c) Residue masses are given for the neutral residues. For the masses of the parental amino acids, the mass of water needs to be added (18). 
BFCA: Bifunctional chelating agent 
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In addition to the twenty natural amino acids, unnatural amino acids are often incorporated in 
peptide sequences to improve the metabolic stability and/or the receptor binding properties, as well 
as to optimize the pharmacodynamics and bioavailability. A small selection of the wide variety of 
unnatural amino acids is given in Figure 1. Ligands in the D-amino acid configuration, which are 
naturally not incorporated by organisms into proteins, maintain their binding characteristics to their 
target protein of the natural handedness, while avoiding degradation by enzymes that act upon 
natural L-peptides [36]. For example, Octreotide (Sandostatin) is a synthetic somatostatin octapeptide 
analogue engineered with a tryptophan residue in the D-configuration that has a 50 times longer half-
life than somatostatin [37,38]. The radioactive compound 111In-DTPA-Octreotide (OctreoScan) has 
already been registered. The β-amino acids, which have the amino function bonded to the β-carbon 
atom, can introduce main-chain modifications when incorporated into peptides. Additionally, they are 
able to form stable and well-defined structures (e.g. helices [39]) and are stable against common 
peptidases [40]. [Dmt]DALDA is a synthetic peptide containing a dimethyltyrosine instead of the 
natural tyrosine that is responsible for a higher selectivity for the µ-opioid receptor [41]. Other 
examples from the biomedical research fields are amino acids containing immunogenic groups (p-
nitrophenylalanine [pNO2pa]) [42], chemical reactive groups (p-boronophenylalanine [pBO2pa]) [43] 
and photocrosslinkers (p-azidophenylalanine [pAzpa]) [44]. 
 
 
Figure 1. Selection of common unnatural amino acids. 
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Radionuclides 
Radionuclides are typically classified by their physical characteristics: decay mode, half-life and energy 
transfer, which determine their application possibilities (Table 2). 111In emits i.a. high linear energy 
transfer particles, i.e. Auger electrons, which are able to deliver high doses within a very short range 
(<10 µm) and thus can be used for radiotherapy. β--emitters (e.g. 90Y) emit energetic negatively 
charged β-particles, electrons, from the nucleus and are used for therapeutic purposes; β+-emitters 
(e.g. 18F) use positively charged particles, named positrons and are used for PET imaging. γ-emitters 
(e.g. 99mTc) use electromagnetic radiation of high energy (photons), which are detected by a gamma 
camera in SPECT imaging. Finally, also α-particles (4He) can be emitted by α-emitting radionuclides 
(e.g. 213Bi), offering tumour cell killing properties with minimal collateral damage to surrounding 
healthy tissue [24,45-50]. The physical half-life and radiation energy of the radionuclide is ideally 
related to the wanted in vivo pharmacokinetics of the radiopharmaceutical, i.e. tumour retention time 
and clearance [51].   
Most radionuclides, used in nuclear medicine as diagnostics or therapeutics, are artificially produced 
by cyclotrons (charged particle bombardment), nuclear reactors (neutron bombardment) or 
radionuclide generators [52]. Radionuclide generators use a long-lived parent radionuclide (e.g. 99Mo) 
which decays to a daughter radionuclide (e.g. 99mTc); the daughter isotope is then separated from the 
parent radionuclide by a chemical or physical process due to different characteristics (e.g. solubility) 
[38,47,53,54]. 
CHAPTER IX – DEVELOPMENT OF PEPTIDE AND PROTEIN BASED RADIOPHARMACEUTICALS 
 
 
184 
Table 2. Some radionuclides used in radiopharmaceutical tracers. 
Radionuclide Half-life Decay mode Energy (keV) Application 
99mTc 6.0 hours 
Auger 
γ 
15 (2%) 
141 (89%) 
Imaging 
64Cu 12.9 hours 
β+ 
β- 
653 (18%) 
579 (39%) 
Imaging and therapy 
67Cu 2.5 days 
γ  
β- 
91 (7%), 93 (16%), 185 (49%) 
392 (57%), 484 (22%), 577 (20%) 
Therapy 
123I 13.3 hours γ 529 (1.4%), 159 (84%) Imaging 
131I 8.0 days 
β- 
γ 
606 (90%), 334 (7%) 
364 (82%), 284 (6%), 637 (7%), 80 (3%) 
Therapy 
111In 2.8 days 
Auger 
γ 
19 (16%) 
171 (90%), 245 (94%) 
Imaging and therapy 
67Ga 3.3 days γ 300 (17%), 185 (21%), 93 (39%) Imaging 
68Ga 68 minutes 
β+ 
γ 
2921 (9%), 1899 (88%) 
1077 (3%) 
Imaging 
18F 109.8 minutes β+ 1655 (3%), 634 (97%) Imaging 
90Y 2.7 days β- 2280 (100%) Therapy 
86Y 14.7 hours 
β+ 
 
γ 
2242 (13%), 1988 (4%), 1595 (5%), 1545 (6%), 1474 (9%), 1409 (14%), 
1314 (7%), 1221 (12%) 
1153 (31%), 1077 (83%), 627 (33%) 
Imaging 
177Lu 6.7 days 
γ  
β- 
113 (6%), 208 (11%) 
498 (79%), 385 (9%), 177 (12%) 
Imaging and therapy 
125I 60.1 days γ 35 (7%) Research 
3H 12.3 years β- 19 (100%) Research 
14C 5730 years β- 156 (100%) Research 
213Bi 45.6 minutes 
α 
β- 
5870 (94%), 5549 (7%) 
1427 (65%) 
Therapy 
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Radiolabelling starting materials 
Peptides and proteins can be directly radioiodinated on tyrosine and histidine amino acids. Indirect 
radioiodination can be achieved using the Bolton-Hunter reagent (N-succinimidyl 3-(4-
hydroxyphenyl) propionate): this modifying group is incorporated via amide bond formation with a 
free amino group (e.g. lysine ɛ-amino functions and N-terminal α-amino groups). This technique is 
frequently used when direct I-labelling on tyrosine or histidine moieties is impossible, due to the 
absence of these necessary amino acids or when a modification diminishes receptor binding or 
bioactivity [55,56]. However, due to rapid in vivo dehalogenation of phenolic aromatic compounds, 
non-phenolic aromatic compounds have been developed to overcome this stability problem, e.g. N-
succinimidyl-3-iodobenzoate (SIB) and N-succinimidyl-5-iodo-3-pyridinecarboxylate (SIPC). These 
radioiodinated prosthetic groups are again conjugated via a covalent bond to a free amino group of 
the peptide [57,58]. 
Radiometal complexation is the most frequently applied radiolabelling technique, using macrocyclic 
or acyclic chelators (Bifunctional Chelating Agent, BFCA, Figure 2), with different characteristics: 
charge, cavity size, denticity, chemical character of the donor binding groups and formation or 
dissociation rate of the complex [59]. 99mTc-labelling of biomolecules is mostly achieved through a 
[Tc=0]3+ core, forming square pyramidal Tc(V)-oxo complexes with tetradentate chelators, e.g. N2S2 
diamidedithiols (DADS), N3S triamidethiols, N2S2 monoamidemonoaminedithiols (MAMA) and N2S2 
diaminedithiols (DADT). Besides, also *Tc≡N+2+ or [Tc(CO)3]
+ cores can be used to label pharmaceutical 
peptides or proteins. The use of 6-hydrazinonicotinamide (HYNIC) for 99mTc-labelling of biomolecules 
is also frequently reported. However, since HYNIC can only occupy one or two coordination sites, a 
coligand (e.g. tricine) is often needed to complete the coordination sphere of 99mTc [60]. Next, 
gallium (68Ga), indium (111In) or copper (64Cu) labelling can be performed using the macrocyclic and 
acyclic chelating agents diethylenetriaminepentaacetic acid (DTPA), 1,4,7-triazacyclononane-1,4,7-
triacetic acid (NOTA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) [61]. Due 
to the high complex constants, dissociation of the radiometal from the complex is unfavourable, 
minimizing the accumulation of e.g. free 68Ga and 111In in liver and lungs caused by transferrin 
binding: formation constants (log K) of e.g. Ga3+ with transferrin equals 20.3, whereas with DOTA or 
NOTA, log K = 21.33 and 30.98, respectively [60,62-65]. However, it was shown that 64Cu chelators 
such as 64Cu-DOTA had disappointing kinetic stability due to dissociation and transchelation to other 
proteins. This led to the development of NOTA chelators which form five and six coordinate copper 
complexes with improved tumour specific uptake of e.g. bombesin analogues [66]. Moreover, 64Cu-
labelling of the anti-CD20 antibody rituximab with NOTA showed significant advantages over e.g. 
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DOTA and DTPA coupling, as radiolabelling could be performed rapidly at room temperature, under 
dilute conditions, resulting in high specific activity [67]. 
The coupling of large bulky BFCA’s to the small peptides often significantly influences structure and 
therefore, also receptor binding properties, together with changed pharmacokinetic characteristics 
[3,5]. For that reason, linker molecules can be placed between the biomolecule and chelating agent, 
e.g. polyethylene glycol (PEG), hydrocarbon chain or hydrophilic or lipophilic amino acid sequence 
[57,60,68]. PEGylation of the radiopharmaceutical can improve pharmacokinetics and distribution 
patterns by increasing the molecular mass of proteins and peptides and shielding them from 
proteolytic enzymes [69,70]. 
Peptides or proteins cannot be 18F-labelled by direct labelling procedures, but need the use of a 
prosthetic group. The most suitable group for fluorination is the N-succinimidyl-4-[18F]fluorobenzoate 
([18F]SFB) molecule because of favourable in vivo stability characteristics and labelling yield [57]. 
 
 
Figure 2. Bifunctional Chelating Agents (BFCA’s) differing in chemical and physical properties (R: biomolecule). 
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3. PREPARATION OF RADIOTRACERS 
Iodination 
Direct iodination. Peptide radioiodination is a technique commonly used for in vitro radioligand 
binding studies as well as for medical imaging and therapy. Several iodination methods exist, mainly 
differing in the nature of oxidizing agent for converting I- into the reactive species, like I2 or I+ [71-73].  
(1) Iodogen method: This iodination procedure was described by Salacinski et al. and uses iodogen 
(1,3,4,6-tetrachloro-3α,6α-diphenyl glycoluril) (Figure 3) as a solid-phase oxidizing agent: the 
iodogen solution forms a film at the bottom of a polypropylene or glass vial, so reaction can 
easily be stopped by removing the reaction solution from the vial [74,75]. 
(2) Chloramine-T: The chloramine-T method, developed by Hunter and Greenwood in 1962 [76], is 
commonly used for protein and peptide radioiodination. However, Chloramine-T (Figure 3) is a 
powerful oxidizing agent with high chlorine potential, damaging certain peptides and proteins 
containing readily oxidizable groups, like thiols and thioethers. Oxidation reactions are then 
stopped by the addition of excess reductant (e.g. sodium metabisulphite) [72,77]. 
(3) Lactoperoxidase: The procedure, using the enzyme lactoperoxidase and the substrate hydrogen 
peroxide to iodinate proteins or peptides, is described by Marchalonis. Reaction is again stopped 
by adding an excess of reductant to the reaction mixture (e.g. 2-mercaptoethanol) [78,79]. 
(4) Iodo-Beads: This technique uses a chemical oxidizing reagent, N-chloro-benzenesulfonamide 
(Figure 3), which is covalently coupled to non-porous polystyrene spheres. Again, reaction is 
stopped by removing the reaction mixture from the beads in the reaction tube [80]. 
Comparing the different iodination techniques revealed that the Iodo-Beads method was inferior in 
terms of peptide recovery and formation of mono- and di-iodinated peptides. For iodination of 
peptides or proteins that are not sensitive to oxidation reactions, the chloramine-T technique was 
recommended based on its efficiency, simplicity and cost; peptides and proteins carrying oxidation-
susceptible amino acids are preferably iodinated using the Iodogen method, due to the high 
iodination yield and peptide recovery [71,73,74].  
 
 
CHAPTER IX – DEVELOPMENT OF PEPTIDE AND PROTEIN BASED RADIOPHARMACEUTICALS 
  
 
188 
 
Figure 3. Oxidation reagens used in iodination reactions. 
A: Iodogen; B: Chloramine-T; C: N-chloro-benzenesulfonamide 
 
Indirect iodination. The Bolton-Hunter reagent, SIB or SIPC can be applied for indirect iodination of 
peptides or proteins, through acylation of a free amino group. The N-hydroxysuccinimide ester can 
be iodinated before or after covalent conjugation to the protein or peptide, in the absence of 
oxidizing agents to accelerate the conjugation reaction. With this method, biomolecules that are 
sensitive to oxidative damage can be radioiodinated [56,81]. 
 
Chelator coupling 
Radiometal labelling is performed using the BFCA’s, often involving several conjugation groups (e.g. 
hydrazides, esters, isothiocyanates), which can be radiolabelled before or after biomolecule coupling. 
An overview of typical conjugation reactions for reactive groups on the peptide or protein is given in 
Figure 4. The reactivity of an amine is mainly dependent on its basicity and class. Aliphatic amines 
such as the ε-amino group of lysine are moderately basic and reactive with most acylating reagents. 
However, the concentration of the free base form of aliphatic amines below pH 8 is very low, 
indicating that the kinetics of amine acylation by isothiocyanates, succinimidyl esters or other 
reagents are strongly pH-dependent; a pH of 8.5 to 9.5 is usually optimal for modifying lysine 
residues. In contrast, the α-amino group at the N-terminus usually has a pKa of ~7, so it can 
potentially be selectively modified by reaction at near neutral pH. Furthermore, although amine 
acylation should usually be carried out above pH 8.5, the acylation reagents tend to degrade in the 
presence of water, with the rate increasing as the pH increases. Protein modification by succinimidyl 
esters can typically be performed at pH 8.3, whereas isothiocyanates usually require a pH >9 for 
optimal conjugations; this high pH may be a factor when working with base-sensitive proteins. When 
performing amine coupling, avoiding amine containing buffers as TRIS and glycine is a prerequisite. 
Isothiocyanates form thioureas upon reaction with amines [82]. Direct NOTA- and DOTA-peptide 
conjugation is achieved by the formation of a stable peptide bond linkage between one of the 
carboxyl groups of NOTA or DOTA and a primary amine of the peptide. Therefore, the carboxyl group 
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is activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-
hydroxysuccinimide (NHS), affording an intermediate that can react with the different groups in the 
peptide [19,57] (Figure 4). Maleimide coupling is an alternative method that exploits thiol groups on 
the peptide or protein, resulting in a thioether bond [83] (Figure 4). However; the conjugation site is 
very important for maleimide coupling: highly solvent accessible sites rapidly loses their conjugator 
by exchange of the maleimide with thiol-reactive constituents; on the other hand, a partially 
accessible site with a positively charged environment has a positive effect by hydrolysis of the 
succinimide ring, thereby preventing the exchange reaction [84]. Recent studies have improved the 
chemical stability of maleimide linkers by modification of the succinimide ring [85]. HYNIC-peptide 
conjugates are produced via amide linkage formed through reaction of the active ester derivative of 
the ligand [62].  
 
 
 
Figure 4. Conjugation reactions.  
Conjugation groups are mentioned above each reaction as well as the functional group of the peptide. 
 
Fluorination 
18F-labelling can be achieved using a prosthetic group (e.g. [18F]SFB), as described before. The 
labelling occurs through 18F-fluoroalkylation, 18F-fluoroacylation and 18F-fluoroamidation of primary 
amino groups at the N-terminus or amino acid side chains or thiol functions on cysteine residues. The 
radiolabelling of peptides with [18F]SFB usually occurs in four steps: (1) 18F-fluorization, (2) acid or 
base hydrolization, (3) acid activation and (4) final acylation [19]. Recently, a one-step radiosynthesis 
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of 18F was described by chelation of a NOTA-conjugated peptide (e.g. octreotide) with Al18F; the 18F-
labelling of cyclic RGD-peptide derivatives using a specific arene group was also successfully applied 
[86-88+. Also the ‘click chemistry’ approach has been used for 18F labelling of peptides, based on the 
copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction (CuAAC) between terminal alkynes 
and azides resulting in 1,4-disubstituted 1,2,3-triazoles [89]. 
 
3H/14C labelling 
The 3H and 14C isotopes are widely used in research studies, because of the frequent occurrence of 
these atoms in biomolecules. These radionuclides are incorporated into the peptide structure by 
acetylation using [14C]- or [3H]-acetic anhydride or reductive alkylation using e.g. [3H]-sodium 
cyanoborohydride or [14C]-formaldehyde. Both labelling reactions occur through binding on free 
amino groups of the peptide or protein structure. Next, 3H- or 14C-labelling at cysteine residues can 
take place as well, using [14C]- or [3H]-iodoacetic acid or [14C]-iodoacetamide, resulting in a stable 
carboxymethylated cysteine amino acid. Radiolabelled peptides can also be produced using solid 
phase peptide synthesis with 3H- or 14C-labelled amino acids [90,91]. 
 
 
4. QUALITY CONTROL OF PEPTIDE AND PROTEIN 
RADIOPHARMACEUTICALS 
General quality attributes 
Because several peptides are already registered as active drugs in different clinical areas, the quality 
specifications of new drugs (i.e. quality attributes, procedures and acceptance criteria) are extremely 
important [92]. The same applies for radiopharmaceuticals (e.g. 99mTc-Annexin V): as site-specific 
radiolabelling of a protein or peptide is preferred for conservation of biological properties (e.g. 
receptor-binding), its quality control after the radiolabelling procedure is essential [5,30,31,93]. 
Vergote et al. suggest some typical peptide quality attributes to overcome toxicity or efficacy 
problems based on the European Pharmacopoeia (Ph. Eur.) and the United States Pharmacopeia 
(USP). First, due to the production process of some proteins or peptides, contaminating substances 
from cells or culture medium can be present; therefore, extraction and purification procedures have 
to be performed. Next, the identity of the peptide or protein needs to be analysed as well, using i.a. 
peptide mapping for the determination of the amino acid composition or reference-comparison 
using chromatographic or spectrometric techniques [47,92]. The characterization of peptide 
impurities, originating from synthesis or instability problems [94], is of great importance too, as they 
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can be toxic or can have unexpected pharmacological effects compared to the native peptide: for 
example, crude peptide material of INSL6[151-161] was found to trigger a contractile response in 
guinea pig ileum longitudinal smooth muscle cells, while the 95% purity sample did not [29,95]. 
Besides, the radiopharmaceutical preparations for parenteral administration should meet the 
requirements for sterility testing as described in the Ph. Eur. and USP. However, due to small batch 
sizes and short half-life values, sterility validation of the production process, instead of the product, is 
often required. Finally, for certain radiopharmaceutical preparations, a test for bacterial endotoxins 
is prescribed [47]. 
Seen the increasing interest in peptide and protein radiopharmaceuticals, the European and US 
institutions are currently updating their guidelines regarding these theranostics. For peptide or 
protein radiopharmaceuticals, the guidelines from the International Atomic Energy Agency (IAEA), 
the World Health Organisation (WHO), the FDA and the European Association of Nuclear Medicine 
(EANM), concerning the requirements for registration of radiopharmaceuticals, are under discussion 
for harmonization [96]. Moreover, a draft guideline on radiopharmaceuticals based on monoclonal 
antibodies is planned for consultation in 2012 by the European Medicines Agency (EMA), taking into 
account both ‘the guideline on Development, Production, Characterization and Specifications for 
Monoclonal Antibodies and Related Products’, as well as ‘the guideline on Radiopharmaceuticals’ 
[97,98].  
 
Radionuclidic purity 
The radionuclidic purity represents the ratio, expressed as percentage, of the radioactivity of the 
desired radionuclide to the total radioactivity of the radiopharmaceutical preparation. The most 
generally useful technique to determine radionuclidic purity of γ-emitters is that of gamma 
spectrometry: the γ-energies on the spectra are identified. These radionuclidic impurities are limited 
in the individual monographs as these impurities can be responsible for unwanted increased 
radiation dose to the patient or obscure scintigraphic images [47,99,100]. For 111In, photopeaks at 
energies of 171 and 245 keV are required, limiting 114mIn and 65Zn impurities, i.e. the amount of 114mIn 
and 65Zn is not greater than 3 kBq per MBq of 111In in e.g. 111In-pentetreotide parenteral injections 
*101+. Pure β-emitters can be evaluated for radionuclidic purity with a β-spectrometer or using a 
liquid scintillation counter [47]. 
In the past, radionuclidic impurities often occurred with generator-produced radionuclides due to 
breakthrough of the parent radionuclide during elution procedures of the daughter nuclide, e.g. 68Ge 
or 99Mo impurities in 68Ga or 99mTc radionuclide samples, respectively. However, new developments 
have contributed to the production of generators with a satisfactory radionuclidic purity [54,102].  
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Radiochemical purity 
The radiochemical purity represents the fraction (%) of the total radioactivity in the desired chemical 
form in the radiopharmaceutical. Therefore, determination of the radiochemical purity requires the 
separation of the different chemical substances containing the radionuclide. These radiochemical 
impurities can originate from different steps in the radiopharmaceutical development process: 
radionuclide production, chemical (radiolabelling) procedures, incomplete preparative separation or 
storage-related chemical degradation. The radiochemical purity is an important quality parameter for 
radiopharmaceuticals as it has a pronounced effect on the in vivo behaviour of the radiolabelled 
product, e.g. free 99mTc-pertechnetate or 111In-DTPA molecules are observed to localize into stomach 
and bladder, respectively, resulting in altered biodistribution and potentially poor image quality 
[47,99,103,104]. 
To separate the different substances in the radiopharmaceutical preparation, any analytical 
separation method can be applied, e.g. paper chromatography (PC), thin-layer chromatography 
(TLC), electrophoresis, size-exclusion chromatography (SEC), gas chromatography and liquid 
chromatography (LC). For each EU-approved radiopharmaceutical product, the method of choice is 
given in the individual monograph in the European Pharmacopoeia or USP. In hospital environment, 
paper chromatography and instant thin-layer chromatography (ITLC) are frequently used, due to its 
simplicity and fast measurement procedures. The radioactive spots or areas are then detected by 
autoradiography or by measurement of radioactivity over the length of the chromatogram 
[47,104,105]. The radiochemical purity of 111In-Ibritumomab Tiuxetan i.v. injection (Zevalin) for 
example, can be investigated by using a 1 x 8 cm instant silica gel strip as stationary phase, along with 
a 0.9% sodium chloride mobile phase solution. The distribution of radioactivity on the chromatogram 
is then investigated by scanning the strip with a suitable collimated radiochromatogram strip 
scanner; not less than 95% of the 111In activity is present as a band between the Rf values of 0 and 
0.1, corresponding to the 111In-Ibritumomab Tiuxetan immunoconjugate [106]. 
 
Chemical purity 
The chemical purity of a radiopharmaceutical is the fraction of the biomolecule in the desired 
chemical form. The determination of this quality factor thus requires quantification of the individual 
chemical impurities, as specified in the Ph. Eur. or USP monograph of the approved 
radiopharmaceutical. Chemical impurities may arise from instability problems of the material, before 
or after radiolabelling, as well as from the manufacturing process (e.g. residual solvents); these 
impurities can be responsible for in vivo adverse reactions and pharmacological or toxic effects by 
competing for active transport mechanisms and enzyme- or receptor-binding [47,95,99,100].  
   CHAPTER IX – DEVELOPMENT OF PEPTIDE AND PROTEIN BASED RADIOPHARMACEUTICALS 
  
 
193 
The identification and semi-quantification of the radiolabelled [18F]-6-fluorolevodopa, together with 
its impurities dopa, trimethyltin chloride (impurity A) and 6-hydroxydopa (impurity B), is performed 
using liquid chromatography on a spherical end-capped octadecylsilyl silica gel stationary phase 
column (4.0 x 250 mm). Based on the results with reference solutions for these impurities, 
identification and semi-quantification with a spectrophotometer (200 nm) and radioactivity detector 
is achieved: relative retention times (RRT), with reference to 6-fluorolevodopa (retention time = 6 
min) (i.e. RRTdopa = 0.8 and RRTA/B = 0.7), together with quantity limits (i.e. 6-fluorolevodopa = 15 
mg/V, dopa = 1.0 mg/V, A = 0.5 mg/V, B = 0.025 mg/V and V being the maximum recommended dose 
in millilitres) are determined [107]. 
 
Assay: activity  
Beta-emitting radionuclides are assayed with the use of a liquid-scintillation detector system, 
determining the disintegration rate of these radionuclides. This technique converts the radiation 
energy into fluorescence radiation using a liquid scintillator (e.g. 2,5-diphenyloxazole), after which 
the fluorescence wavelengths are detected by the multiplier phototubes [104]. Gamma photons 
interact with e.g. a NaI detector crystal by means of the Photoelectric Effect; the electrons released 
from this interaction then interact with the crystal to produce light (scintillation), which in turn is 
detected by the photo-multiplier tubes [48].  
For some radiopharmaceutical preparations, a physiological distribution test is performed to 
evaluate the suitability and in vivo biodistribution of the product for the intended purpose. In 
general, each of three animals is injected intravenously with the preparation to be tested, after 
which they are placed in a separate cage, allowing individual excreta collections. At the specified 
time after injection, the animals are euthanized and dissected: the selected organs are assayed for 
their radioactivity and the distribution calculated (expressed as e.g. % of total injected dose or 
radioactivity per tissue mass). If the distribution of at least two of the three animals complies with 
the specifications, the radiopharmaceutical preparation meets the requirements of the physiological 
distribution test [47]. This biological distribution test is described in the USP and Ph. Eur. for e.g. 
99mTc-labelled albumin aggregates, used as a scintigraphic imaging agent to evaluate pulmonary 
circulation [108-110]. In brief, a volume (not exceeding 0.2 ml) of 99mTc-macroaggregated albumin is 
intravenously injected into the caudal vein of each of three rats or mice (specified weight). After 5-15 
minutes post injection, the animals are euthanized, after which the lungs, liver and (eventually) 
spleen are isolated and radioactivity measured, relative to the radioactivity of the remaining carcass. 
The percentage of radioactivity in the different organs is then calculated using the following formula: 
percentage radioactivity = (A/B) x 100, where A is the radioactivity in the organ of interest and B the 
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total radioactivity (carcass and isolated organs). To meet the specifications, at least 80% of the 
radioactivity should be found in the lungs and not more than a total of 5% is found in the liver and 
spleen, in not less than two of the three animals [108,109]. 
 
Specific activity 
The specific radioactivity is the amount of radioactivity of a radionuclide per unit mass of the 
element or of the peptide or protein radiopharmaceutical concerned [47]. For example, for [18F]-6-
fluorolevodopa, the USP describes a specific activity specification of not less than 0.463 mCi per mg 
of L-fluorodopa [111]. For carrier-free radioisotopes, this quality parameter remains constant over 
time as a decay will alter the molecule as well, while it decreases for carrier-added elements or 
molecules; if non-radioactive isotopes of the same radionuclide are present, the mass of the element 
changes less than the radioactivity after radioactive decay (Figure 5) [104]. For peptide and protein 
radiopharmaceuticals, separation of the radiolabelled molecule from non-radiolabelled analogues is 
often difficult. Therefore, specific activity is usually calculated taking into account the radioactive 
concentration and the concentration of the chemical substance being studied, i.e. unmodified and/or 
modified peptide or protein assuming similar biological properties, after determining radionuclidic 
and radiochemical purity. This quality attribute is called ‘effective specific activity’ *112+. 
Contamination of the radiopharmaceutical with compounds of similar biological activity will 
therefore reduce the effective specific radioactivity in vivo [47,100].  
To explain the progress of the effective specific activity, distinction must be made between the 
different labelling techniques: the radioisotope can be included into the peptide structure (e.g. 14C, 
11C or 13N-labelling) or can be attached to the peptide or protein without interfering with its basic 
structure (e.g. 68Ga-NOTA-labelling). After radioactive decay of a 14C-labelled molecule for example, 
the elemental composition and structure of the molecule significantly changes and therefore most 
probably influences its biological activity; in this case, both the amount of radioactivity and molecule 
concentration decrease in time. In case of chelated molecules, the peptide or protein structure is not 
directly modified after radioactive decay of the metal radionuclide, having the same biological 
activity as the starting radiopharmaceutical; the effective specific activity is then significantly 
decreased. 
Moreover, the determination of synthetic peptide and protein concentrations is not straightforward, 
due to the presence of counter ions or salts, water or organic solvents. Due to these impurities, the 
actual peptide content can be reduced to 90 – 20% of the expected concentration based on mass, 
thus remarkably influencing specific activity calculations [92,113]. Peptide and protein content can 
be determined by quantitative amino acid analysis, which is not a routine quality assay [114,115]. 
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Counter ions, salts and moisture content can be quantified using e.g. HPLC, gas chromatography, 
atomic spectroscopy or Karl Fisher methods [92,116,117].  
 
In experiments involving saturable processes, the target-to-background ratio is often improved by 
increasing the specific activity of the radiopharmaceutical [118]. However, this phenomenon is not 
unambiguous: uptake of [111In-DTPA]octreotide in octreotide receptor-positive tissues is not maximal 
at the lowest possible peptide amount with maximum specific activity [119,120]. Moreover, also the 
labelling procedure influences specific activity: 111In-labelling of DTPA- and DOTA-conjugated 
compounds in MES or HEPES buffer instead of acetate buffer leads to the production of 111In-labelled 
compounds with higher specific activities [118]. 
 
Specific activity = constant
Carrier-free Carrier-added
T1/2 T1/2
Specific activity = decreased
Radioactive isotope Non-radioactive isotope
 
Figure 5. Specific activity of element 
 
Stability and storage 
Radiopharmaceutical stability is influenced by the specific activity of the radioactive material, the 
energy of the emitted radiation, the half-life of the radionuclide and the stability towards light, 
temperature variations and radiolysis of the peptide or protein itself [99]. For example, 90Y-labelled 
2IT-BAD-Lym-1 monoclonal antibodies, formulated at a specific activity of 1-2 mCi/mg, showed good 
radiochemical purity (≥ 80%) and immunoreactivity (≥ 75%) over 3 days when stored at 4-8°C. 
However, increasing the specific activity to 4 and 9.4 mCi/mg revealed a decrease in radiochemical 
purity to 65% and 21%, respectively, while immunoreactivity even reduced to 3% with the highest 
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specific activity solution. This phenomenon was ascribed to the interaction of the moderate energy 
β-particles emitted by 90Y with water molecules in the solution, generating highly reactive free 
radicals; these radicals can degrade the metal chelator as well as the biomolecules attached 
[121,122]. 
Radiopharmaceuticals should be stored in an airtight container, in a place that is sufficiently shielded 
to protect personnel from irradiation. The container itself should comply with the national and 
international regulations concerning the storage of radioactive substances. Interestingly, as 
containers may darken due to irradiation, this does not necessarily mean degeneration of the 
product [47]. 
During storage, the container should be appropriately labelled: name of product and manufacturer, 
identification number (marketing authorisation number), total radioactivity (MBq or mCi) at a stated 
date and time, total volume (if liquid or gaseous preparation), route of administration, expiry date, 
name and concentration of any added antimicrobial preservative and, if necessary, special storage 
conditions *47+. Next, the statement ‘Caution – Radioactive material’ is labelled onto the package of 
radiopharmaceuticals [101,106]. The labelling characteristics of a radiopharmaceutical are 
summarized in e.g. the European public assessment report (EPAR), describing the particulars to 
appear on the outer package, as well as the immediate packaging units of each vial of the 
reconstitution kit [123]. 
 
 
5. IN VITRO BIOMEDICAL CHARACTERIZATION 
Chemical and metabolic stability 
A main challenge for the use of peptides as radiopharmaceuticals is their low stability to peptidases 
and proteases found in most tissues, catalyzing the hydrolytic degradation and thus resulting in a 
short biological half-life. Consequently, the in vivo application of these metabolically unstable 
molecules is limited as insufficient amounts of peptide reach their target [23]. However, peptide 
stability can be improved by different methods: introduction of unnatural or D-amino acids, 
substitution of peptide bonds, terminal capping (N-acetylation or C-amidation) or cyclisation. [5].  
Peptides can also be vulnerable to chemical and/or enzymatically catalyzed oxidation or reduction 
reactions. For example, oxidation by hydrogen peroxide (H2O2) of 
99mTc-labelled 
radiopharmaceuticals can lead to increased levels of free 99mTc-pertechnetate [103]. The radiolytic 
generation of free radicals can add to the degradation of radiolabelled biomolecules as well, resulting 
in a decreased stability and purity profile of the radiopharmaceutical. These stability studies are of 
increasing importance, as denatured proteins can precipitate and localize in lungs, liver en spleen 
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tissues, leading in turn to adverse reactions in vivo [103,124,125]. Radiolysis however, can be 
prevented or diminished by the inclusion of radioprotectants (e.g. ascorbic acid or human serum 
albumin) in the formulation of 111In-bombesin conjugates or other radiopharmaceuticals 
[122,125,126]. Moreover, freezing the radiolabelled biomolecules can minimize diffusion of free 
radicals in the aqueous solution, protecting the peptide or protein for radiolytic degradation: 
radiolytic damage of 131I-labelled monoclonal antibodies was largely eliminated by freezing at -70°C, 
while 80-90% of immunoreactivity was lost after storage at 4°C for 1 to 12 days [122,127]. The 
phenomenon of trans-chelation, where the isotopic metal is released from the radiopharmaceutical 
also needs to be examined. For example, a metabolic study of a 64Cu-labelled octreotide analogue 
demonstrated that Cu(II) dissociates from macrocyclic chelators and binds to superoxide dismutase 
in rat liver [128,129].  
Both chemical and metabolic stability can be investigated by incubation in buffer, cell medium, 
enzyme solution, blood or plasma and tissue homogenates, after which the degradants, including the 
free radionuclide, can be detected, identified and quantified. This can be performed using e.g. 
chromatographic techniques coupled to spectrometric (Ultra-Violet (UV) spectrophotometer and 
mass spectrometer (MS)) and radioactivity detectors [130-132]. 
Peptides are traditionally separated using reversed-phase liquid chromatography (RP-LC) on an alkyl 
(C18, C8, C4) bonded silica column and identified using mass spectrometry (MS), having good 
sensitivity and accuracy characteristics [133,134]. The most common RP-methods used for peptide 
separation involve isocratic or gradient elution, using a water and acetonitrile composing mobile 
phase in the presence of an acidic modifier (e.g. formic acid (FA) or trifluoroacetic acid (TFA)) 
[135,136]. Moreover, next to the alkyl functional groups, RP-LC can also be performed by linking 
other groups to the silica support: phenyl-hexyl linkers, ether-linked phenyl groups or polar 
functional groups (e.g. amide) within an alkyl chain, with different endcapping strategies [137]. 
Although RP-LC is a powerful separation technique, retention of polar biomolecules cannot be 
achieved using these RP-columns. Therefore, Hydrophilic-Interaction Chromatography (HILIC) was 
developed, which provides the separation of proteins and peptides using aqueous mobile phases and 
polar stationary phases [138,139]. Classical ion-exchange chromatographic procedures are based on 
the net charges of proteins and peptides, located either on a functional residue or on the N- or C-
terminus. At acidic pH-values, peptide carboxyl groups are protonated and ion-exchange 
chromatography thus primarily depends on the number of basic amino acid residues (i.e. cation 
exchange chromatography) [136]. Size-exclusion chromatography can be used in the separation of 
polypeptides, based on differences in molecular weight. However, non-specific interactions can occur 
as well, e.g. hydrophobic or electrostatic effects. Therefore, spheric silica particles of various pore 
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sizes are coated with a hydrophilic film and are used for the separation of peptides and proteins, 
resulting in a good recovery and stability [136].  
 
Receptor-binding characterization 
Most radiolabelled peptides are currently marketed as diagnostics or therapeutics for their use in 
oncology. One of the main reasons for this prevalence of cancer-research, is the detection of 
peptide-receptor over-expression in many primary cancers, in comparison to their expression in 
normal tissues. These receptors (e.g. somatostatin, vasoactive intestinal peptide and bombesin 
receptors) can thus be used as molecular targets for the radiolabelled peptides and proteins. 
However, it should be noticed that species differences may exist for different receptors, emphasizing 
the importance of using native human receptors in in vitro characterization assays of 
radiopharmaceuticals for human use [140,141]. 
To determine the different receptor-binding properties of radiolabelled peptides and proteins, 
radioligand binding studies on receptor-membranes or receptor-overexpressing cells can be 
performed. Using these assays, the receptor affinity (KD), maximum density of receptors (Bmax) and 
the association (kon) and dissociation (koff) rate constants can be calculated to quantify the 
peptide/protein-receptor interaction. One method to determine these characteristics is by saturation 
analysis, where the amount of radioligand added is increased, while keeping the specific activity 
constant, or where the radioligand concentration is kept constant while decreasing the specific 
activity by the addition of unlabelled peptide. Non-specific binding is determined at each 
concentration by co-incubation with an excess (100- to 1000-fold) of unlabelled peptide. The amount 
of radioactivity bound to the cells is then verified using filtration methods after equilibrium 
conditions were reached, resulting in the determination of KD and Bmax values. The equilibrium 
constant KD determines the strength of interaction of the radiolabelled biomolecule with the 
receptor; it is the ligand concentration that will occupy 50% of the receptors. Bmax is expressed as 
amount of ligand bound per mass of protein. However, it is important to realize that the results 
obtained by filtration methods are highly dependent on the inherent adsorption and instability 
characteristics of the peptides, as well as the high response-sensitivity to operational conditions. 
Selection of appropriate ligand receptor binding conditions (e.g. temperature, time, buffer 
conditions) is therefore critical for peptides to avoid false negative results. Filter adsorption of e.g. 
125I-labelled vasoactive intestinal peptide (VIP) can be reduced by pretreatment procedures with 
polyethylenimine (PEI) and bovine serum albumin (BSA); the use of bacitracin protease inhibitor 
during incubation also decreased adsorption phenomena [142]. 
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Next, kinetic binding experiments can be performed to determine the time course of ligand-receptor 
association (kon) and dissociation (koff), so the time period for reaching binding equilibrium is 
obtained. Having determined the KD of a radiolabelled peptide for a target receptor in a saturation 
assay, the receptor binding potencies of (unlabelled) peptides can be compared by a competition 
binding assay: the displacement of radiolabelled peptide from the receptor is analysed after the 
addition of increasing concentrations of the unlabelled analogue [142-145].  
Radioligand binding assays are widely performed by scientists in the biomedical and pharmaceutical 
research fields, for example to characterize and localize different subtypes of the endothelin receptor 
in tissue sections of the human atrioventricular conducting system [146]. Iodinated adrenomedullin 
derivates have been characterized for their effectiveness for lung nuclear medicine [147]. SOM230, a 
somatostatin peptidometic resulting from rational drug design, was characterized as potential drug 
as the compound had high affinity to the five human somatotropin release inhibiting factor receptor 
subtypes [148].  
 
In addition to intact cells or membranes, isolated receptors can be analysed as well by immobilization 
on a sensor chip. Study of ligand-receptor interactions can then be performed using surface acoustic 
wave (SAW) or surface plasmon resonance (SPR) technologies, where label-free peptides/proteins 
can be used. SAW biosensors give information on affinity (KD), kinetics (kon and koff), viscoelastic 
effects and conformational changes; using SPR optical sensors, the refractive index is linearly related 
to the deposited mass, but does not generally allow for the detection of conformational alterations 
[145,149].  
 
Cell interactions 
Radiolabelled biomolecules can interact with cells in different ways: (1) the receptors are used as 
binding sites for peptide analogues, after which internalization of the ligand-receptor complex, and 
therefore accumulation of radiotracer in the cell, takes place; (2) radioligands can bind with high 
affinity to peptide receptors without inducing cell-internalization, justifying their use as diagnostic 
tools for different clinical applications [140,141,150]. In general, agonistic peptides have the ability to 
internalize into tumour cells and desensitize the receptor. After internalization, the receptor can be 
recycled to the plasma membrane (resensitization) or degraded into the lysosomes 
(downregulation); this degradation phenomenon is aimed for radiotherapeutic peptides or proteins 
[151]. In contrast to agonists, antagonists show unsurpassed imaging characteristics: the 
somatostatine receptor antagonists 111In-DOTA-sst2-ANT and 111In-DOTA-sst3-ODN-8 showed 
extremely high tumour accumulation, due to a more than 15-fold increased number of accessible 
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binding sites per cell compared to their agonistic analogues [141]. However, although there is a 
consensus that antagonists generally do not trigger receptor-internalization, cholecystokinin, 
endothelin and neuropeptide Y antagonistic analogues are reported to stimulate internalization as 
well [152]. But what is the fate of the label when the protein or peptide is catabolised? Some labels 
are membrane permeant or are actively excreted from the catabolic cell, while others remain 
trapped inside the cell because of their charge and can persist for the lifetime of the cell [153]. The 
iodinated labels are catabolised to iodotyrosines, and leave the cell for recycling. The dehalogenase 
enzymes then scavenge the iodine for processing in the thyroid gland, especially iodine atoms 
present ortho- to a hydroxyl group on a phenyl ring, i.e. the product for most iodination labelling 
strategies. For the BFCA’s, which make mainly use of lysines or cysteines, the label remains trapped 
inside the cell as charged lysine adducts upon catabolism [154]. 
Internalization assays are typically performed at 37°C, together with a low pH buffer (acid wash, e.g. 
glycine buffer pH 3) to dissociate surface-bound ligand after incubation. During the separation of 
bound and free radioligand, however, temperature is lowered because of a slower dissociation rate 
of the receptor-ligand complex [24,143].  
Cell internalization of radiolabelled peptides or proteins can also be accomplished by the 
complexation or conjugation to cell-penetrating peptides, targeting intracellular, intranuclear or 
extracellular receptors for imaging or therapy. Kersemans et al. recently summarized the different 
strategies in molecular imaging using cell-penetrating peptides. To target the p21 cyclin-dependent 
kinase inhibitor in the nucleus of breast cancer cells, a TAT (trans-activating transcriptional activator) 
cell penetrating peptide was site-specifically conjugated to the Fc tail of anti-p21 antibodies and 123I-
labelled for imaging purposes. The higher uptake in the tumour compared to normal tissue is 
achieved because of the enhanced perfusion rate and hyperfenestration, together with an 
upregulation of the receptor in the tumour cells. Next, the radionuclide can directly be attached to 
the cell-penetrating peptide via a chelating group, so without conjugation to a specific biomolecule, 
e.g. 111In-DOTA-TAT is internalized and transported to the nucleus of HeLa cells as well as mouse 
lymphocytes in vitro [155-157]. However, as different peptides and proteins (e.g. fibroblast growth 
factor A and B, epidermal growth factor, parathyroid hormone-related protein or angiotensin II) 
operate in part through an intracellular mode of action, transcellular transport is also possible 
without the use of cell-penetrating peptides. In some cases, e.g. for parathyroid hormone-related 
protein, association with the nucleus is reported, owing to the nuclear targeting sequence present in 
the native peptide or protein sequence [158-160]. 
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6. IN VIVO ANIMAL-MODEL STUDIES 
Pharmacokinetics 
Next to the targeted tumour-uptake of radiopharmaceuticals and their metabolisation, their in vivo 
potential is also influenced by other pharmacokinetic properties of the molecules, i.e. non-tumour 
tissue distribution, non-specific binding to other organs and excretion patterns. These properties are 
influenced by the receptor expression in the different malignant and normal tissues, as well as by the 
metabolic and physicochemical characteristics (lipophilicity and charge) [141]. The in vivo tissue 
distribution is analysed using mice (or other animals), carrying specific tumours: at several time 
points after injection, biodistribution is measured using PET or SPECT imaging techniques or by organ 
radioactivity measurements after animal dissection. Moreover, excretion pathways into urine or via 
the hepatobilliary system can be analysed as well [24]. 
Radioiodination and radiofluorination usually increase lipophilicity of the molecule, leading to 
increased hepatobiliary clearance. The introduction of PEG molecules or carbohydrates and polar 
amino acids as a linker molecule, reduces tracer lipophilicity and thus induces renal excretion 
pathways [57,60,68,141]. For 111In-labelled RGD peptides, Dijkgraaf et al. investigated the effect of 
linker variation on tumour and organ uptake: insertion of lysine caused enhanced kidney retention, 
while PEG showed the highest tumour-to-blood ratio and the lowest uptake in kidney and liver [68]. 
The addition of a charged amino acid spacer (i.e. –(arginine)3- or –(ornithine)3-) to a bombesin 
analogue was advantageous for biodistribution, pharmacokinetics and tumour targeting ability, 
because it reduced the upper abdominal radioactivity levels and increased tumour/normal tissue 
contrast ratios [161]. The pharmacokinetic properties of 99mTc-labelled peptides are predominantly 
influenced by the labelling-chemistry, generally leading to hydrophilic 99mTc-complexes that are 
excreted by the kidneys. Moreover, the pharmacokinetics of chelator-coupled peptides or proteins is 
greatly influenced by the type of chelator that is used: tumour and liver accumulation (whether or 
not by trans-chelation, see above [128,129]) and renal uptake can change between the different 
BFCA’s. For example, changing the chelator for 111In in the Tyr3-octreotide analogue from DTPA to 
DOTA resulted in slightly increased tumour accumulation and significantly higher renal tracer uptake. 
Moreover, substituting 111In by 68Ga in the DOTA-derivative in turn led to an increased tumour uptake 
but reduced renal accumulation [141].  
In vivo pharmacokinetic studies revealed the high renal activity concentration of most radiolabelled 
peptides and proteins, leading to severe nephrotoxicity. This clearance phenomenon occurs by 
glomerular filtration and reabsorption by the tubular cells of the kidneys, followed by lysosomal 
metabolisation. However, coinfusion of positively charged amino acids, i.e. lysine and arginine, can 
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block this tubular reabsorption process, without altering tumour uptake and biodistribution pattern. 
This was shown with 111In-DTPA-octreotide, where coadministration with Lys and Arg led to a 
reduction in renal radio-accumulation of 43%. The coadministration of a gelatin-based plasma 
expander (e.g. Gelofusine) also reduced renal radiation of 111In-labelled octreotide with 45%, without 
inducing any side effects [45,141,162-165].  
 
Dosimetry 
Before in vivo human studies can be performed, dosimetry of normal organs and tumour tissue is 
needed to avoid high radiation doses to non-target tissues (e.g. liver, kidney, bone marrow). One of 
the challenges in this drug development process is to deliver the highest activity to the tumour, while 
protecting normal tissue. Therefore, from the activity determined in the different organs using 
biodistribution studies and corresponding time-activity curves, the absorbed doses are estimated 
during in vivo studies [45,166,167].  
Peptide radiopharmaceuticals can deliver high absorbed doses to the kidneys and may lead to 
permanent nephropathy. Reliable dosimetry of kidneys is thus crucial for safe and effective 
radiotherapy [168]. Besides the kidneys, the bone marrow is a potentially dose-limiting organ as well. 
The radiation dose to the bone marrow is usually calculated from the accumulated radioactivity of 
the radiopharmaceutical in the blood. However, as considerable variation in bone marrow absorbed 
dose between patients is reported, individual calculation of the bone marrow absorbed dose is 
necessary, leading to individual dose optimization [45,169]. 
To determine e.g. kidney dosimetry, the internal dosimetry scheme of the Medical Internal Radiation 
Dose (MIRD) Committee of the Society of Nuclear Medicine can be applied. However, due to 
excessive interpatient variability of kidney absorbed doses, crucial improvements of this method are 
necessary; the inclusion of actual kidney masses and kidney regional distribution in the dosimetric 
estimates can prevent unexpected renal toxicity of radiopharmaceuticals [45,170,171]. Moreover, 
the effective dose-equivalent, describing the biological effect that can be observed for a specific 
organ, should be calculated using the current weighting factors established by the International 
Commission on Radiological Protection (ICRP) [172,173,98]. To obtain an indication of how exposure 
can effect overall health (i.e. effective dose), the equivalent dose can be multiplied by a tissue 
weighting factor related to the risk for a particular tissue or organ [174]. 
Moreover, the choice of radionuclide defines the radiation dose as well: 68Ga, with a 68 minutes half-
life, has a lower effective dose than those of other radioisotopes with longer half-lives; 11C-labelled 
radiotracers have significantly lower doses than 68Ga- and 18F-labeled radiotracers [174]. 
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7. IN VIVO HUMAN STUDIES AND APPLICATIONS 
From animals to humans 
Finally, the results of the in vivo animal studies have to be translated to human models to predict 
pharmacokinetics and pharmacodynamics of the radiopharmaceutical. This is not straightforward as 
species-specific physiological differences can lead to pharmacokinetic variations, indicating the 
increasing importance of data interpretation [175]. 
Phase 0 trials can be performed to evaluate these properties through administration of sub-
pharmacological doses (microdoses, less than 1/100th of the dose calculated based upon animal data) 
for a short time period to a low number of humans, without any diagnostic or therapeutic purpose. 
Potential radiolabelled peptides or proteins then enter the Phase I – III clinical trials, where dose, 
safety and efficacy in humans are analysed. The Phase 0 clinical trials are designed to improve drug 
development: time periods from hit to first-in-human studies can markedly be reduced due to an 
earlier evaluation of human pharmacology and thus earlier selection of promising biomolecules for 
further development [176,177]. 
 
Oncology 
The vast majority of radiopharmaceuticals is registered for cancer imaging or radiotherapy [178]. To 
date, the 111In-DTPA-labelled somatostatin analogue, OctreoScan, is the most successful radiopeptide 
for tumour diagnosis, imaging several types of neuroendocrine tumours. Gastro-entero-pancreatic 
neuroendocrine tumours are relatively rare, with an estimated incidence of 3.6 to 13 cases per 
million population per year (in 2009) and a vast majority of the tumours not presenting clinically. 
Therefore, OctreoScan can be classified into the orphan medicinal products [23,179]. 90Y-labelled 
Ibritumomab Tiuxetan (Zevalin), a recombinant murine IgG1 kappa monoclonal antibody, is indicated 
for the treatment of CD20-positive follicular B-cell non-Hodgkin’s lymphoma. However, as the CD20 
antigen is located on the surface of malignant and normal B-lymphocytes, rituximab pretreatment is 
necessary to clear circulating B-cells, so 90Y-Ibritumomab Tiuxetan delivers radiation more specifically 
to the lymphoma B-cells [180]. 131I-Tositumomab (Bexxar), a murine IgG2a lambda monoclonal 
antibody, also binds to the CD20 antigen and can be used in the treatment of B-cell non-Hodgkin’s 
lymphoma [181]. 99mTc-Arcitumomab (CEA-Scan) comprises a murine Fab’ monoclonal antibody 
(IMMU-4) fragment that targets the carcinoembryonic antigen (CEA), secreted by tumour cells. This 
radiopharmaceutical is indicated for imaging of recurrent colorectal cancer, the fourth biggest cause 
of cancer deaths in 2008 (i.e. 608 000 deaths) [182,183]. Finally, 99mTc-Nofetumomab merpentan 
(Verluma) and 111In-Capromab pendetide (ProstaScint) are also marketed for the imaging of (small 
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cell and non-small cell) lung carcinoma and prostate carcinoma, respectively [6,8,60]. An overview of 
these FDA- or EMA-approved radiolabelled peptides and proteins is given in Table 3 [123,184]. 
Other receptor-targeting radiolabelled peptides are currently under development as well, some of 
them already entering preclinical and clinical trials: cholecystokinin or gastrin analogues, glucagon-
like peptide-1, bombesin, chemokine receptor CXCR4 targeting peptides and RGD peptides 
[60,185,186].  
Receptor mediated tumour targeting is nowadays a hot topic in the field of molecular targeting. The 
molecular species involved are the peptides or antibodies (targeting agents) directed against cell 
membrane receptors present on tumours (targets). The targeting agents may itself evoke a 
therapeutic effect (simplex system) or it can act as a therapeutic carrier e.g. containing a chelator 
linked radiometal (duplex systems). Next to those systems already discussed in this review paper, 
three-component peptide heterodimer-effector conjugates have been described interacting with two 
targets while also a pretargeting/targeting-effector conjugate was published binding to one target 
(triplex system). Heterodimers has emerged as a promising strategy to improve peptide affinity. In a 
peptide heterodimer, two different peptides targeting different receptors are covalently attached by 
a linker (either flexible or rigid), as tumours co-express multiple peptide receptors [187]. Peptide 
homodimers on the other hand have been well documented to have higher avidity for targeting 
tumour cells than peptide monomers [188] or higher cellular uptake characteristics [189]. In addition, 
a target agent may be a peptide multimer (e.g. dendrimer) to which the therapeutic principle is 
attached. This multiplex system has already been described for the neurotensin peptide, which was 
synthesised as a tetrabranched form and linked to different units for therapy or diagnosis, while 
obtaining its biological activity and becoming resistant to proteolysis [190]. Also multiplex systems 
with dual-labelled imaging agents have been described, e.g. (111In-DTPA)n-trastuzumab-(IRDye 
800CW)m which contains multiple γ-emitters and near infrared fluorescent dyes [191]. In some cases, 
receptor mediated tumour targeting is not an immediate option. Malignant gliomas are 
characterized by a high rate of local recurrence after surgery within the region of the original tumour, 
combined with very low incidence of distant metastases and poor prognoses of the patients. 
Therefore, a combination of gene therapy and receptor mediated tumour targeting are under 
investigation. Ter Horst et al. describe the locoregional delivery of adenoviral vectors encoding the 
somatostatin receptor subtype 2 (sst2). Intravenous injection of 
99mTc-labelled octreotate (99mTc-
Dermotate 2) showed high sst2 expression in the transfected xenograft tissue, underlining the 
potential of the increasing tumour sensitivity to targeted peptide radiotherapy [192].  
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Infection and inflammation 
Next to tumour-targeted radiopharmaceuticals, research also focuses on peptide receptor 
radionuclide imaging (PRRI) of inflammatory markers (e.g. Vascular Adhesion Protein-1 (VAP-1)) or 
infection through leukocyte or microorganism binding [16,193]. As the tuftsin receptor is expressed 
by neutrophils, monocytes and macrophages, tuftsin analogues are currently investigated for their 
use in the diagnosis of infection or inflammation (e.g. 99mTc-RP128). Moreover, also chemotactic 
peptides targeting white blood cells, interleukin-8 derivatives and platelet factor 4 analogues are 
explored for their use in inflammation/infection imaging. Next, infection-selective agents, like e.g. 
defensin, ubiquicidin analogues, human lactoferrin peptides and alafosfalin are (pre)clinically 
investigated [16]. 
Osteomyelitis can already be located using either of the two authorized 99mTc-radiolabelled 
antibodies, i.e. LeukoScan or Scintimun. 99mTc-Sulesomab (LeukoScan), an IMMU-MN3 mouse IgG1 
Fab’ monoclonal antibody fragment, is registered for diagnostic imaging, determining the location 
and extent of infection or inflammation in bone of patients with suspected osteomyelitis. This 
antibody recognizes the NCA-90 antigen of granulocytes [8,194]. Another radiolabelled monoclonal 
antibody, 99mTc-Besilesomab (Scintimun), targeting the NCA-95 antigen, is indicated for scintigraphic 
imaging of inflammation or infection in peripheral bone, in patients with suspected osteomyelitis 
[195] (Table 3). 
 
Table 3. Examples of (FDA/EMA) approved radiopeptides and proteins. 
Radioligand Trade name Target/Receptor Application 
111
In-DTPA-
Pentetreotide 
OctreoScan SST2 Imaging of neuroendocrine tumours 
90
Y-Ibritumomab 
Tiuxetan 
Zevalin CD20 Therapy of non-Hodgkin’s lymphoma 
131
I-Tositumomab Bexxar CD20 Therapy of non-Hodgkin’s lymphoma 
99m
Tc-Arcitumomab CEA-Scan CEA Imaging of colorectal carcinoma 
99m
Tc-Nofetumomab 
merpentan 
Verluma 
40-kDa 
glycoprotein 
Imaging of small cell and non-small cell 
lung carcinoma 
99m
Tc-Sulesomab LeukoScan NCA-90 Imaging of osteomyelitis 
111
In-Capromab 
pendetide 
ProstaScint 
100-kDa 
glycoprotein 
Imaging of prostate carcinoma 
99m
Tc-Besilesomab Scintimun NCA-95 
Imaging of infection or inflammation 
(osteomyelitis) 
SST: somatostatine receptor; CD20: B-lymphocyte antigen; GRP-R: gastrin-releasing peptide receptor; CEA: 
carcinoembryonic antigen; NCA-90: non-specific cross-reacting antigen 90; NCA-95: non-specific cross-reacting antigen 
95 
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8. ALTERNATIVES FOR RADIOPEPTIDES AND THEIR APPLICATIONS 
The concept of receptor mediated tumour targeting can also be applied in targeted chemotherapy, 
where small peptides are used to deliver cytotoxic drugs to tumours. In contrast to radiopeptides, 
cytotoxic peptides are hybrid molecules composed of (1) a peptide carrier, which binds to receptors 
on tumour cells, and (2) a cytotoxic moiety instead of a chelator-linked radiometal. Ideally, tumour 
cells that bind these peptides would be killed, while normal cells would be spared. Cytotoxic 
compounds (e.g. Arg-Gly-Asp molecules) linked to analogues of somatostatins have been developed 
for targeting somatostatin receptors and therefore are more selective for killing cancer cells [196] 
Semi-conductor nanocrystal quantum dot labelled peptides, which serve as ligands for cellular 
receptors, provide an alternative to radionuclide imaging techniques [197]. These nanoparticles 
exhibit unique optical and spectroscopic properties, useful in imaging receptor distribution and 
targeting specific tissues and cell types. For example, quantum dot coated with a lung targeting 
peptide accumulated in the lungs of mice after intravenous injection [198]. 
 
 
9. CONCLUSIONS 
Due to the over-expression of different peptide-receptors in several (malignant) tissues, 
radiolabelled peptides and proteins are currently developed as theranostics for a number of clinical 
applications (e.g. cancer, inflammation and infection). This is reflected by the numerous peptides and 
proteins that are currently under investigation in preclinical and even in clinical Phase I/II/III trials. 
However, quality control (e.g. radionuclidic, radiochemical and chemical purity) and subsequent in 
vitro biomedical and in vivo pharmacokinetic analyses are of increasing importance to enhance 
success rate of the preclinical-to-clinical transfer of radiopharmaceuticals.  
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SUMMARY & GENERAL CONCLUSIONS 
As described in Chapter I, the human microbiome recently gathered great attention due to its 
possible role in the health of the host. The general aim of this research was to further explain this 
microbiome-host interaction. More specifically, we focussed on its possible association with cancer, a 
life-threatening and -debilitating pathology. Research in oncology mainly focused on the role of 
bacterial (geno)toxin production or inflammation-induced carcinogenesis, with the role of the 
quorum sensing peptides being highly neglected. However, previous results of other quorum sensing 
signal molecules (i.e. AHLs) indicate a possible interaction with mammalian cells, next to the strong 
correlation observed between the quorum sensing mechanisms and tumour metastasis. Hence, this 
work was intended to investigate, as an initial, exploratory proof-of-principle, if the human 
microbiome, through the use of quorum sensing peptides, can influence cancer. 
Since many decades, the quorum sensing process is thoroughly described in literature, thereby 
focussing on i.a. molecule identification, pathway elucidation and structure-activity relationships 
(SAR). In Chapter II, this information was summarized through a comprehensive database 
(Quorumpeps®: http://quorumpeps.ugent.be), presenting the chemical information of the quorum 
sensing (derived) peptides, next to their species origin and quorum sensing functionality (i.e. 
methodology, target and activity). Currently, 231 quorum sensing peptides (or analogues thereof) are 
listed in this database, with the possibility of adding new peptide entities by the database users.  
The structural information of these quorum sensing peptides, described in the Quorumpeps® 
database, served as a start of this study: the chemical space of the quorum sensing peptides was 
investigated using multivariate techniques, i.a. in order to select ‘model peptides’ to explore our 
crosstalk hypothesis. As described in Chapter III, the quorum sensing peptides were categorized in 3 
chemically distinct clusters, which again could be subdivided in smaller clusters. Peptide size and 
compactness, lipophilicity, cyclisation and the presence of sulphur atoms and aromatic amino acids, 
were mainly found to determine this chemical classification. Moreover, it was noticed that most of 
the bacterial species produce chemically similar peptides (i.e. in same classification), except for 
Bacillus subtilis, for which peptides are described with structures covering the total chemical space of 
quorum sensing peptides. 
Based on these clustering results, a selection of quorum sensing peptides was made to use for 
further functionality investigations. After chemical synthesis of these peptide structures, identity and 
SUMMARY & GENERAL CONCLUSIONS 
  
 
222 
purity was screened in Chapter IV in order to correctly correlate peptide structure with the observed 
biological results. A large number of peptides did not meet our requested purity specifications (> 95% 
purity) and even contained peptide impurities “outperforming” the desired peptide concentration. 
Therefore, for these peptides, conclusions should be cautiously made. 
These purity results were also used to select quorum sensing peptides for further functionality 
investigations. As this study was primarily intended to explore the microbiome-mammals crosstalk, 
and hence not meant to be exhaustive investigating all quorum sensing peptides in detail, we 
decided to use a purity cut-off value of 80% instead of the intended 95% purity level, i.e. peptides 
with a purity < 80% were excluded in our functionality evaluation.  
In Chapter V, the interaction between these sufficiently pure quorum sensing peptides and human 
cancer cells, more particularly with colon cancer cells, was explored. It was clear that some quorum 
sensing peptides indeed interact with these cells, thereby promoting cancer cell invasion and 
angiogenesis. Moreover, an initial pathway map was suggested for this process: through the 
activation of i.a. the epidermal growth factor receptor (EGFR) or the IL-6 pathway, tumour 
progression can be initiated. These first results now open new perspectives on the role and 
applications of the microbiome on the guest’s health, with the possibility of translating these findings 
into other biological and applied medical fields as well.  
The same settings were used in Chapter VI, where the influence of quorum sensing peptides on 
breast cancer cells was further explored. Again, tumour invasion and angiogenesis were induced 
after quorum sensing peptide treatment, thereby confirming the existence of a crosstalk 
phenomenon previously observed with colon cancer cells.  
Before investigating the effect of the quorum sensing peptides on brain cancer (and other central 
nervous system diseases), the permeability of these peptides through the blood-brain barrier, once 
they have reached the blood circulation, was studied. The results of this study are described in 
Chapter VII: some quorum sensing peptides indeed cross the blood-brain barrier, with the more 
lipophylic peptide showing the highest brain influx (Kin = 1.33 µl/(g×min)). These results can stimulate 
new research on exploring the effect of these quorum sensing peptides on brain (cancer) cells, based 
on the recent suggestions of a microbiome-brain disease correlation and our findings of tumour-
promoting properties for some of these peptides. 
In Chapter VIII, we analysed the permeability of some quorum sensing peptides through the 
intestinal barrier. Using a Caco-2 model, some peptides were found to cross this physiological barrier 
and reach the blood circulation, indicating a possible (tumour-promoting) effect throughout the 
human body for these quorum sensing peptides; the effects are thus not limited to the site of origin 
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and research should therefore expand to various cancer tissues. Next to the BBB-penetrating 
properties of these peptides, these initial intestinal permeability properties also stimulate in-depth 
pharmacokinetic (barrier) investigations, in order to link microbiota composition with different 
pathologies. Moreover, most of the quorum sensing peptides were found to remain sufficiently 
stable in cell medium and human plasma, thereby confirming the in vitro and in vivo functionality of 
the investigated peptides. No haemolytic and direct cell-killing effects were observed, next to limited 
in silico probability of organ and tissue toxicity. 
Finally, within the DruQuaR tradition, the last chapter encompasses a regulatory-quality theme. 
Chapter IX gives an overview concerning the development of radiolabelled peptide and protein 
based radiopharmaceuticals. The increasing number of peptides and proteins in research as well as in 
clinical trial settings can benefit from their radiopharmaceutical equivalents. However, to increase 
their success rate as radiopharmaceuticals, a thorough and regulatory accepted quality control 
(including radionuclidic, radiochemical and chemical purity) and subsequent in vitro biomedical and 
in vivo pharmacokinetic analyses are indispensable.  
 
 
Based on the results obtained during this study, our main research question, i.e. “Do quorum sensing 
peptides influence tumour cell behaviour?”, could be answered: YES, quorum sensing peptides do 
interact with human cancer cells, thereby promoting cancer cell invasion and neo-angiogenesis. 
However, this is only the first step... Although we have laid the foundations for new research 
concerning the microbiome-disease association, even more questions remain unanswered, awaiting 
further investigations concerning chemical as well as in vitro and in vivo aspects. 
First, we should investigate if the other groups of quorum sensing peptides (i.e. lantibiotics and 
isoprenyl modified peptides) demonstrate (similar) biological effects? As a proof-of-principle, in this 
initial exploratory study presented here, we only selected quorum sensing peptides from the linear 
and cyclic (thio)lacton peptide groups. However, the effect of other chemically diverse quorum 
sensing peptides should be investigated as well. This requires the availability of these chemically 
rather special peptides, which poses quite some synthetic challenges. 
Moreover, the peptide purity is an underestimated concern in the biomedical research field, and we 
were (and are) still confronted with it in our research as well. Therefore, the investigated peptides 
with low purity levels should be resynthesized and/or purified at a sufficiently high purity, followed 
by further functional studies. Apart from the observed biological effects due to impurities (and not 
the main compound), it has also been demonstrated in other biological fields that peptide impurities 
can antagonize the effect of the main peptide itself, thereby rendering fals negative conclusions. On 
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the other hand, if this phenomenon is observed, these peptide impurities can be used as 
therapeutics to block the effect of the endogenous quorum sensing peptide; radiolabelled analogues 
of these peptide antagonists may be useful in the diagnosis of cancer. 
 
As demonstrated during this study, quorum sensing peptides influence cancer cell behaviour in vitro, 
promoting cancer cell metastasis behaviour. The effect of the quorum sensing peptides on tumour 
cell morphology and invasion, revealed an epithelial-to-mesenchymal (EMT)-like transition of both 
the colon and breast cancer cells. These EMT-like characteristics are currently however only visually 
observed, and thus need to be confirmed biochemically by analysing e.g. E-cadherin, vimentin and N-
cadherin concentrations after quorum sensing peptide treatment. Confirmation of this EMT 
behaviour thereby can strengthen our results of metastasis-promoting characteristics of some 
quorum sensing peptides. 
In this research, we also found that some quorum sensing peptides can pass the blood-brain barrier. 
Therefore, it would be interesting to investigate if these peptides, in accordance with our results on 
colon and breast cancer cells, induce brain tumour cell invasion and angiogenesis.  Moreover, the 
study about the causative relationships between the available quorum sensing peptides and different 
neurological disorders can contribute to the exciting microbiome-brain research as well. For 
example, the quorum sensing peptide PhrCACET1, which is synthesized by Clostridium species and 
largely passes the blood-brain barrier, and comparable quorum sensing peptide analogues, should be 
investigated for their effect on brain cancer and neurological disorders. The yet uninvestigated 
isoprenyl modified peptide structures, which are produced by Bacillus species and have similar 
lipophilic properties as PhrCACET1, should be investigated for their effect on brain (cancer) cells as 
well.   
While we have currently limited our exploration to cell tests and initial kinetic data, we definitely 
need to know if and to what extent these quorum sensing peptides influence cancer in vivo? 
Therefore, a very burning question is: Are quorum sensing peptides present in the human body, 
under what conditions and to what extend? We already investigated the in vitro effect of quorum 
sensing peptides on human cancer cells and some initial ADME characteristics. However, the 
presence of these quorum sensing peptides in the human body is not yet demonstrated. Seen the in 
vivo presence of quorum sensing-mediated biofilms in the human body, and the observation of AHL 
signal molecules in diverse biological samples, the in vivo presence of quorum sensing peptides 
seems very likely. Therefore, to strengthen our obtained results, the in vivo existence of quorum 
sensing peptides should be investigated as well, requiring the analysis in e.g. faeces, skin, mucosa, 
sputum and plasma samples of different stratae of both healthy and diseased (cancer) patients. 
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Next to the in vivo quorum sensing peptide profiles, the relation with the microbiome should be 
clarified as well. It has become clear that quorum sensing peptides are produced under different 
conditions by different subspecies of bacteria, making this relation ‘multi-variate’ complex. Studying 
the microbiota composition, in relation with the quorum sensing peptide profiles, can broaden our 
knowledge, thereby extending the possible microbiome-cancer relationship already found in our in 
vitro research. 
If quorum sensing peptides are found in the human body, it will thus be important to investigate 
their in vivo behaviour using appropriate animal models. First, the pro-metastatic effects of the 
quorum sensing peptides should be investigated after treatment of the mouse tumour model with 
the purified peptides themselves. Second, gnotobiotic mice should be screened for the presence of 
quorum sensing peptides, and eventually the effect of these bacteria and their peptides on cancer 
progression analysed. In a next step, clinical samples of healthy individuals and cancer patients, 
carrying either metastasized or non-metastasized tumour lesions, should be investigated over time 
for their quorum sensing peptide profiles, as well as microbiota composition to finally offer 
convincing and clinically useful insights on the microbiome-cancer outcome relationship. 
 
 
Although we mainly obtained in vitro results during our exploratory research, which need to be 
confirmed in vivo as earlier described, our findings can potentially be of high importance for the 
patient. If our assumptions are valid (i.e. quorum sensing peptides are available in vivo in nano- or 
micromolar concentration and these peptides show pro-metastatic effects in vivo), the patient can 
rationally adapt his/her life style to combat the complex, heterogeneous and multi-variate disease 
that cancer is. The use of probiotics for example could help to suppress undesired bacteria in the 
human gut, and thereby diminish the synthesis of pro-metastatic quorum sensing peptides. However, 
the choice of probiotics should be well considered in function of the disease, as some of these 
bacteria can possibly synthesize undesirable quorum sensing peptides. The gut microbiota 
composition can be adapted by variations in diet as well, which in turn may influence the quorum 
sensing peptide profile of the patient. Hygienic measures can prevent changes in microbiota 
structure of the gut, next to other tissues like the skin, breast and mouth. Attention should thus be 
paid to avoid bacterial contaminations of food or materials, which can negatively influence the 
microbiome of the patient. Future studies should however prove and deepen these as yet 
hypotheses and reflections, in order to correctly inform, diagnose and/or treat the patients, the 
ultimate objective of our science.    
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“Achter de veranderlijke vormen van de natuur ligt een 
onveranderlijke zuivere werkelijkheid.” 
 
Piet Mondriaan 
(°1872 - †1944, Nederlandse schilder)  
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SAMENVATTING & ALGEMENE CONCLUSIES 
Zoals beschreven in Hoofdstuk I, geniet het humaan microbioom heel wat aandacht voor zijn 
mogelijke rol in de beïnvloeding van de gezondheid van de gastheer. Het algemene doel van dit 
onderzoek bestond er dan ook in de interactie tussen dit microbioom en de gastheer na te gaan; 
meer specifiek hebben wij ons gericht op de mogelijke associatie met kanker, een levensbedreigende 
en slopende aandoening. Het algemeen onderzoek naar de rol van de bacteriën bij kanker focust zich 
momenteel op de invloed van bacteriële toxines of het effect van inflammatie op de 
tumorontwikkeling. De rol van quorum sensing peptiden, geproduceerd door deze bacteriën, werd 
echter nog niet onderzocht. Voorgaand onderzoek heeft reeds aangetoond dat bepaalde andere 
quorum sensing signaalmoleculen (AHLs) kunnen interageren met zoogdiercellen. Daarnaast worden 
ook heel wat gelijkenissen gezien tussen het quorum sensing mechanisme en het metastase proces 
bij kanker. Op basis van deze recente bevindingen stelden wij de hypothese dat het microbioom, met 
behulp van quorum sensing peptiden, het gedrag van kankercellen kan beïnvloeden. In deze thesis 
hebben we deze hypothese onderzocht, waarbij we voor het eerst de interactie tussen de quorum 
sensing peptiden en humane kankercellen wensen aan te tonen. 
De voorbije decennia werd het quorum sensing proces reeds uitvoerig beschreven in de literatuur, 
waarbij voornamelijk gefocust werd op molecule identificatie, pathway opheldering en structuur-
activiteitsrelaties (SAR) van deze signaalmoleculen bij bacteriën. In Hoofdstuk II werd deze 
uitgebreide informatie samen gebracht in een databank (Quorumpeps: 
http://quorumpeps.ugent.be), waarbij de chemische informatie van de quorum sensing peptiden (en 
analogen) wordt weergegeven, naast hun bacteriële oorsprong en quorum sensing functionaliteit 
(methodologie, receptor en activiteit). Momenteel zijn 231 quorum sensing peptiden in deze 
databank opgelijst, waarbij gebruikers de mogelijkheid hebben om nieuwe gegevens aan deze 
databank toe te voegen. 
De structurele gegevens van de quorum sensing peptiden, beschreven in de Quorumpeps databank, 
werden vervolgens geanalyseerd en gebruikt als de start van dit onderzoek: de chemische ruimte van 
de quorum sensing peptiden werd onderzocht met behulp van multivariate data-analyse, waarna 
diverse ‘modelpeptiden’ werden geselecteerd voor verder functioneel onderzoek. Zoals beschreven 
in Hoofdstuk III kunnen de quorum sensing peptiden onderverdeeld worden in 3 chemisch 
verschillende groepen, waarbij deze zelf kunnen opgesplitst worden in diverse kleinere clusters. De 
peptide grootte en compactheid, lipofiliciteit, cyclisatie en de aanwezigheid van zwavelatomen en 
aromatische aminozuren zijn de bepalende factoren voor deze chemische classificatie. Daarenboven 
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werd opgemerkt dat de meeste bacteriële soorten chemisch gelijkende peptiden synthetiseren 
(zelfde groepering), met uitzondering van Bacillus subtilis waarbij quorum sensing peptiden werden 
beschreven met uiteenlopende chemische eigenschappen. 
De geselecteerde quorum sensing peptiden werden vervolgens synthetisch aangemaakt, waarna de 
identiteit en zuiverheid werden onderzocht (Hoofdstuk IV). Deze zuiverheidsbepaling is noodzakelijk 
om de verkregen biologische functionaliteitsresultaten correct te correleren met het quorum sensing 
peptide; peptide onzuiverheden kunnen namelijk sterk de functionaliteit beïnvloeden. Uit de 
resultaten bleek dat een groot aantal van de aangemaakte quorum sensing peptiden niet de 
gewenste zuiverheid bevatten (> 95% zuiverheid), waarbij de concentratie aan onzuiverheden de 
gewenste peptide concentratie zelfs ‘overtreft’. De biologische resultaten van deze peptiden dienen 
dus met voldoende voorzichtigheid te worden geïnterpreteerd. 
Deze resultaten werden ook gebruikt bij de selectie van quorum sensing peptiden voor verdere 
functionaliteitsstudies. Gezien dit onderzoek de intentie had om een eerste inzicht te krijgen in de 
microbioom-zoogdier interactie, en dus geen allesomvattend onderzoek was waarbij alle quorum 
sensing peptiden in detail werden bestudeerd, werd een zuiverheidslimiet aangewend van 80%; de 
quorum sensing peptiden met een zuiverheid < 80% werden dus niet geïncludeerd tijdens de verdere 
functionaliteitsstudies. 
In Hoofdstuk V werden de interacties tussen de weerhouden quorum sensing peptiden en humane 
kankercellen, meer bepaald colonkankercellen, onderzocht. Het was duidelijk dat een aantal quorum 
sensing peptiden inderdaad interageren met deze cellen, waarbij het invasieve karakter van de 
tumorcellen en de aanmaak van nieuwe bloedvaten (angiogenese) werd bevorderd. Daarenboven 
werden een aantal pathways voor de activatie van dit proces voorgesteld: na activatie van o.a. de 
epidermale groeifactor receptor (EGFR) of de interleukine-6 pathway wordt kanker progressie 
geïnitieerd. Deze resultaten openen dus nieuwe perspectieven over de rol en toepassingen van het 
microbioom op de gezondheid van de gastheer, met de mogelijkheid om deze bevindingen in andere 
biologische en medische gebieden aan te wenden. 
Dezelfde benadering werd toegepast in Hoofdstuk VI, waarbij de invloed van de quorum sensing 
peptiden op borstkankercellen verder werd onderzocht. Er werd opnieuw een verhoogde 
tumorcelinvasie en angiogenese waargenomen na quorum sensing peptide behandeling, waarbij de 
microbioom-interactie, die initieel werd geobserveerd bij colonkankercellen, dus werd bevestigd. 
Alvorens we de effecten van de quorum sensing peptiden onderzoeken op hersentumorcellen (en 
andere aandoeningen van het centraal zenuwstelsel), is het noodzakelijk om de permeabiliteit van 
deze peptiden, eens aanwezig in de bloedbaan, doorheen de bloed-hersenbarrière na te gaan. De 
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resultaten van deze studie worden weergegeven in Hoofdstuk VII: een aantal quorum sensing 
peptiden passeren effectief de bloed-hersenbarrière, waarbij het meest lipofiele peptide de hoogste 
herseninflux (Kin = 1.33 µl/(g×min)) vertoont. Deze resultaten kunnen dus het onderzoek naar de 
effecten van deze quorum sensing peptiden op hersen(tumor)cellen stimuleren; de herseninflux van 
bepaalde quorum sensing peptiden kan daarbij nieuwe inzichten bieden in het onderzoek naar de 
associatie tussen het microbioom en diverse hersenaandoeningen.   
In Hoofdstuk VIII werd de permeabiliteit van enkele quorum sensing peptiden doorheen de 
darmwand onderzocht. Met behulp van een Caco-2 model werd aangetoond dat deze quorum 
sensing peptiden deze fysiologische barrière kunnen doorbreken en op die manier de bloedbaan 
bereiken. Deze quorum sensing peptiden kunnen dus hun mogelijks (tumor-bevorderend) effect op 
diverse plaatsen in het lichaam uitoefenen, waarbij hun functionaliteit dus niet wordt beperkt tot de 
plaats van aanmaak. Het kankeronderzoek naar deze peptiden dient dus te worden uitgebreid naar 
diverse weefsels, met aandacht voor farmacokinetische (barrière) studies; het onderzoek naar de 
associatie tussen het microbioom en diverse aandoeningen kan op die manier worden gestimuleerd. 
Daarenboven werd aangetoond dat de meeste quorum sensing peptiden voldoende stabiel blijven in 
celmedium en humaan plasma, wat de bekomen in vitro en in vivo resultaten van de onderzochte 
peptiden bevestigd. Er werden geen hemolytische en celdodende effecten geobserveerd voor de 
quorum sensing peptiden, evenals geen in silico orgaan- en weefseltoxiciteit. 
Tenslotte werd, naar goede gewoonte bij DruQuaR, in het laatste hoofdstuk een regulatoir-
kwaliteitsaspect bestudeerd. Hoofdstuk IX geeft een overzicht van de technieken die gebruikt 
worden bij de radiolabelling van peptiden en proteïnen (radiofarmaca). Het toenemend aantal 
peptiden en proteïnen in zowel onderzoek als klinische trials kan uitgebreid worden met hun 
radiogemerkte equivalenten. Om het slaagpercentage bij de ontwikkeling van radiofarmaca te 
verhogen zijn echter grondige en gereguleerde kwaliteitscontroles (inclusief radionuclidische, 
radiochemische en chemische zuiverheid) noodzakelijk, evenals geschikte in vitro biomedische en in 
vivo farmacokinetische testen. 
 
 
Op basis van de bekomen resultaten kan onze belangrijkste onderzoeksvraag “Kunnen quorum 
sensing peptide het gedrag van kankercellen beïnvloeden?” worden beantwoord: JA, quorum sensing 
peptiden kunnen inderdaad interageren met humane kankercellen, waarbij deze de tumorcelinvasie 
en angiogenese bevorderen. Deze studie is echter slechts een eerste stap… Hoewel we de basis 
hebben gelegd voor nieuw onderzoek betreffende de associatie tussen het microbioom en diverse 
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ziekten, blijven er heel wat vragen onbeantwoord die via verdere chemische, in vitro en in vivo 
onderzoeken dienen te worden opgelost.  
Vooreerst dienen we te onderzoeken of ook de andere groepen van quorum sensing peptiden (met 
name de lantibiotica en isoprenyl-gemodificeerde peptiden) vergelijkbare biologische effecten 
veroorzaken. Om onze hypothese initieel te verifiëren, hebben wij enkel de lineaire en cyclische 
quorum sensing peptiden onderzocht naar hun functionaliteit. De effecten van de andere groepen 
van quorum sensing peptiden dienen dus ook te worden geanalyseerd. De synthese van deze 
chemisch afwijkende peptiden brengt echter heel wat uitdagingen met zich mee.  
De zuiverheid van peptiden is en blijft een onderschatte factor in het biomedisch onderzoek. Daarom 
zullen de onderzochte onzuivere peptiden opnieuw moeten worden aangemaakt en/of opgezuiverd 
met een voldoende hoge zuiverheid, waarna hun effect op de tumorcellen opnieuw dient te worden 
onderzocht. Naast de reeds gerapporteerde biologische effecten van peptide onzuiverheden, kan het 
effect van het quorum sensing peptide ook worden geblokkeerd door deze peptiden, waarbij dus 
vals-negatieve resultaten worden bekomen. Wanneer dit fenomeen wordt waargenomen kunnen 
deze peptide onzuiverheden echter verder worden onderzocht voor hun gebruik als therapeuticum 
om het effect van de endogeen aanwezig quorum sensing peptiden te blokkeren; radiogemerkte 
analogen van deze peptiden kunnen daarnaast gebruikt worden als diagnosticum bij kanker. 
Zoals werd aangetoond in deze studie beïnvloeden bepaalde quorum sensing peptiden het gedrag 
van kankercellen in vitro, met mogelijks een bevordering van de tumormetastase. Het effect van de 
quorum sensing peptiden op de tumorcel morfologie en invasie toonde een epitheliaal-
mesenchymale verandering (EMT) aan van zowel de colon- als borstkankercel. Deze EMT-
karakteristieken werden echter enkel visueel waargenomen, waarbij het biochemische aspect (een 
verandering in o.a. E-cadherine, vimentine en N-cadherine expressie) nog verder dient te worden 
onderzocht. Een bevestiging van dit EMT-gedrag kan daarbij de metastase-bevorderende 
eigenschappen van bepaalde quorum sensing peptiden bekrachtigen. 
In dit onderzoek werd ook aangetoond dat sommige quorum sensing peptiden de bloed-
hersenbarrière kunnen passeren. Het is dus interessant om de effecten van deze peptiden ook op 
hersentumorcellen te onderzoeken. De studie naar het oorzakelijke verband tussen de beschikbare 
quorum sensing peptiden en diverse neurologische aandoeningen kan daarnaast ook bijdragen tot 
het microbioom-hersen onderzoek. Zo kan het effect van bijvoorbeeld PhrCACET1, een quorum 
sensing peptiden dat geproduceerd wordt door Clostridium species en sterk de bloed-hersenbarrière 
doorkruist, op hersentumorcellen en neurologische aandoeningen interessante informatie 
opleveren. De effecten van de isoprenyl-gemodificeerde quorum sensing peptiden, die geproduceerd 
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worden door Bacillus species en vergelijkbare lipofiele eigenschappen vertonen als PhrCACET1, 
dienen ook te worden onderzocht. 
Hoewel wij ons in deze studie hebben beperkt tot celtesten en initiële kinetische studies, is het 
belangrijk om te onderzoeken of de quorum sensing peptiden ook het gedrag van de tumorcellen in 
vivo beïnvloeden. De vraag “Zijn quorum sensing peptiden aanwezig in het lichaam, onder welke 
omstandigheden en in welke mate?” dient dus absoluut te worden onderzocht. Gezien de in vivo 
aanwezigheid van quorum sensing gemedieerde biofilms en de reeds aangetoonde andere quorum 
sensing signaalmoleculen (AHL), lijkt ook de aanwezigheid van de quorum sensing peptiden in het 
lichaam zeer waarschijnlijk. Om onze in vitro resultaten kracht bij te zetten, zullen dus diverse 
biologische matrices (bv. feces, huid, sputum en plasma) van gezonde en zieke (kanker) patiënten 
moeten worden onderzocht naar de aanwezigheid van quorum sensing peptiden. 
Naast de bepaling van het in vivo quorum sensing peptide profiel, dient ook de relatie met het 
microbioom te worden uitgeklaard. Het is duidelijk dat quorum sensing peptiden onder diverse 
omstandigheden en door diverse soorten bacteriën worden aangemaakt, waardoor deze relatie 
multi-variaat en complex is. Het onderzoek naar de samenstelling van het microbioom, en de 
verhouding met het quorum sensing peptide profiel, kan onze kennis verbreden en dus de mogelijke 
relatie tussen het microbioom en kanker uitbreiden. 
Wanneer deze quorum sensing peptiden in het lichaam worden aangetoond, zal hun effect 
vervolgens ook in vivo worden onderzocht met behulp van geschikte diermodellen. Vooreerst dient 
het pro-metastaserend effect van het zuivere quorum sensing peptide in het muis kankermodel te 
worden nagegaan. Vervolgens moeten muizen met een gekend microbioom (gnotobiont) worden 
gescreend naar de aanwezigheid van quorum sensing peptiden, en het effect van deze bacteriën en 
peptiden op tumor progressie geëvalueerd. In een volgende stap zullen klinische stalen van gezonde 
individuen en kankerpatiënten (met en zonder metastase letsels) in functie van de tijd moeten 
worden geanalyseerd naar zowel hun quorum sensing peptide profiel als microbioom samenstelling, 
om uiteindelijk overtuigende en klinisch bruikbare inzichten te krijgen in de relatie tussen het 
microbioom en kanker. 
 
 
Hoewel wij in deze studie enkel in vitro resultaten hebben verkregen, welke dus in vivo moeten 
worden bevestigd, kunnen onze resultaten mogelijks van betekenis zijn voor de patient zelf. Indien 
onze aannames geldig blijken (i.e. quorum sensing peptiden zijn aanwezig in het lichaam in nano- of 
micromolaire concentraties en deze peptiden vertonen ook pro-metastaserende effecten in vivo), zal 
de patiënt zijn levensstijl rationaal moeten wijzigen om de complexe, heterogene en multi-variate 
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ziekte die kanker is te verslaan. Zo zou bijvoorbeeld het gebruik van probiotica kunnen helpen bij de 
onderdrukking van ongewenste bacteriën in de darm, en op die manier de synthese van metastase-
bevorderende quorum sensing peptiden helpen verminderen. De keuze van de probiotica dient 
echter goed te worden overwogen, gezien bepaalde van deze bacteriën zelf ongewenste quorum 
sensing peptiden kunnen aanmaken en op die manier de progressie van de tumor kunnen 
beïnvloeden. De samenstelling van het microbioom van de darm kan ook wijzigen na variaties in de 
voeding, welke dus opnieuw het quorum sensing peptide profiel van de patiënt kan aanpassen. 
Daarnaast kunnen hygiënische maatregelen een verandering in het microbioom van de darm 
verminderen, evenals de huid, de borst en de mond. Er dient dus voldoende aandacht te worden 
besteed aan hygiëne om veranderingen in het microbioom ten gevolgd van bacteriële contaminaties 
(voeding en materialen) te vermijden. Verdere studies dienen deze diepgaande gedachten echter uit 
te werken, zodat de patiënt correct kan worden geïnformeerd. 
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“Succes is not the key to happiness, happiness is the key to success.” 
 
 
Albert Schweitzer 
(°1875 - †1965, German philosopher) 
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